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General introduction 
The substance 3,6-dinicotinoylmorphine (Vilan®, Nicomorphine) is the 
nicotinic acid di-ester of morphine and was introduced in 1959 in medicine 
to serve as a narcotic analgesic [Zirm and Pongratz 1959]. Initial animal and 
clinical data showed that indeed 3,6-dinicotinoylmorphine had a potent 
analgesic effect and that in comparison to the more traditional drug, 
morphine, there were certain benefits upon its systemic use: faster onset 
and an intermediate duration of action. Subsequent studies showed that 
after epidural administration little respiratory depression occurred: there 
was a lack of both early and, more relevantly, the late respiratory depression 
that is seen with morphine [Maas et al. 1987]. Thus one benefit claimed for 
this drug stood out in particular: respiratory depression appeared to be less of 
a problem while potent analgesic effects were maintained. However, 
3,6-dinicotinoylmorphine failed to exhibit interaction at the receptor site 
[Lobbezoo et al. 1982], and this resulted in a contradiction: Le. no action via 
the receptor but a potent analgesic effect. This is most likely a strong 
indication that active metabolites evolve from the proven inactive parent 
compound [Pinckaers et al. 1982; Dirksen et al. 1987]. The name for this 
type of a compound is "prodrug" [Rowland and Tozer 1989]. 
The confirmation that 3,6-dinicotinoylmorphine's analgesic effectiveness 
depends on the presence of one or several of its metabolites [Pinckaers et al. 
1982; Dirksen et al. 1987] was the subject of our various studies on the 
drug's pharmacokinetics. Theoretical considerations assisted in defining the 
benefits or disadvantages of the drug's use. One benefit is that 
3,6-dinicotinoylmorphine has a greater lipid solubility than morphine. 
Therefore, it will penetrate more effectively than morphine into the central 
nervous system, where opioid binding sites are known to be present [e.g. 
Thorpe 1984]. A second benefit is that because the main principal peak 
serum concentration is limited to the inactive drug, the severity of any side-
effects, such as respiratory depression, is expected to be less than when 
peak serum concentrations are caused by active compounds. 
However, when a prodrug (by definition inactive) is administered, it has to be 
converted into active metabolites in order to take action. Thus, the 
effectiveness of the prodrug is fully dependent on the ability of the biological 
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system to convert it to active metabolites. Unfortunately, no data on the 
biotransformation pathway of 3,6-dinlcotinoylmorphlne were available. 
When we commenced our studies, it was unknown which metabolites 
caused the effect. The search for metabolites began and nowadays these are 
classified as either active or inactive. At present, we recognize that the effects 
of the administration of the parent prodrug will be a result of the combined 
and sequential actions of the parent compound Itself and all of Its 
metabolites. This insight underscores the general relevance of the 
identification and quantitation of all metabolites in order to explain the 
(overall) effect of a drug. At least part of this definition of the 
pharmacodynamic effects has been achieved by the pharmacokinetics 
described in this thesis. 
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Objective 
The objective of the studies described In this thesis was to investigate the 
following questions: 
1 Is it possible to show the initial presence and disposition of 
3,6-dinicotinoylmorphine in the serum after its administration? 
2 How fast do the various metabolites appear in the blood and is the 
analgesic effect of the parent compound be produced by these 
metabolite(s)? 
3 Do different routes of administration of 3,6-dinicotinoylmorphine 
result in differences in the quantity and sequence of appearance of the 
metabolites? 
The first attempt to outline the pharmacokinetics of 3,6-dinicotinoyl­
morphine and its metabolites in man failed to show the presence of the 
parent compound 10 minutes (first sample) after intramuscular 
administration of 10 mg 3,6-dinicotinoylmorphine into 5 patients [van Rooij 
et al. 1984]. This indicated a rapid conversion of 3,6-dinicotinoylmorphine 
into its metabolites, and this notion was corroborated by data on the drug's 
fast onset of action. Thus, it was to be expected that the parent drug would 
be present only for a very brief period after administration. Consequently, we 
may expect the early appearance of various metabolites, since the human 
body contains an extensive metabolic conversion capacity. Those metabolites 
actually detected in the serum can be classified as being either active or 
inactive. Once the active metabolites are identified and quantified, we may 
start to consider how the effectiveness of the parent drug involves the 
endorphin systems and its many different (sub)types of receptor sites. 
Finally, the route of administration of 3,6-dinicotinoylmorphine may result 
in a difference in the pharmacokinetics of parent compound and metabolites. 
There Is an obvious limitation on the pharmacokinetic studies in serum. The 
blood is part of the general transport system in the human body, and the 
concentrations of parent substances and metabolites will only give an 
χ 
impression of all the complex chemical and enzymatic processes within the 
body compartments. Yet, we have no technique to measure the 
concentration of parent drug and Its metabolites in the effector 
compartments of humans. 
In all, this thesis presents pharmacokinetic data on 3,6-dinicotinoyl-
morphine in order to answer the questions mentioned above, and the kinetic 
data must be evaluated to explain the analgesic action of this prodrug. 
Objective xi 
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Chapter I 
I Introduction 
A wide variety of drugs are used to relief pain, and three interrelating factors, 
physicochemical properties, pharmacokinetics and interactions with the 
biological system, are the key to understanding their effectiveness. With 
respect to morphine, these effects include, next to powerful analgesia, a 
variety of "side-effects", e.g. early and late respiratory depression, nausea, 
vomiting, severe confusion and obstipation [Bowman and Rand 1980; Zylicz 
and Twycross 1991]. The chemical structureof morphine is shown in Fig 1-1. 
By introducing minor chemical modifications to the morphine molecule that 
has left the morphine skeleton unchanged, one has attempted to build 
different drugs that has the optimum structure for a desired main effect (Fig 
1-1); among these drugs ranks 3,6-dinlcotinoylmorphine. It is generally 
recognised that the arrangement of atoms into molecules defines a drug's 
physicochemical properties, and that these are important for the drug's 
pharmacokinetics. Moreover, the chemical structure of a drug and especially 
its three-dimensional shape determines how it interacts at different receptor 
sites. 
Below the data are reviewed on the three interrelating factors 
(physicochemical properties, pharmacokinetics and receptor interactions) for 
morphine (as reference substance) and the C3 -and/or C6-substituted 
morphine analogues that are in clinical use: codeine, heroin (dlamorphlne, 
3,6-diacetylmorphlne) and 3,6-dinicotinoylmorphIne. 
It can be seen from Fig I-1 that methyl substitution at the phenolic C3 site 
results In codeine (Fig 1-1). This drug is a potent antitussive that has 1/10 
of the potency of morphine in reducing acute peripheral pain. Substitution 
at only the C6 position does not result In a drug which is in clinical use at 
the moment. Removal of the hydroxyl group at the C6 position of codeine 
results in dextromethorphan. Hydromorphone, an isomer of morphine with 
the same bruto chemical formula, has a double bonded oxygen at C6. It is in 
clinical use, but in addition to the change at the C6 atom there is also a 
minor modification in the morphine skeleton: it contains a saturated C7-C8 
bond while in morphine this bond is unsaturated. Because of these extra 
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modifications, dextromethorphan and hydromorphone will not be included in 
the comparison of these C3 -and/or C6-substituted morphine derivatives. 
Figure 1-1 visualises the slight modifications in chemical structure. 
Substitution of both hydroxyl groups at position C3 and C6, due to an ester 
formation with acetic acid, results in the well-known drug heroin (3,6-
diacetylmorphine, diamorphine) (Figl-l). When the two hydroxyl groups 
form ester bonds with nicotinic acid 3,6-dinicotinoylmorphine results. 
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I-I Physicocbemical properties 
Physicochemlcal properties are a set of chemical and physical properties 
characteristic of each chemical compound (e.g. melting point, boiling point, 
solubility in various liquids etc.). In Table 1-1, three physicochemlcal 
properties greatly influencing the behaviour of chemical compounds in the 
human body are listed: the molecular weight of a compound, the acid-base 
equilibrium constant (pKJ and the lipid solubility. 
1. The molecular weight (mw) can be calculated from the bruto chemical 
formula and expresses the weight of a certain number of molecules (number 
of Avogadro: 6.0220.1023 mol"1)· In the practice of dosing drugs, this means 
that 10 mg morphine (mw 285) contains 1.7 times more molecules than 10 
mg 3,6-dinicotinoylmorphine (mw 495); in other words, 10 mg 
3,6-dinicotinoylmorphine corresponds with 7 mg morphine. The molecular 
weight of a compound gives some indication of the ability of that compound 
to cross membranes, but its three-dimensional structure is of even more 
importance. 
2. The pKa, the acid-base constant, is defined as the pH at which 50% of 
the compound is in the ionised form. Given the pH of the environment, the 
amount of ionisation can be calculated by using the Henderson-Hasselbalch 
equation, which includes the pKa value of the compound. In the human body 
only the non-ionised part of the compound can penetrate into the lipid layers 
or tissues. 
3. The lipid solubility can be expressed as an octanol-water partition 
ratio or, in general, as the distribution ratio of the compound between two 
non-miscible solvents. The octanol-water distribution ratio (D0/w) describes 
the distribution of the non-ionised compound between the apolar octanol 
phase and the polar water phase. This distribution ratio predicts the 
distribution of a non-Ionised compound between the blood (polar phase) and 
the central nervous system (apolar phase), where octanol often serves as a 
standard for body lipids. A standard procedure for determining lipid 
solubility is not available at present, thus we can only provide some data 
obtained under many different and often undefined conditions that yield 
conflicting results fTable 1-1). At best we may rank the lipid solubility of 
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these substances in the following order: 3,6-dlnicotlnoylmorphine > heroin > 
codeine > morphine. 
Table 1-1 
Molecular weight (mw), the acid-base constant (ρΚ&) and the lipid solubility 
of morphine and its clinically used C3-C6 derivatives [Dirksen et al. 1987; 
Martindale 1993; Koopman-Kimenai et al. 1994a]. 
Drug C3 C6 mw pKa partition ratio 
Morphine OH OH 285 8.0 (20 °C) 6.23 (octanol/water) 
0.79 (octanol/pH=7.4) 
0.15 (oil/water)* 
C3-substttuents 
Codeine methyl OH 299 8.2 (20 °C) 3.98 (octanol/pH=7.4) 
C6-substituents 
C3 - and C6-substituents 
Heroin acetyl acetyl 369 7.6 (23 °C) 1.58 (ether/pH=7.0) 
17 (oil/water)* 
DNM nicotinoyl nicotinoyl 495 7.5 (--) 34.7 (octanol/water)* 
data from Nourypharma (Oss, The Netherlands). 
pKa values in water at 20 or 23 °C 
* data from Watson et al. [1984] 
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1-2 Pharmacokinetics 
Goodman Gilman et al. [1980] described pharmacokinetics as: "the 
application of kinetics to pharmakon (which is the Greek word for drugs and 
poisons)". Thus, pharmacokinetics means the study of concentrations of 
drug and metabolite(s) as a function of time and the construction of models 
suitable to interpret such data. In essence, pharmacokinetics describes the 
absorption, distribution, biotransformation and excretion of drugs. The 
physicochemical properties, coupled with dosage, will determine the 
concentration of a drug as a function of time [Goodman Gilman et al. 1980]. 
In this thesis the term pharmacokinetics is used when absorption, 
distribution, metabolic handling and excretion by the human body are 
described in a mathematical way. After being absorbed, the administered 
drug will have to be distributed throughout the body in order to be able to 
reach its site of action. 
The measurement of the concentration of a drug and its metabolites in the 
body is usually limited to the blood (or the plasma or serum) or bodily 
excretion products, the main reason being that the samples for analysis are 
easily obtained. Moreover, blood is not only a practical source, but it also 
represents one of the main distribution systems of the body. After uptake 
from the site of administration, the drug is carried in this medium to all the 
tissues of the body, including those in which the drug acts and those in 
which it will be eliminated from the body. 
Various sites are suitable for drug administration, and the route may be 
classified as intravascular or extra vascular. Intravascular administration 
refers to the injection of a drug directly into the blood, most commonly a vein 
(i.e. intravenously). Extra vascular modes of administration include the 
intramuscular, oral or rectal route. The drug administered extravascularly 
must be absorbed from its site of administration and subsequently 
distributed throughout the body. 
A drug may also be administered locally and this method is selected to limit 
the presence of a drug to a specific site of action. Local administration to 
obtain regional effects includes, for example, administration into the 
cerebrospinal fluid. It is a method designed to attain a high concentration of 
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the drug in the vicinity of the site of effect and to minimize drug 
concentrations at distant sites. 
Once absorbed, a drug is distributed to various tissues of the body. Both the 
rate and extent of distribution are determined by: how well each tissue is 
perfused with blood, tissue size, binding of the drug to plasma proteins and 
tissue components and the permeability of tissue membranes. 
Elimination, the irreversible loss of the drug from the body occurs by two 
processes, excretion and metabolism. Excretion is the irreversible loss of the 
chemically unchanged drug, while metabolism is the conversion of one 
chemical species to another called metabolite [Rowland and Tozer 1989]. 
Metabolism is not to be taken for elimination for although the parent drug is 
lost, metabolites appear and may exert action. Thereafter, the metabolites 
can be further metabolised or they can be eliminated by excretion. After 
regional administration a different situation arises. Then the blood is not a 
medium that transports from the site of administration to that of action. 
Rather, blood concentrations reflect the elimination of the compound from 
its site of administration. 
l-2a Pharmacokinetics of morphine 
In 1987 Säwe and Odar-Cederlöf reported a kinetic study on patients with 
renal failure in comparison to a control group of cancer patients with normal 
kidney and liver function. The terminal elimination half-life of morphine 
varied between 1.5 and 4.0 h (mean 2.4 h). They found no statistical 
difference between the pharmacokinetic data from the patients with kidney 
failure and those with normal kidney function. The elimination half-life of 
M3G in patients with kidney failure varied between 14.5 and 118.8 h (mean 
49.6 h), which differs from the 2.4 to 6.7 h (mean 4.0 h) found in patients 
with normal kidney function. The elimination half-lives of M6G were similar 
to those of M3G, but due to interfering peaks the quantitation of M6G was 
not possible in plasma in two out of the seven patients. The quantitation 
limit of morphine, M3G and M6G in plasma was reported to be 4 nmol.l1. In 
this study both of the possible indicators of enterohepatic recirculation: a 
secondary plasma concentration peak of morphine and prolonged plasma 
half-life, were not seen. Further studies have provided additional 
information. Hasselström and Säwe [1993] described morphine 
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pharmacokinetics and metabolism in humans. After administering an 
intravenous dose of 5 mg morphine hydrochloride (morphine.HCl.ЗН2О, 
corresponding to 3.8 mg base), they found that the decline could be fitted to 
a triexponential equation, resulting in half-lives for morphine t(2)i/2 of 
1.8 ± 0.4 h and t(3)i/2 of 15.1 ± 6.5 h. The concentrations of morphine-
3-glucuronide and morphine-6-glucuronide showed a biphasic decline: for 
M3G the half-lives are t(2)i/2,M3G 2.9 ± 0.6 h and t(3)i/2,M3G 11.6 ± 2.7 h 
and for M6G t(2)i/2,M6G 2.5 ± 0.7 h and t(3)i/2,M6G 12.9 ± 4.9 h. In order to 
relate the oral bioavailability of morphine, they compared an intravenous 
dose of 5 mg morphine hydrochloride with an oral dose of 20 mg. They found 
normorphine in some of the plasma samples only after oral administration 
but not after intravenous administration. The limits of quantitation after the 
double extraction procedure (as described by Svensson et al. [1982] and 
Svensson [1986]) were 1 nmol.l·1 for morphine, M3G and M6G (equivalent to 
3.5 ng.ml"1 for morphine and 2.2 ng.ml'! for M3G and M6G). 
I-2b Pharmacokinetics of codeine 
The pharmacokinetics of codeine was described by Yue et al. [Yue et al. 
1991a,b]. Codeine is metabolised mainly by glucuronidation to codeine-
6-glucuronide; minor routes of metabolism include O-demethylation to 
morphine and N-demethylation to norcodeine. Yue et al. [1991a,b] found 
similar plasma half-lives for codeine, codeine-6-glucuronide, morphine and 
norcodeine (2.34 h, 2.79 h, 2.10 h and 2.62 h, respectively) in an adult 
Caucasian population after oral administration of 50 mg codeine. The 
O-demethylation of codeine proved to be phenotype dependent: some 
patients are not able to O-demethylate codeine into morphine [Chen et al. 
1991; Vree and Verwey-van Wissen 1992]. This coincides with the phenotype 
of dextromethorphan [Mortimer et al. 1989] and dihydrocodeine [Fromm et 
al. 1995], where no C6 glucuronidation can take place, and C3 
glucuronidation is only possible after 3-O-demethylation. 
I-2c Pharmacokinetics of heroin 
The pharmacokinetics of heroin (diamorphine) was first described by Boemer 
et al. [1975]. They found that heroin has a half-life in blood of less than 
20 min and is deacetylated by the human body to 6-monoacetylmorphine 
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(6MAM) and morphine. Further data were obtained by Inturrisi et al. [1984]. 
This group measured an elimination half-life of heroin of 3.0 ±1.3 min after 
intravenous administration (dose range 4 to 16 mg). After these doses, the 
serum concentration of 6MAM and morphine remained below the 
quantitation level (12.5 ng.ml"1 for 6MAM, morphine and heroin) in their 
patients, but both metabolites were present in blood samples taken from 
patients after the administration of larger doses of heroin (infusion of 
112μg.min- 1 for 150 min = 16.8 mg heroin). After intramuscular 
administration of heroin, this group was able to quantify heroin, 6MAM and 
morphine (2 patients receiving 4 mg). Maximum concentrations of heroin 
and 6MAM were measured 10 min after i.m. administration, and thereafter 
the concentrations of both compounds declined rapidly. Blood 
concentrations of morphine reached a maximum 15 min after administration 
and declined more slowly than the blood concentrations of heroin and 
6MAM. Both of the morphine glucuronides, morphine-3-glucuronide and 
morphine-6-glucuronide, were not measured. Oral administration of heroin 
resulted in measurable blood levels of morphine but not of heroin or 6MAM. 
In another study, in 26 new-born premature neonates, an infusion of heroin 
resulted in a steady-state morphine level, while in only one patient (2 plasma 
samples) could a low concentration of 6MAM be detected [Barrett et al. 
1991]. Heroin was not detected by this group. Morphine and 6MAM were 
detected by HPLC after derivatization yielding highly fluorescent dansyl 
derivatives. The quantitation limit in plasma was 10 ng.ml"1 for morphine 
and 25 ng.ml - 1 for 6MAM. The elimination half-life of morphine was 
8.9 ± 3.3 h, and there was a trend towards a prolonged half-life of morphine 
at a lower gestational age. No data on morphine-glucuronides were given. 
Data from urine samples were obtained by Elliott et al. [1971]. They found 
0 . 1 3 % unchanged heroin in the urine of four volunteers after an 
intravenous infusion of heroin (70 ± 5 mg in 7 h). In this study 1.3 % of the 
dose was found as 6MAM and 43.6 % was recovered as morphine, 4.2 % in 
the free form and 38.3 % was conjugated morphine; no 3MAM 
(3-monoacetylmorphine) was detected (data are mean values). 
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I-2d Pharmacokinetics of 3,6-аіпісоигюуЬтютрНіпе 
The pharmacokinetics of the drug 3,6-dinicotinoylmorphine was extensively 
studied in this thesis. Early reports indicated a marked renal elimination of 
unchanged 3.6-dinlcotinoylmorphlne [Szabó and Wesseling 1980], bu t 
others noted that there was an apparent lack of data [Noach 1980]. Data 
were almost completely absent or incorrect. 
Inali: 
After administration of morphine or a morphine analogue, the process 
of metabolisation starts: the conversion of the parent compound to 
other chemical substances (metabolites). These metabolites enter the 
general circulation and may reach the target system, thereby interacting 
and contributing to the overall effect. The analysis of the concentration -
time relationship of both parent compound and (all) metabolites is 
required to explain effects in the biological system. 
1-3 Targets for an opioid in the biological system 
Next to drug transfer, a drug acts by interacting with its specific targets. 
Opioids act through endorphin receptors. This section describes these 
targets for opioid actions. It is important to recognise that all compounds 
derived from the administered drug, together with the parent drug, 
constitute the population of chemical constituents available for receptor 
interactions or/and interaction with non-specific targets. Unfortunately, only 
parent compounds are tested in receptor binding studies, and even these 
data are scarce or absent. Therefore, we resorted to theoretical descriptions, 
which included a description of type, condition and state of the effector 
system. A summary of chemical structures that interact with receptors - and 
especially with the complex endorphin subtypes - serves the purpose to 
define how we may consider the physicochemical properties and the 
pharmacokinetics in relation with these targets in the biological system. 
Introduction 
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I-3a Drug-receptor interaction 
The action of a drug may be described In terms of availability, affinity and 
intrinsic activity of the receptor [Ariens et al., 1960, Ariens 1964a, Ariens 
and Simonis 1964b]. 
The availability of a drug at the target is the result of the above described 
pharmacokinetics or drug transference. The aim is to create an optimum 
concentration of active compounds at the receptor site. The receptor 
interaction may be defined in terms of intrinsic activity and affinity. Affinity 
is defined as the tendency of a chemical compound to form a complex with 
the receptor, and the inverse of the dissociation constant can be used as a 
measure for affinity. The intrinsic activity is defined as the contribution to 
the effect per unit of drug-receptor complex (unit is taken as a defined 
fraction of the total amount of receptors) [Van den Brink 1969, 1977; Van 
Ginneken 1977]. An agonist and an antagonist both form a drug-receptor 
complex, but the former will have a high and the latter a low intrinsic 
activity [Goldstein 1974]. 
The search for an opioid receptor resulted in the discovery of a complex of 
different receptors scattered through the entire body. 
I-3b Structural and spatial requirements of chemical compounds 
for opioid receptor binding 
The action of opiates has been explained by specific interaction with a 
receptor called the opiate receptor. The opiates are full agonists of the opiate 
receptor. Naloxone also binds to the opiate receptor, but is an antagonist. 
When morphine is administered in order to relieve pain, then the 
administration of naloxone will annihilate all effects mediated via the opiate 
receptor including analgesia. The presence of opiate receptors in the 
physiological system implies the presence of an endogenous compound(s), 
whose action results from interaction with these specific receptors. 
Exogenous drugs are recognised by endogenous structures or resemble 
endogenous structures in order to take action. 
In 1974-1975 a "morphine-like factor" was Isolated from brain tissue 
[Hughes 1975a]. Further examination demonstrated that two endogenous 
pentapeptides, methionine-enkephalin and leucine-enkephalin, exhibited 
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opioid properties [Hughes et al. 1975b, Hughes et al. 1975c]. Receptor 
binding studies showed that the very same sites that mediate the actions of 
these enkephalines are addressed by the opiates as well. In the normal 
situation, without pain, the opioid receptor system is in rest, and 
administration of naloxone has no effect. The enkephalines are rapidly 
converted by amino- and carboxypeptidase activity, which explains the 
virtual absence of the expected effects. Its vulnerability to enzyme actions 
regulates to a large extent their effect. The intrinsic activity of these 
enkephalines can only be measured in in vitro receptor binding experiments. 
Because of the high degree of selectivity in action and the stereoselectivity of 
enkephalines and opiates it would be reasonable to suggest large structural 
similarities. When the chemical structure of the enkephalines and morphine 
are compared the following similarities are obvious: the presence of the 
tyrosine part and the phenylpiperidine structure (in morphine) closely 
resembling the phenylalanine (in the enkephalines). The smallest naturally 
occurring opioid peptides are leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) and met-
enkephalin (Tyr-Gly-Gly-Phe-Met). Removal of the free amine destroys 
biological activity while methylation (as to simulate morphine) increases 
potency. Removal of the phenolic hydroxyl or of the tyrosine group altogether 
inactivates the pentapeptides. Removal at the carboxy-terminal of the Met or 
Leu residue yields active compounds, but removal of the Phe residue gives 
inactive compounds, although some variation at this point, e.g. saturation or 
ring reduction, preserves its activity. 
Opiates and endorphins (enkephalines are a special class of endorphins: 
peptides containing 5 amino acids) are quite different chemical structures, 
but closer examination of the three-dimensional structure of opiates and 
endorphins using X-ray diffraction [Horn and Rodgers 1976,1977; Smith and 
Griffin 1978J. nuclear magnetic resonance (NMR) [Bleich et al. 1979] and 
high field proton magnetic resonance (PMR) [Jones et al. 1976; Roques et al. 
1976] showed some striking structural similarities [Dirksen and Nijhuis 
1981]. These similarities in three-dimensional structure explain the ability of 
drugs to bind to endogenous structures, opioid receptors, in order to exert 
an effect. 
A three-dimensional model of the opioid receptor was developed by Thorpe 
[Thorpe 1984] to gain knowledge on the activity and structural requirements 
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of opiates and endogenous opioid peptides. This knowledge can be used to 
estimate the activity of new compounds and metabolites. 
The molecular structure of morphine is rigid: it contains well-defined 
intramolecular active sites and therefore must reflect the surface or spatial 
arrangement of at least a portion of the opioid receptor. Its skeleton consists 
oí five rigidly interlocked rings and bears several functional groups at its 
periphery. The pentacyclic structure conforms to a 'T" shape with a 
piperidine ring forming one crossbar and a hydroxylated aromatic ring lying 
in the vertical axis (Fig 1-2). 
In the 1950s the structural characteristics that are shared by all potent 
narcotics and thought to be necessary for opioid activity were: 
- a tertiary positively charged basic nitrogen; 
- a quaternary carbon (C-13 in morphine) separated from the basic 
nitrogen by an ethyl chain (-CH2-CH2-) and attached to a phenyl group; 
- and the presence of a phenolic hydroxyl (positioned on C-3) or a ketone 
group [Braenden et al. 1955; Reynolds and Randall 1957]. 
Morphine contains 5 asymmetric carbon atoms (C5, C6, C9, С13, С14), 
thereby providing the possibility of a large number of isomers and 
enantiomers. The naturally occurring (-)-morphine, which is active and 
rotates the plane of polarized light in the negative direction, possesses a 
centre at C-9 resembling D(-)-Alanine. Its dextrorotatory mirror image, (+)-
morphine, is devoid of analgesic activity [Janssen and Vander Eycken 1968]. 
This high stereo specificity supports the concept of a spatially specific 
receptor that recognises only one mirror image isomer (or enantiomer). 
The amino group: The basic amino group appears to be essential for 
narcotic activity, and substitution at this moiety results in a profound 
alteration in activity. Potent narcotic antagonists emerge when the nitrogen 
methyl is replaced by short chain alkyl groups [Foldes et al. 1964]. The most 
effective chain length is 3 carbons: e.g. allyl (resulting in N-allylnormorphine, 
nalorphine) or cyclopropylmethyl (resulting in N-cyclopropylmethyl-
normorphine). The positively charged nitrogen ion probably acts at a critical 
site of the receptor. Under physiological conditions antagonists bind more 
strongly and are clinically more potent than agonists. The addition of a small 
antagonist subgroup to the amino site yields compounds with mixed agonist-
antagonist properties for the opioid receptor. 
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Figure 1-2 The "T"-shaped molecule of morphine with a piperidine ring 
forming one crossbar and a hydroxylated aromatic ring lying in the 
vertical plane. 
A quaternary carbon: The effect of subst i tut ion at the level of t h e carbon 
skeleton depends strongly on its position. When С14 is hydroxylated or 
brominated, in addition to an antagonist subgroup to the amino site, pure 
antagonism for the opioid receptor is achieved. For C3, s i tuated a t the 
bottom of the T-shape model, subst i tuents appear to promote binding if they 
are hydrophilic in n a t u r e , indicating t h a t t h i s position of t h e molecule 
probably faces a n aqueous environment, far away from the receptor surface. 
The phenolic moiety: Replacing the free hydroxyl group (C3-OH) with a 
methoxy group produces codeine, and this drug h a s a potency more t h a n 
tenfold lower t h a n t h a t of morphine. The C-6 hydroxyl is not necessary for 
activity and actually h a s been shown to hinder binding to the opioid receptor 
(Dextromethorphan lacks the C6 hydroxyl moiety). Subst i tuents here lie in a 
hydrophobic area of the receptor during binding. 
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І-Зс Opioid receptors 
When the opioid receptor was demonstrated biochemically for the first time it 
was assumed that opioid ligands produced their actions through one 
receptor. Today a wide range of biochemical, pharmacological and 
behavioural evidence indicates the presence of at least four opioid binding 
sites: μ-, δ-, к-, and ε-sites [Paterson et al. 1983; Chang 1984; Goodman and 
Pasternak 1984; Stengaard-Pedersen 1989]. 
The μ-binding site exhibits its highest affinity for morphine and related 
alkaloids. The μ-binding sites are found in most regions of the central 
nervous system, being especially dense in cortical, thalamic, hypothalamic 
and brain stem areas. Effects exerted through the μ-binding site include 
analgesia and other classical opioid effects. 
The δ-binding site exhibits its highest affinity for met- and leu-enkephalin. 
Most brain regions contain many δ-binding sites, in particular the basal 
ganglia and the limbic structures. These sites may be involved in the 
regulation of mood and emotions and, in addition, movement, analgesia, 
endocrine functions etc. 
The K-binding site binds ketocyclazocine-like opiates and dynorphin at a 
high affinity. The most selective localisation of κ-binding sites occur in some 
layers of the cerebral cortex, which are thought to play a role in emotional 
processes. Besides analgesia, the κ-ligands also produce ataxic and sedative 
effects. 
The ε-binding site is a possible unique binding site for ß-endorphin but is 
less well characterised than other sites. Actions at all four of these sites can 
be reversed by the opioid antagonist naloxone, with increasing doses being 
required as we go from μ- to δ-binding sites. All of the binding sites will be 
involved in the evolution of binding of endogenous endorphins. Chemically or 
naturally synthesised opioids may bind to these endogenous binding sites. 
In vitro assays (e.g. effect on smooth muscle contractions in the guinea pig 
ileum, mouse vas deferens etc.) and in vivo methods (e.g. effects on 
analgesia, respiratory depression, seizures, food intake etc.) have been 
valuable for determining the dose response effects of agonist and antagonist 
interaction [Holaday and Tortella 1984]. These experiments also support the 
existence of multiple opioid binding sites of the μ-, and δ-types. Moreover, 
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the data indicate that the μ- and δ-binding sites are inter converting sites, 
possibly via interactions between parts of the same macromolecule. 
I-3d Opioid receptor subtypes 
When effects other than CNS-mediated analgesia are considered (miosis, 
ataxia, euphoria, respiratory depression), it becomes evident that the various 
opiates may stimulate several different receptor types. Although there is 
considerable cross-activation, compounds have been synthesised that are 
quite specific for either receptor [Audigier et al. 1980; Foumie-Zaluski et al. 
1981]. Audigier et al. have shown that similar δ - and μ-receptor types are 
found in the CNS and that it is the CNS μ-receptor that is best correlated 
with analgesia. Binding to the δ-receptor can either augment or diminish the 
expression of μ-receptor activity. It is believed that the δ- and μ-receptors 
coexist within the same physical receptor complex and that endogenous 
activation of the μ-receptor can be regulated depending on whether leu-or 
met'enkephalin predominates at the partner δ-receptor [Audigier et al. 
1980]. 
I-3e Peripheral opioid receptors 
Until now the antinociceptive effect of opioids has been related to activation 
of receptors located in the central nervous system. Recently, the existence of 
peripherally distributed receptors has been postulated on the basis of 
experimental animal models [Ferreira and Nakamura 1979]. The existence of 
μ-, к- and δ-receptor subtypes on afferent nociceptive neurons has been 
postulated, but leukocytes and sympathetic nerve terminals may also exhibit 
this property [Stein 1993]. The analgesia following stimulation of these 
receptors is inhibited by naloxone [Stein et al. 1991]. Raja et al. [1992] found 
no evidence for a peripheral opioid-receptor-mediated analgesia in their 
patients undergoing arthroscopic knee surgery under epidural anaesthesia. 
Possible explanations for these conflicting results are that the activation of 
the peripheral opioid receptors depends on the presence of chemical 
mediators of inflammation or that the use of epidural anaesthesia (in 
contrast to general anaesthesia) prevents the activation of peripheral opioid 
receptors dependent on neuroendocrine responses. 
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1-3/ Data on opioid receptor binding of morphine, codeine, heroin 
and 3,6-dinicotinoylmorphine 
Morphine binds to the μ opioid receptor. From the theoretical point of view 
the morphine-6-glucuronide will bind to the μ opioid receptor and can be 
regarded as an active metabolite, while morphine-3-glucuronide, which lacks 
the free C3 hydroxyl group, will be inactive. Shimomura et al. [1971) 
investigated the analgesic effect of morphine glucuronides. They found that 
morphine-6-glucuronide showed an analgesic effect in mice after 
subcutaneous or intracerebral administration but that morphine-
3-glucuronide showed no analgesic effect. In 1973 the biochemical basis of 
the analgesic activity of morphine-6-glucuronide was reported by Yoshimura 
et al. [1973]. Recently there have been reports of the analgesic activity of 
morphine-6-glucuronide after its administration to humans [Osbome et al. 
1988; Hanna et al. 1990, 1991]. After M6G administration no morphine or 
morphine-3-glucuronide was detected in the plasma at any time. Receptor 
binding studies confirmed the binding of morphine-6-glucuronide to the μ 
receptor [Christensen and Jorgensen 1987; Pasternak and Bodnar 1987]. 
Codeine, as stated above, will bind to the μ opioid receptor, but at a lower 
affinity. Its metabolite codeine-6-glucuronide, which retains its phenolic 
moiety, must theoretically be regarded as an active substance. 
Heroin does not displace radio labelled naltrexone and etorphine, suggesting 
that heroin does not bind to the μ opioid receptor. This is in contrast to its 
metabolites, 6-monoacetylmorphine (6MAM) and morphine, which do bind to 
the μ opioid receptor [Inturrisi et al. 1983; Rady et al 1994a]. Rady et al. 
[1994a,b] established that heroin and 6MAM activate supraspinal δ 
receptors, and they documented the occurrence of subtypes of the δ receptor 
and the availability of selective antagonists. When these selective antagonists 
were used it was found that heroin activated supraspinal δι receptors and 
6MAM acted on supraspinal 62 receptors to produce antinociception in 
Swiss-Webster mice [Rady et al. 1994a]. In a different strain of mice, ICR 
mice, intracerebroventricular heroin activates the μ rather than δ receptor in 
the brain. These results indicated that heroin and its metabolites, 6MAM 
and morphine, have different receptor selectivity's that depend on the mouse 
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species used. Evidence is lacking for a δ agonist action of heroin i n h u m a n s 
[Rady et al. 1994b]. 
3,6-dinicotinoylmorphine contains no free hydroxyl group a t t h e C 3 a n d 
does not bind to the μ opioid receptor [Lobbezoo et al. 1982]. I t s a c t i v i t y 
must be explained from the formation of active metabolites: i.e. t h e a i m of 
our study. 
I-3g Tolerance, physical dependence and withdrawal symptoms 
after (long-term) opioid administration 
Opioids are drugs that relieve severe pain, such as per i-operat ive a n d 
chronic pain. Pain intensity is expressed as a VAS-score (Visual A n a l o g u e 
Scale: a (horizontal) line with two extremes indicating "no" or " the w o r s t p a i n 
imaginable"), and pain scores are used to help to adapt dose s c h e m e s s u c h 
as to diminish pain to an acceptable level. In this thesis we are d e a l i n g w i t h 
a single dose administration of an opiate under general a n a e s t h e s i a , w h i c h 
must be distinguished from long-term opiate treatment. We c a n n o t e x c l u d e 
that the chronic administration of opiates in general and of 3,6-dinicotinoyl­
morphine in particular may result in changes in the p h a r m a c o k i n e t i c s a n d 
also in the adaptation of the dynamic biological system. W h e n l o n g - t e r m 
treatment is needed the term tolerance refers to a p h e n o m e n o n i n w h i c h 
exposure to a drug results in the diminishing of an effect a n d t h e r e f o r e t h e 
need for a higher dose to maintain an effect [Jaffe 1985]. T h e p a r t i c u l a r 
effects of opioids to which tolerance develops are analgesia, a n t i d i u r e s i s , 
dysphoria-euphoria, nausea and emesis, hypotension a n d r e s p i r a t o r y 
depression. Unfortunately, it has been proposed that t o l e r a n c e m a y n o t 
develop to some other effects such as constipation; s p a s m of i n t e s t i n a l 
smooth muscle and inhibition of secretion of gonadotrophins. P h y s i c a l 
dependence refers to the potential for an abstinence s y n d r o m e following 
abrupt dose reduction, discontinuation of the drug or a d m i n i s t r a t i o n of a n 
antagonist [Jaffe 1985, 1990]. 
Withdrawal symptoms occur when prolonged opioid treatment is s t o p p e d o r 
diminished. The severity of the withdrawal symptoms (Table 1-2), d e p e n d 
upon many factors, such as the particular drug, the total daily d o s e u s e d , 
the duration of the use and the health and personality of the p a t i e n t / a d d i c t . 
In the case of morphine, heroin, 3,6-dinicotinoylmorphine or μ a g o n i s t s w i t h 
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s i m i l a r duration of action, non purposive symptoms, such as lacrimation, 
r h i n o r r h e a , yawning and sweating, appear about 8-12 hours after the last 
d o s e . After 12-14 hours the effects are tossing and restless sleep. As the 
s y n d r o m e progresses, additional signs and symptoms appear, consisting of 
d i l a t ed pupils, anorexia, gooseflesh, restlessness, irritability and tremors. 
"With morphine and heroin, non purposive symptoms reach their peak at 48 
to 7 2 hour s . At peak intensity, the patient exhibits increasing irritability, 
i n s o m n i a , marked anorexia, violent yawning, severe sneezing, lacrimation, 
coryza , weakness and depression. Nausea and vomiting, intestinal spasm 
a n d diar rhea are pronounced. Heart rate and blood pressure are elevated. 
M a r k e d chilliness, alternating with flushing and excessive sweating is 
c h a r a c t e r i s t i c . Pilomotor activity resulting in waves of gooseflesh is 
p r o m i n e n t and the skin resembles that of a plucked turkey. This feature is 
t h e b a s i s of the expression "cold turkey". Without treatment most of the 
gross ly observable symptoms disappear in 7 to 10 days. 
Never the less , great concern regarding the adaptations of the biological 
s y s t e m does not apply in the case of patients who are terminally ill; here 
op io ids should be given to prevent the reoccurrence of pain, rather than "as 
needed" . 
Table 1-2 
S i g n s a n d symptoms of opioid withdrawal as described in addict populations 
[Portenoy 1994]. 
S i g n s Symptoms 
Hyper tension Pain (abdominal cramps, myalgia, allodynia) 
Tachycard ia Dysphoria (fear, anger) 
T a c h y p n e a Insomnia 
Hyper thermia Drug craving 
D i a r r h e a 
Mydr ias i s 
Rh ino r rhea 
Chi l l s 
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I-3h Properties of morphine metabolites 
Morphine, the most frequently used opioid, is known to bind to the μ 
receptor, and to a lesser extent to the δ and к receptor. The metabolites of 
morphine, morphine-3-glucuronide and morphine-6-glucuronide, possess 
the properties Usted in Table 1-3. 
The original idea was that glucuronide conjugates were inactive waste 
products that were more water-soluble than the parent compound so that 
they could easily be excreted in the urine. Morphìne-6-glucuronide and 
morphine-3-glucuronide were reported to have unexpected lipophilicity 
[Carrupt et al. 1991]. Moreover, the renal clearance value of M3G and M6G 
was similar (100 ml.mür1) and less than that of the parent drug, morphine 
(250 ml.min"1), as reported in this thesis. 
Table 1-3 
Properties of morphine metabolites [Portenoy 1994]. 
Morphine-6-glucuronide Morphine-3-glucuronide 
More potent than morphine Not analgesic 
Unexpected penetration into Unexpected penetration into the CNS 
the CNS No affinity for opioid receptors 
Can cause hyper excitability 
No antagonism of spinal opioid analgesia 
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ТаЫе 1-4 
Physicochemical propert ies a n d receptor activities of 3,6-dinicotinoyl-
morphine and its metabolites [Dirksen et al. 1987]. 
Drug 
DNM 
6MNM 
3MNM 
M 
M3G 
M6G 
mw 
495 
391 
391 
285 
462 
462 
pKa* 
7.45 
7.64 
7.61 
7.93 
2.83t 
3.23+ 
Do/w* 
34.67* 
24.55* 
n.d.a. 
6.23 
n.d.a. 
n.d.a. 
P7.1 
10.70 
5.5 
n.d.a. 
0.80 
n.d.a. 
n.d.a. 
P7.4 
16.34 
8.97 
0.05 
1.42 
n.d.a. 
n.d.a. 
IC50 
0.01 
0.7 
1 
n.d.a. 
n.d.a. 
* data from Nourypharma (Oss, The Netherlands). 
t data from Carrupt et al. [1991]. 
pKa values in water 
Do/w octanol/water distribution ratio 
Ρ lipid solubility at pH 7.1 and 7.4 
IC50 inhibition of *H-Fentanyl binding to whole brain membrane fraction, 
relative to morphine (data from Lobbezoo et al. [1982]) 
n.d.a. no data available 
mw molecular weight 
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1-4 Summary 
The description of drug action involves physicochemical properties, 
pharmacokinetics and a dynamic biological system that adapts to actions of 
the drug and its metabolites. The following aspects were presented: 
1. Physicochemical properties. 
Molecular weight is important if one wants to compare the administration of 
different drugs: to administer the same number of molecules one must weigh 
different amounts (dose equivalence). 
The acid-base constant shows that the ranking in amount of ionisation (at 
physiological blood pH 7.4) is: 3,6-dinicotinoylmorphine > 3,6-diacetyl-
morphine > morphine > codeine. 
There is a marked difference in lipid solubility, and this determines to a large 
extent the passage through the blood-brain barrier, giving rise to higher 
central concentrations for heroin and DNM. The data available on the 
physicochemical properties and receptor activities of 3,6-dinicotinoyl-
morphine and its metabolites are listed In Table 1-4 [Dirksen et al. 1987]. 
2. Pharmacokinetics. 
Fig 1-3 shows the hypothetical pathways of biotransformation of 
3,6-dinicotinoylmorphine, resulting in morphine, and here their common 
pathway starts (also applicable for morphine, codeine, and heroin 
administration). Note that all metabolites should be screened for their 
pharmacological action. 
3 . Receptor interaction. 
The data from receptor interaction studies of opioids are limited at this time. 
There are no standard procedures, and clear definitions of the different 
receptor subtypes are not complete yet. Data on the receptor binding of 
metabolites is limited to some metabolites and rare. Hopefully, in the future 
these data will become available. 
4. Dynamics of the biological system. 
This will result in a different condition of the biological system after drug 
action due to tolerance and perhaps relevant changes in the drugs 
pharmacokinetics. 
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3,6-dlnlcotinoylmorphine 
3,6 dMiicotmc у (пол 
3-mononicotinpylmorphine 
3 mononicotv юуІпоптюгрЫпе 
3-mononicotlnoylmorphine-ö-glucuronide 
3 mononicoHnoylnormorphine^e glucuronlde 
e-monouteqtinoylmorphine 
6 mononicotinoi flnormorphine 
6-mononicotipoyImorphlne-3-glucuronide 
6 mononicotmoylnormorphme-3 ghicuronide 
4
 morphin 
normorphxnè 
morphine-6-^Iucuronide morphine-Bfgluciiroiiide 
normorphine-6 glucworude normorphine 3 glucurontde 
Figure 1-3 Hypothetical p a t h w a y s of b i o t r a n s f o r m a t i o n of 
3.6-dinicotinoylmorphine involving N-demethylation and conjugation 
with glucuronic acid on account of its chemical s t ructure . 
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Chapter Π High Performance Liquid Chromatography 
II-1 Methods for quantitation of opioids in biological 
samples 
II-2 Basic principles of chromatography 
II-3 High performance liquid chromatography of 
3,6-dinicotinoylmorphine and its unconjugated 
metabolites: 3-mononicotinoylmorphine, 6-mono-
nicotinoylmorphine and morphine 
II-4 High performance liquid chromatography of 
morphine and its conjugated metabolites: 
morphine-3-glucuronide and morphine-
6-glucuronide 
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Π-l Methods for quantitation of opioids in biological 
samples 
The advantages and disadvantages of four methods used for the 
determination of opioids will be discussed below. 
1. Radio-immunoassay (RIA) 
Early quantitative measurements of opioids in biological samples were made 
using radio-immunoassay techniques [Berkowitz BA et al. 1975; Spector 
1971], which are based on the occurrence of immunological reactions in 
animals. Briefly, rabbits were immunised with 3-carboxymethyl-morphine-
bovine serum albumin for a period of time and antiserum was subsequently 
collected. The blood samples to be measured were mixed with the antiserum, 
a small fixed amount of radiolabelled morphine-derivative (3H-
hydromorphone), an amount of normal rabbit serum and some buffer, and 
then incubated. After incubation, the proteins were precipitated and washed. 
The final precipitate was counted in a scintillation counter. The reaction is 
based on the displacement of the radioactive substance added by the 
unlabelled molecules of the drug to be measured. Higher concentrations of 
the drug in the sample will replace more radioactive substance, and a lower 
count in the scintillation counter results. A part of each assay includes the 
construction of a standard curve containing known amounts of drug. 
This method has the advantage that administration of the radioactive drug is 
not required and that only small volumes of blood (5-50 μΐ) are needed for 
drug analysis. It is also sensitive: low detection levels can be reached. The 
disadvantage of this kind of method is that the antibody used is not selective 
enough as it will also react with some or all of the metabolites (the method is 
not specific). Incorrect values are obtained when the cross-reactivity is high. 
However, low cross-reactivity does not exclude incorrect values, especially 
when the concentrations of the cross-reacting compounds are high. Quinn et 
al. described an elaborative method to circumvent the problems caused by 
the aspecific antibody. The parent compound is separated from the 
metabolites using extraction procedures. Thereafter, each extracted fraction 
is subjected to a RIA [Quinn et al. 1988]. Although the parent compound is 
separated from its metabolites, no information about the nature and/or the 
quantity of the metabolites is obtained. 
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2. Administration of radiolabelled drug (labelled drug) 
This method is based on the administration of radioactive-labelled drug, and 
therefore it is not suitable for the use in humans. Once administered, the 
drug will be converted into metabolites, of which some or all will be 
radioactive (depending on the site of labelling). However, no distinction 
between the administered drug and the metabolites can be made when the 
amount of radioactivity is measured (this method is not specific). A major 
advantage of this method is its ability to determine the drug's concentration 
in brain and/or other tissues. For example, Lindner et al. [1981) 
administered radioactive 3,6-dinicotinoylmorphine (N 1 4СНз-тогрЫпе-
3,6-dinicotinoyl-ester) to the rat. However, they did use additional separation 
techniques to distinguish the parent compound from its metabolites. They 
needed the radioactive labelling because the normally available UV-detection 
used in combination with the separation technique could not reach the 
expected concentration range of ng.ml"1 in the blood. In using 2 ml blood 
they achieved detection limits of one ppb (parts per billion) for 
3,6-dinicotinoylmorphine, 6-mononicotinoylmorphine and morphine. 
3. Gas chromatography- Mass Spectrometry (GC-MS) 
Gas chromatography is suitable for volatile compounds and heat-stable 
compounds that can enter the gaseous phase upon heating without 
decomposing. When the compounds to be quantified are not volatile, a 
derivatisation step is required. The gas Chromatograph has to be supplied 
with a detector, for example a mass spectrometer for selective ion monitoring 
and sensitivity. Therefore, this method is time-consuming, expensive, 
difficult and operator-dependent. 
4. High performance liquid chromatography (HPLC) 
In contrast to the gas chromatographic method (GC-MS), high perfomance 
liquid chromatography does not need derivatisation reactions but only 
extraction or clean-up procedures. The basic principles of this technique will 
be discussed in the next paragraph. 
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Table Π-1 
Four analytical methods used for the measurement of opioids and their 
advantages and disadvantages. 
Method 
advantages disadvantages 
1. Radio-immunoassay 
sensitive not specific 
no administration of labelled drug 
small volumes of blood 
2. Administration of radiolabelled drug 
not specific 
not suitable for humans 
3. Gas chromatography- Mass Spectrometry 
specific time-consuming 
sensitive operator dependent 
derivatization necessary 
not for thermally labile compounds 
4. High performance liquid chromatography 
specific 
sensitive 
convenient 
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Π-2 Basic principles of liquid chromatography 
Partition chromatography is a general term applied to a wide variety of 
separation techniques based upon the sample partitioning between a moving 
phase, which can be a gas or a liquid, and a stationary phase, which may be 
either a liquid or a solid. When the moving phase is a gas it is called gas 
chromatography, and when the moving phase is a solvent it is called liquid 
chromatography. In an extraction procedure, a compound is distributed 
between two immiscible phases and expressed in the form of a partition 
coefficient. During chromatography this extraction procedure is repeated 
over and over again, i.e. it is a multi-stage extraction procedure. Gas 
chromatography can be carried out when the compound is in a gaseous 
phase. If the compound is not a gas, it must be heated or derivatized to a 
gaseous and heat-stable compound. With respect to drugs, we are dealing 
with compounds in solution so liquid chromatography can be regarded as a 
possibility. 
Liquid chromatography was Initially carried out using a silica-filled column 
(polar) and apolar solvents that passed through this column by the force of 
gravity. When a pigment mixture was placed on top of the column, all of the 
different components of the mixture passed through the column at different 
rates resulting in a separation at the end of the column. The more apolar 
components preferred the solvent over the column material and passed 
through the column quickly; the more polar compounds preferred the 
column material over the solvent and adsorbed to the column to varying 
extents as indicated by their partition coefficient. This technique was called 
straight phase liquid chromatography. However the method proved to be 
unsuitable for biological samples because of their water-soluble nature. 
The term reversed-phase liquid chromatography is used in partition 
chromatography when the mobile phase is more polar than the stationary 
phase. For example, the stationary phase is apolar, e.g. an octadecyl group 
chemically bonded to the inert support (silica), and the mobile phase is 
polar, e.g. water, methanol, and/or acetonitrile. This polar mobile phase 
makes this method useful for biological samples. The elution order is 
generally related to the increasing hydrophobic nature of the compound. In 
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general, this means that the more soluble a compound is in water, the faster 
it will elute. 
High Performance Liquid Chromatography (or High Pressure Liquid 
Chromatography, HPLC) is a form of straight or reversed-phase liquid 
chromatography in which the liquid or mobile phase does not pass the 
column by gravity force but is pumped through the column. The stationary 
phase consists of very small particles (3-8 μπι) that are closely packed into a 
stainless steel column. The small particle size needs forced movement of the 
solvent through the column and a high pressure in the system will result 
(100-300 atm). The composition of the solvent or mobile phase is a powerful 
variable influencing the separation of the various compounds. HPLC is 
especially suitable for those compounds that are thermally labile or non­
volatile (unsuitable for Gas Chromatography). 
We chose to use this HPLC technique to separate 3,6-dinicotinoylmorphine 
and its metabolites. The way a compound can be visualised or detected 
depends upon its physicochemical properties. The most common methods 
used are UV-detection (absorption of light at a specific wave-length) and 
fluorescence detection (absorption of light at a specific wave-length and 
emission of light at a specific wave-length). Methods using HPLC with 
different detection techniques for morphine are described by Tagllaro et al. 
[1989]. We use an electrochemical detector containing two electrodes 
because of its sensitivity and specificity. Between these two electrodes there 
exists a potential difference at which an electrochemically active compound 
can be oxidised or reduced. 
A two-stage analysis was developed: one to measure the relatively apolar 
compounds, 3,6-dinicotinoylmorphine, 6-mononicotinoylmorphine and 
morphine [Koopman-Kimenai et al. 1987b], and a second analysis to 
measure morphine-3-glucuronide, morphine-6-glucuronide and morphine. 
In varying the mobile phase we were able to measure 3,6-dinicotinoyl­
morphine, 6-mononicotinoylmorphine and morphine in one run. However 
this resulted in a long retention time for 3,6-dinicotinoylmorphine, which 
gave rise to peak broadening, resulting in a quantitation limit that was not 
low enough. 3,6-dinicotinoylmorphine is not electrochemically active and can 
be detected by UV-methods. Morphine and 6-mononicotinoylmorphine are 
detected by electrochemical detection, which is far more sensitive than UV-
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detection. Because of the reasons outlined above, we measured 
3,6-dinicotinoylmorphine on a HPLC system using UV-detection. Another 
HPLC system using electrochemical detection was used to measure 
morphine and 6-mononicotinoylmorphine. Apart from being separated from 
all other endogenous and exogenous compounds and metabolites, the 
retention time of 3,6-dinicotinoylmorphine was chosen to be as short as 
possible to reach the lowest possible quantitation limit. Fortunately, this 
could be done in the same samples exposed to the same clean-up procedure. 
Details are described in Section II-3. 
For the more water-soluble metabolites, the HPLC conditions and the clean-
up procedure were quite different. The HPLC method used for morphine and 
its glucuronide conjugates is a modification and improvement of that 
described by Svensson et al. [1982] and Svensson [1986). Morphine and 
morphine-6-glucuronide are electrochemically active; morphine-
3-glucuronide is electrochemically inactive and can be detected by UV-
detection. Details are described in Section II-4. Initially, Aitkenhead et al. 
[1984] reported that morphine-glucuronide was not electrochemically active, 
but they overlooked the existence of two glucuronides, one being 
electrochemically active and one being inactive. 
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Π-3 High performance liquid chromatography of 
3,6-dinicotinoylmorphine and its unconjugated 
metabolites: 3-mononicotinoylmorphine, 
6-mononicotinoylmorphine and morphine 
Published In: J Chromatogr, 416. 382-387, (1987a) 
Drugs 
Morphine, 3-mononicotinoylmorphine (3MNM), 6-mononicotinoylmorphine 
(6MNM) and 3,6-dinicotinoylmorphine (DNM) were obtained from 
Nourypharma (Oss, The Netherlands). 
Reagents and standards 
Acetonitrile for far UV was purchased from Fisons (Betron, Rotterdam, the 
Netherlands). All other chemicals were purchased commercially and were of 
analytical grade. Drug-free human serum was obtained from the Blood Bank 
(St. Radboudziekenhuis, Nijmegen, the Netherlands). 
Stock solutions were made in water. The calibration curves were prepared by 
adding a variable quantity of stock solution to blank serum or blank urine. 
The blood samples were centrifuged at 3000 rpm and the serum was stored 
at -20 °C until analysis. 
Sample preparation 
Serum aliquote (0.5 ml) were extracted with the Baker-10 extraction system 
(Baker Chemicals, cat. nr. 70180, Deventer, The Netherlands) fitted with 1-
ml disposable extraction columns packed with cyanopropylsilane bonded to 
silicagel (Baker Chemicals, cat. nr. 7021-1, Deventer, The Netherlands). The 
extraction column was conditioned with two column volumes of methanol, 
two column volumes of water and 1 ml 500 mM diammoniumsulphate (pH 
9.3). The serum was brought on top of the column, and the column was 
washed with 1 ml 5 mM diammoniumsulphate (pH=9.3). The sample was 
eluted with five 0.5 ml aliquote of chloroform-propanol (90:10). This organic 
phase was evaporated to dryness under a stream of nitrogen at 37 °C. The 
residue was dissolved in 200 μΐ of water. 
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HPLC of3,6-dinicotinoylrnorphine 
For 3,6-dinicotlnoylmorphine measurements, a Spectra-Physics 3500 В high 
performance liquid Chromatograph (Spectra-Physics, Eindhoven, The 
Netherlands) was used, with a Spectroflow variable-wavelength detector 
(Model 773. Rotterdam, The Netherlands) operated at 265 nm. The detector 
was connected to a recorder (BD7, Kipp & Zonen, Delft, The Netherlands). A 
stainless-steel column (150x4.6 mm I.D.) packed with Hypersil 50DS, 
particle size 5 μιη (Chrompack, Middelburg, The Netherlands) was used. A 
guard column (75x2.1 mm I.D.) tap-filled with pellicular reversed-phase 
material (Chrompack) was placed between the sampling valve and the 
analytical column. The injection volume was 50 μΐ. 
The solvent contained water, tetramethylammonium hydroxide (TMAOH) and 
acetonitrile: 7 ml of TMAOH (10% solution in water, Merck, Darmstadt, 
F.R.G.) was adjusted to pH 4.0 with phosphoric acid (total volume 300 ml 
with water), after which 150 ml of acetonitrile were added. The flow-rate was 
1.6 ml.mirr 1 at a pressure of 9.1 MPa. 3,6-Dinicotinoylmorphine had a 
retention time of 2.7 min as shown in Fig II-1. 
HPLC of the 3,6-dinicotinoylmorphine metabolites: morphine, 
3-mononicotinoylmorphine and 6-mononicotinoylmorphine 
A Spectroflow 400 high performance liquid Chromatograph (Kratos, 
Rotterdam, The Netherlands) equipped with an electrochemical detector 
(Model 5100A, ESA, Kratos) was used. The analytical cell (Model 5010, ESA) 
consisted of two units, which could be regulated separately. The potentials of 
detector cell 1 and detector cell 2 were +0.13 V and +0.80 V, respectively. 
Both cells were connected to a two-channel 10 mV recorder (BD 41, Kipp & 
Zonen, Delft, The Netherlands). 
A stainless-steel column (150x4.6 mm I.D.) packed with Hypersil 5 ODS, 
particle size 5 μιτι, was used in combination with a guard column. The 
injection volume was 20 μΐ. The solvent contained 0.5 g of sodium chloride 
dissolved in 350 ml of 0.00IM disodium hydrogen phosphate and 50 ml of 
0.001 M potassium dihydrogen phosphate, and an organic part consisting of 
300 ml of methanol and 100 ml of acetonitrile (pH=7.4). The water and the 
organic part were separately filtered (0.5 цт), then mixed and degassed with 
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a gentle stream of helium. The flow-rate was 1 ml.miir1 at a pressure of ca. 
11.1 MPa. In this case, HPLC-grade water from Fisons (Betron, Rotterdam, 
The Netherlands) was used to minimize the background current. 
All the other reagents were of analytical-reagent grade and were obtained 
from Merck. The chromatographic procedures were carried out at room 
temperature (21 °C). Under these conditions morphine, 6MNM and 3MNM 
had retention times of 3.1, 6.6 and 7.0 min, respectively, as shown in 
Fig II-2 and к' values of 1.2, 3.7 and 4.0, respectively. 
Recovery and reproducibility 
Calibration curves were prepared by adding various amounts of stock 
solution to blank serum. The calibration samples for electrochemical 
detection (morphine and 6MNM) and UV detection (3,6-dinicotinoyl-
morphine) were prepared separately. The calibration graphs were linear for 
morphine in the concentration range 15-300 ng.ml·1 (r = 0.9975), for 6MNM 
and 3MNM in the concentration range 15-300 ng.ml·1 (r = 0.9915 and 
0.9810, respectively) and for 3,6-dinicotinoylmorphine in the concentration 
range 70-800 ng.ml 1 (r = 0.9965). 
After the extraction of patient samples, the sample has a volume of 200 μΐ. 
This enables the simultaneous injection of the same sample on both HPLC 
systems: a 20 μΐ injection volume for electrochemical detection and 50 μΐ for 
UV detection. In this way only 0.5 ml of serum were needed to determine all 
known metabolic concentrations. The detection limit for morphine and 
6MNM is 10 ng.ml-1, for 3MNM 30 ng.ml·1 and for DNM 40 ng.ml-1. 
The recoveries of the extraction procedure for morphine, 6MNM, 3MNM and 
DNM were 87, 96, 91 and 69%, respectively. The reproducibility was ca 5 % 
for the concentration ranges of all compounds mentioned above. 
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DNM 0.005 A 
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Figure II-1 shows chromatograms of DNM in a relatively high 
concentration of 503 ng.ml" I (A) and in a low concentration of 70 ng.ml"1 
(B) in the serum of a patient. The compound is well separated from the 
endogenous compounds present in blank serum. 
The metabolite 3MNM was never detected in the serum of patients. 
eeng/ml 169ng/ml 
M 6MNM 
blank 
τ — ι — ι — ι — ι — ι — ι — ι — ι — ι 
2 4 6 β 10 
ι—Γ 
ο 
- ι — ι — ι — ι — ι — ι — ι — ι — ι 
2 4 6 8 10 min 
Figure Π-2 shows chromatograms of the metabolites 6MNM and M in a 
relatively high (A) and low (B) serum concentration. The compounds are 
well separated from the endogenous compounds present in blank serum. 
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Π-4 High performance liquid chromatography of 
morphine and its conjugated metabolites: 
morphine-3-glucuronide and 
morphine-6-glucuronide 
Drugs 
Morphine (M) was obtained from Nourypharma (Oss, the Netherlands). 
Morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) were 
obtained from Sigma (St Louis, MO, USA). 
Reagents and standards 
Acetonitrile for far UV was purchased from Fisons (Betron, Rotterdam, the 
Netherlands). All other chemicals were purchased commercially and were of 
analytical grade. Drug-free human serum was obtained from the Blood Bank 
(St. Radboudziekenhuis, Nijmegen, the Netherlands). 
Stock solutions were made in water. The calibration curves were prepared by 
adding a variable quantity of stock solution to blank serum or blank urine. 
The blood samples were centrifuged at 3000 rpm and the serum was stored 
at -20 °C until analysis. 
Sample preparation 
Serum aliquote (0.6 ml) were extracted with the Baker-10 extraction system 
(Baker Chemicals, Deventer, the Netherlands) fitted with 1-ml disposable 
cyclohexyl cartridges (СбНб, Baker, cat. nr 7212-01). The extraction column 
was conditioned with two column volumes of methanol, two column volumes 
of water and 1 ml of 500 mM diammoniumsulphate (pH=9.3). The serum (0.6 
ml) was diluted with 0.6 ml 500 mM diammoniumsulphate (pH=9.3) before it 
was brought on top of the extraction column. It was washed with 2 ml of 50 
mM diammoniumsulphate (pH=9.3) after which it was allowed to dry for 15 
seconds. The elution was carried out with 0.5 ml 0.01 M KH2PO4 buffer, 
pH=2.1, containing 11 % acetonitrile. From this elute 50 μΐ was injected on 
the analytical column. 
In the case of urine slight modifications were introduced: 
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In urine the concentrations were much higher, so 100 μΐ urine diluted with 
1 ml 500 mM diammoniumsulphate (pH=9.3) was subjected to extraction, 
after which it was washed with 5 ml 5 mM diammoniumsulphate (pH=9.3); 
the elutlon volume was 1 ml. 
Chromatography 
The HPLC system comprised a Spectroflow 400 solvent delivery system 
(Kratos, Rotterdam, the Netherlands) equipped with a degasser (Separations, 
HI-Ambacht, the Netherlands), a Marathon auto sampler (Separations, HI-
Ambacht, the Netherlands), a Spectroflow 773 UV detector at λ = 210 nm 
(Separations, HI-Ambacht, the Netherlands) in sequence with an ESA 
electrochemical detector (ESA, Kratos, Rotterdam; present: Interscience, 
Breda, the Netherlands) equipped with an analytical cell (Model 5010). All 
compounds leave the UV detector chemically intact, and so the 
electrochemically active components can be oxidised in the electrochemical 
cell. This type of electrochemical cell contains two separate analytical cells, 
which makes it possible to create a small window of applied potential. The 
detector 2 potential was set at 0.4V, while the detector 1 potential was 0.3V. 
This minimises Interfering peaks because only compounds with an oxidation 
potential from 0.3 to 0.4V are recorded. 
Chromatographic separations were achieved using a Cp-Sper C8 column 
(250x4.6 mm) (Chrompack, Bergen op Zoom, the Netherlands). The mobile 
phase was a 0.01 M KH2PO4 buffer, pH=2.1, containing 11 % acetonltrile 
and 0.4 g.l" ! heptane sulfonic acid. At a flow rate of 2 ml.min-1, M3G had a 
retention time of 2.6 min as is shown in Fig II-3. The retention times were 
3.9 min and 4.8 min for M6G and M, respectively, as shown In Fig II-4. 
Recovery and reproducibility 
For the measurement of M3G, M6G, and M, the calibration samples 
contained all three compounds. In serum all calibration graphs (containing 6 
data points) were linear: for M3G the concentrations ranged from 25-580 
ng.ml 1 (r = 0.9992); for M6G from 5-100 ng.ml·1 (r = 0.9982) and for M. 
from 5-90 ng.ml-1 (r = 0.9963). The quantitation limit (defined as three times 
the noise level) is 25 ng.ml 1 for M3G and 5 ng.ml 1 for M6G and M. In this 
concentration range, the intra-day precision was less than 10% for all 
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compounds as listed in Table II-2, and the accuracy was about 5%. The 
inter-day coefficient of variation is listed in Table II-2 
The recovery from the cyclohexyl extraction procedure for M3G, M6G and M 
were 96%, 97%, and 97%, respectively. 
Procedure for the detection qfglucwonid.es 
Deglucuronidation was carried out with ß-glucuronidase type H-2 from Helix 
pomatia (G-0876, Sigma, St Louis, USA). A sample of 100 μΐ was mixed with 
25 μΐ ß-glucuronidase type H-2 and 125 μΐ buffer (0.2 M sodium acetate, 
pH=5.0). The reaction was carried out overnight and was stopped by the 
addition of 800 μΐ 500 mM diammoniumsulphate buffer, pH=9.3, followed 
immediately by the extraction procedure. Both morphine glucuronides are 
commercially available, and calibration samples, with known amount of 
glucuronides, were subjected to this reaction. Under these conditions the 
glucuronides completely disappeared from the chromatogram while there 
was an equimolar increase in morphine concentration. 
Column stabilisation 
Upon installation of a new analytical Cp-Sper Ce column and after 
stabilising it for 1 hour, both detectors gave a baseline signal. After injection 
of a water standard, the UV detector showed that the three compounds 
completely separated, but no signal was obtained at the electrochemical 
detector. After flushing the complete system with the mobile phase for 24 
hours, the two electrochemically active compounds could be seen with the 
electrochemical detector, while the chromatogram at the UV detector was 
exactly the same as the day before. This effect of an ion-pairing reagent was 
also seen by Wright et al. [1994] (using only electrochemical detection), who 
explained it by the effective coating of unendcapped SiOH groups on the 
stationary phase of the column. On the basis of our UV chromatogram we 
concluded that the separation of all three compounds is complete after 1 
hour of stabilisation. At this time no signal could be seen at the 
electrochemical detector, and the only conclusion to be drawn is that while 
the column is stable after lh, the electrochemical cell needs more time to 
stabilise or needs the ion-pairing agent to function adequately. One possible 
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explanation for the delay In electrochemical response is that the reference 
electrode, based on the Нг/Н+ ion couple, needs more time to stabilise. 
Metronidazol (FlagylR), an antiprotozoal agent often used in the hospital and 
dosed in order of grams, gave strong interference. This electrochemically 
active compound has about the same retention time as M6G but upon 
augmentation of the detector 1 potential from the original value of 0.25V to 
0.3V, the metronidazol was completely oxidised at detector 1 with only a 
minor loss in M6G response: ± 2%. 
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Figure Π-3 shows chromatograms of the metabolite M3G (UV detection) 
with a known serum concentration (A) and blank (B). 
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Figure Π-4 shows chromatograms of the metabolites M6G and M (EC 
detection) with a known serum concentration (A) and blank (B). The 
compounds are well-separated from the endogenous compounds present 
in blank serum. 
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Table Π-2 
Intra-day coefficient of variation (%CV) of spiked morphine and its 
metabolites in human serum (n=5, in vitro). 
Compound 
M3G 
M6G 
M 
Concentration 
added 
ng.ml - 1 
574 
306 
158 
203 
108 
56 
159 
85 
44 
Concentration 
measured 
ng.mH 
561 
293 
161 
195 
101 
54 
154 
80 
42 
Precision 
(CV %) 
1.8 
3.1 
1.9 
3.1 
5.0 
3.7 
5.2 
6.3 
4.8 
Accuracy 
(%) 
2.3 
4.2 
1.9 
3.9 
6.5 
3.6 
3.1 
5.9 
4.5 
Inter-day coefficient of variation (%CV) of spiked morphine and its 
metabolites in human serum (n=8, in vitro). 
Compound 
M3G 
M6G 
M 
Concentration 
added 
ng.ml" l 
574 
306 
158 
203 
108 
56 
159 
85 
44 
Concentration 
measured 
ng.ml - 1 
564 
299 
162 
201 
105 
56 
156 
81 
4 3 
Precision 
(CV %) 
2.5 
3.4 
2.2 
3.7 
5.4 
5.4 
4.4 
5.4 
3.9 
Accuracy 
(%) 
1.7 
2.3 
2.5 
1.0 
2.8 
0.0 
1.9 
4.7 
2.3 
M3G: Morphine-3-glucuronide 
M6G: Morphine-6-glucuronide 
M: Morphine 
accuracy: the ability to measure the quantity of the compound being 
determined, 
precision: a method is precise if it yields the same results for a series of 
replicate determinations. 
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Chapter Ш Patients and methods 
III-l Intravenous administration 
III-2 Intramuscular administration 
HI-3 Epidural administration 
III-4 Rectal administration 
III-5 Oral administration 
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Ш-l Intravenous administration 
Published in Eur J Anaesthesiol, 10, 125-132, (1993) 
Published in Drug Invest, 7, 63-73, (1994a) 
Patients 
The present study was carried out in 15 ASA I-II patients (according to the 
classification of the Association of American Anaesthesiologists), aged 25-50 
years, mean 48 ± 9 у (± SD), with normal body weights: 67 ± 10 kg 
(Table III-1). All patients were scheduled to undergo elective abdominal 
surgery. Approval was given by the local Ethics Committee, and informed 
consent obtained from each patient. Excluded were patients with liver or 
kidney disjunction, known allergic reactions, use of opiates or opiate 
antagonists, or an expected blood loss greater than 500 ml during the 
surgical procedure. The demographic data of the patients are listed in 
Table III-1. 
Anaesthesia 
All patients were premedicated orally with diazepam 10 mg Ih before the 
induction of anaesthesia. A cannula i.v. (18G) drip was inserted into a 
suitable arm vein. Monitoring a non-invasive blood pressure consisted of a 
finger plethysmography and ECG was commenced. After epidural puncture 
at the L2-L3 level, a catheter for injection of bupivacaine was introduced. 
Subsequently, an intra-arterial catheter (20G) was inserted into a radial 
artery. A urine catheter was introduced and connected to a reservoir. 
Epidural anaesthesia was given with 0.5% bupivacaine with adrenaline 
including a test dose of 3 ml and a full dose of 11 ml times the body length 
in meters. The level and intensity of the block was tested 5 and 10 min after 
the injection of the full dose. Epidural analgesia was maintained by infusion 
of 0.25% bupivacaine, 4-6 ml.h"1 epidurally. Induction of general 
anaesthesia with thiopentone (3-4 mg.kg"1) was followed by relaxation with 
vecuronium bromide (0.1 mg.kg"1) and placement of an orotracheal tube 
(Xylocain 2% ointment). Maintenance of anaesthesia was obtained with an 
inhalation gas mixture of 67% nitrous oxide in oxygen. Relaxation was 
maintained with vecuronium bromide 1-2 mg i.v. Respiration was controlled 
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at an end tidal CO2 between 4 and 4.5 vol %. Concomitant therapy was 
noted on the medication form. Care was taken to observe the protocol of the 
study that no narcotic analgesic except 3,6-dinicotinoylmorphine was used. 
Patient groups 
Drug: Vilan® (3,6-dinicotinoylmorphine.HCl) was obtained from 
Nourypharma (Oss, the Netherlands). 
I: Five patients received 30 mg Vilan® i.v. 
II: Five patients 20 mg Vilan® i.v. 
Ill: Five patients 10 mg Vilan® i.v. 
The Vilan® injections were given during maintenance of anaesthesia after the 
start of surgery when the patient's condition was stable. 
Sampling 
Blood samples of 5 ml were taken just before and at regular time intervals 
during and after anaesthesia: 1, 2, 3, 4, 5. 6. 7, 8. 10, 15, 20, 30, 45, 60, 90, 
120, 240, 360, 480 min, 12 h and 24 h after the administration of 
3,6-dinicotinoylmorphine. The samples were centrifuged at 3000 rpm and 
the serum was stored at -20 °C until analysis. 
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Table Ш-1 
Demographic data of the patients undergoing intravenous administration of 
30 mg, 20 mg, or 10 mg Vilan®. 
Patient gender age body body ASA dose 
yr length weight class mg 
(cm) (kg) 
VI 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
V9 
VIO 
Vil 
V12 
V13 
V14 
V15 
mean 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
(±SD) 
47 
55 
63 
50 
54 
47 
69 
44 
46 
43 
44 
37 
33 
40 
54 
48 + 9 
162 
154 
163 
174 
157 
167 
162 
155 
164 
170 
158 
167 
155 
172 
161 
163 ±6 
73 ] 
47 ] 
90 ] 
72 ] 
55 ] 
83 ] 
66 
69 
64 
65 
62 
60 
64 
65 
72 
67 ± 10 
30 
30 
I 30 
30 
I 30 
[ 20 
I 20 
20 
[ 20 
[ 20 
[ 10 
[ 10 
[ 10 
[ 10 
[ 10 
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Ш-2 Intramuscular administration 
PubUshed In Eur J Clin Pharmacol, 41, 375-378, (1991a) 
Published In Int J Clin Pharmacol Ther, 10, 125-132, (1995a) 
Patients 
The study was carried out In 8 ASA I-II patients (healthy patients, according 
to the classification of the Association of American Anaestheslologists), aged 
25-48 years, mean 37 ± 9 y (± SD), with normal body weights: 62 ± 6 kg and 
with normal body lengths: 166 ± 6 cm. All patients were scheduled to 
undergo gynaecological elective abdominal surgery. Approval was given by 
the local Ethics Committee and informed consent obtained from each 
patient. Excluded were patients with liver or kidney dysfunction, known 
allergic reactions, use of opiates or opiate antagonists, or an expected blood 
loss greater than 500 ml during the surgical procedure. 
The pat ients received 20 mg 3,6-dinicotinoylmorphine (Vilan) 
intramuscularly in the deltoid muscle (1.5 cm deep). The Vilan injections 
were given during maintenance of anaesthesia after the start of surgery 
when the patient's condition was stable. The demographic data of the 
patients are listed in Table III-2. 
Drugs 
Vilan® was obtained from Nourypharma (Oss, the Netherlands). 
Sampling 
Blood samples of 5 ml were taken just before and at regular time intervals 
during and after anaesthesia: 1, 2, 3, 4, 5, 6, 7, 8, 10, 15, 20, 30, 45. 60, 90, 
120, 240. 360, 480 min. 12 h and 24 h after the administration of 
3,6-dinicotinoylmorphine. The samples were centrifuged at 3000 rpm and 
the serum was stored at -20 °C until analysis. 
Urine samples were taken from the urine catheter in the intervals: 0-0.5h, 
0.5-1.Oh, l-2h, 2-4h, 4-6h. 6-8h, 8-12h, 12-18h, 18-24h, 24-36h and 36-
48h. The total volume was measured and a sample (in duplo) was stored at 
-20 CC until analysis. 
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Table Ш-2 
Demographic data of the patients undergoing intramuscular administration 
of20mgVilan®. 
Patient gender age body body ASA 
yr length weight class 
(cm) (kg) 
Ml F 
M2 F 
МЗ F 
M4 F 
M5 F 
Мб F 
M7 F 
M8 F 
mean (± SD) 
42 
25 
47 
26 
48 
33 
37 
41 
37 ± 9 
163 
163 
175 
163 
156 
170 
171 
164 
166 ± 6 
63 
65 
70 
54 
56 
60 
68 
62 
62 ± 6 
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Ш-3 Epidural administration 
Published In Pharm Weekbl (Sci). 13, 142-147. (1991b) 
Published In Blopharm Drug Disp, 16, 507-520. (1995b) 
Patients 
The present study was carried out in 10 ASA I-III (according to the 
classification of the Association of American Anaesthesiologlsts) patients, 
aged 16-70 years (mean 48 ± 19 y), with normal body weights. All patients 
were scheduled for thoractomy or chest-wall correction. Approval was given 
by the local Ethics Committee, and informed consent obtained from each 
patient. Excluded were patients with liver or kidney disjunction, known 
allergic reactions, use of opiates or opiate antagonists, or an expected blood 
loss greater than 500 ml during the surgical procedure. 
The 3,6-dinicotinoylmorphine injections were given during maintenance of 
anaesthesia after the start of surgery when the patient's condition was 
stable. The demographic data of the patients are listed in Table III-3. Vilan® 
was obtained from Nourypharma (Oss, the Netherlands). 
Anaesthesia 
All patients were premedicated orally with diazepam 10 mg Ih before the 
induction of anaesthesia. A cannula i.v. (18G) drip was inserted into a 
suitable arm vein. Non-invasive monitoring of blood pressure consisted of a 
finger plethysmography and ECG was commenced. Subsequently, an intra­
arterial catheter (20G) was inserted into a radial artery. 
An epidural catheter was inserted at level T3-T4 using the hanging-drop 
technique. A test dose of 3 ml lidocaine 2% was injected. After this test dose 
a 5-10 ml bupivacaine 0.5%, with epinephrine 5 μg.ml"1 was injected, 
depending on the length and weight of the patient and the extension of the 
blockade after the test dose. 
Induction of general anaesthesia with thiopentone (5-7 mg.kg"1) was followed 
by relaxation with pancuronium (0.1 mg.kg-1)· After endotracheal intubation, 
anaesthesia was maintained with a mixture of 67% nitrous oxide in oxygen 
with halothane 0.3% to 0.5% inspired concentration. Relaxation was 
maintained with pancuronium 1-2 mg i.v. Respiration was controlled at an 
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end tidal CO2 between 4 and 4.5 vol %. Concomitant therapy was noted on 
the medication form. No narcotic analgesic except 3,6-dinicotinoylmorphine 
was used. 
Drugs 
Vilan® was obtained from Nourypharma (Oss, the Netherlands). 
Sampling 
Blood samples of 5 ml were taken Just before and at regular time Intervals 
during and after anaesthesia: 1, 2, 3, 4, 5. 6, 7, 8, 10, 15. 20, 30, 45, 60, 90, 
120 and 240 min after the administration of 3,6-dinlcotinoylmorphlne in the 
patients 1-7. In the patients 8-10 the sampling was continued for a longer 
period: 6, 8, 12 and 24 h after the administration of 3,6-dinicotinoyl-
morphine. The samples were centrifuged at 3000 rpm and the serum was 
stored at -20 °C until analysis. 
Table Ш-3 
Demographic data of the patients undergoing epidural administration of 15 
mg Vilan®. 
Patient gender age body body ASA Surgery 
yr length weight class 
(cm) (kg) 
El 
E2 
E3 
E4 
E5 
E6 
E7 
E8 
E9 
E10 
mean 
M 
M 
M 
M 
F 
M 
F 
M 
M 
M 
(±SD) 
70 
63 
66 
59 
53 
50 
26 
51 
23 
16 
48±19 
178 
163 
175 
183 
169 
175 
180 
180 
184 
175 
176±6 
88 
53 
80 
72 
72 
57 
57 
90 
58 
50 
68: 
II Thoractomy lobectomy 
III Thoractomy lobectomy 
III Thoractomy pneumonectomy 
I Thoractomy lobectomy 
II Thoractomy lobectomy 
II Thoractomy lobectomy 
I Chest wall correction 
III Thoractomy lobectomy 
I Chest wall correction 
I Chest wall correction 
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Ш-4 Rectal administration 
Published In Pharm World Sci. 16, 248-253. (1994b) 
Patients 
The study was carried out in 8 healthy patients, ASA class I-II (classification 
of the Association of American Anaesthesiologists), aged 29-63 years, with 
normal body weights. All patients were scheduled to undergo gynaecological 
elective abdominal surgery. The demographic data of the patients are listed 
in Table III-4. Approval was given by the local Ethics Committee, and 
informed consent was obtained from each patient. Excluded were patients 
with liver or kidney dysfunction, known allergic reactions, use of opiates or 
opiate antagonists, or an expected blood loss greater than 500 ml during the 
surgical procedure. 
Anaesthesia 
All patients were premedicated orally with diazepam 10 mg Ih before the 
induction of anaesthesia. An intravenous drip cannula (18G) was inserted 
into a suitable arm vein, non-invasive blood pressure monitoring consisted 
of a finger plethysmography and electrocardiography was commenced. After 
epidural puncture at the L2-L3 level, a catheter for injection of bupivacaine 
was introduced. Subsequently, an intra-arterial catheter (20G) was 
introduced and connected to a reservoir. 
Epidural anaesthesia was effected by 0.5% bupivacaine with epinephrine 
including a test dose of 3 ml and a full dose of 11 ml times the body length 
in meters. The level and intensity of the block was tested 5 and 10 min after 
the injection of the full dose. Epidural analgesia was maintained by infusion 
of 0.25% bupivacaine, 4-6 ml.lv 1 epidurally. Induction of general 
anaesthesia with thiopentone (3-4 mg.kg-1) was followed by relaxation with 
vecuronium bromide (0.1 mg.kg"1) and placement of an orotracheal tube 
(Xylocain 2% ointment). Maintenance of anaesthesia was obtained with an 
inhalation gas mixture of 67% nitrous oxide in oxygen. Relaxation was 
maintained with vecuronium bromide 1-2 mg i.v. Respiration was controlled 
at an end tidal CO2 between 4 and 4.5% (vol/vol). Concomitant therapy was 
noted on the medication form. Care was taken to observe that, according to 
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the protocol of the study, no opioid analgesic except 3,6-dinicotinoyl-
morphine was used. 
The patients received a 30 mg Vilan® suppository, during maintenance of 
anaesthesia after the start of surgery when the patient's condition was 
stable. 
Drugs 
Vilan® suppositories (containing 30 mg 3,6-dinicotinoylmorphine.HCl) were 
obtained from Nourypharma (Oss, the Netherlands). 
Sampling 
Blood samples of 5 ml were taken just before and at regular time intervals 
during and after anaesthesia: 1, 2, 3, 4, 5, 6, 7, 8, 10, 15, 20, 30, 45, 60, 90, 
120, 240, 360, 480 min, 12 h and 24 h after the administration of 
3,6-dinicotinoylmorphine. The samples were centrifuged at 3000 rpm and 
the serum was stored at -20 °C until analysis. 
Urine samples were taken from the urine catheter in the intervals: 0-0.5h, 
0.5-1.Oh. l-2h, 2-4h, 4-6h, 6-8h, 8-12h, 12-18h, 18-24h, 24-36h and 36-
48h. The total volume was measured and a sample (in duplo) was stored at 
-20 °C until analysis. 
Table Ш-4 
Demographic data of the patients undergoing rectal administration of 30 mg 
Vilan®. 
Patient gender age body body ASA 
yr length weight class 
(cm) (kg) 
RI F 
R2 F 
R3 F 
R4 F 
R5 F 
R6 F 
R7 F 
R8 F 
mean (± SD) 
45 
42 
63 
30 
29 
42 
35 
49 
42 ± 11 
160 
165 
175 
165 
165 
161 
176 
175 
168 + 6 
88 
70 
75 
60 
63 
55 
58 
78 
68 ±11 
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Ш-5 Oral administration 
Patients 
The study on oral 3,6-dlnicotlnoylmorphine administration with volunteers 
was forbidden by the CEOM (Hospital ethical commission), but permission 
was given to cany out this study in patients under anaesthesia. Patients, 
selection criteria and the anaesthetic procedures are similar to those 
described in the earlier study on the intravenous administration of 
3,6-dinicotinoylmorphine [Koopman-Kimenai et al. 1994a]. Four patients 
undergoing anaesthesia, received 30 mg Vilan® (3,6-dinicotinoyl­
morphine.HCl) orally. The demographic data of the patients are listed in 
Table III-5. The pulverised 30 mg Vilan® tablet was administered through a 
nasogastric tube directly into the stomach. 
Drugs 
Vilan® tablets were obtained from Nourypharma (Oss, the Netherlands). 
Sampling 
Blood samples were taken Just before and at regular time intervals during 
and after anaesthesia: 1. 2, 3, 4, 5, 6, 7. 8, 10. 15, 20, 30, 45, 60, 90, 120, 
240, 360 and 480 min after the administration of 3,6-dinicotinoylmorphine. 
In the second patient (02), blood samples and two randomly taken gastric 
fluid samples were taken. 
In the patients 0 3 and 0 4 gastric juice samples were drawn at regular time 
intervals of 15 min (e.g. 0-15 min., 15-30 min., etc.). In patient ОЗ. the last 
sample was taken at 3.5 hours after administration. In patient 04, the last 
sample was drawn at 4 hours after administration; this sample was all 
remaining fluid present at that time in the stomach. 
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Table Ш-5 
Demographic data of the patients undergoing oral administration of 30 mg 
Vilan®. 
Patient gender age body body 
yr length weight 
(cm) (kg) 
Ol 
02 
03 
04 
F 
F 
F 
F 
66 
63 
44 
35 
164 
163 
-
163 
52 
60 
-
59 
data were not recorded 
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IV-1 Intravenous administration 
Published In Eur J Anaesthesiol, 10. 125-132, (1993) 
Published In Drug Invest, 7, 63-73, (1994a) 
Pharmacokinetics 
In the original pharmacokinetic calculations, as published In the European 
Journal of Anesthesiology, the area under the serum concentration-time 
curve (AUCo-~) was calculated using the trapezoidal rule (with 
extrapolation). Peak serum concentrations (C
ma
x) and the time at which 
they occurred (t
ma
x) were read from the serum concentration-time curve. The 
elimination half-life (ti/2) values were calculated from the slope of the 
terminal portion of the semilogarithmic serum concentration by linear 
regression analysis. 
All results published in Drug Investigation concerning pharmacokinetic 
calculations were carried out using the computer package MW/Pharm® 
[Proost and Meyer 1992] obtained from Mediware (Groningen, the 
Netherlands). The area under the serum concentration-time curve (AUCo-*,) 
was calculated from the data of the fitted curve (where ti/2 is the half-life 
of elimination of the different phases) and extrapolated to Infinite time. 
Total body clearance (CL) was calculated as Dose/AUCo—. The steady-state 
volume of distribution (V
ss
) was calculated as CL.MRT. The mean residence 
time (MRT) is VS SCL. The Intrinsic MRT of the metabolite is calculated as 
the MRT of the metabolite minus the MRT of its parent. The maximum 
serum concentration C
m a x
 (ng.ml·1) occurs at t
m a
x (h). The coefficient of 
determination (r2) is an estimation of the goodness of the fit. 
The data for the unconjugated compounds, taken from the European 
Journal of Anaestheslology, were recalculated using the computer package 
MW/Pharm® and Usted In Table IV-1A, IV-IB and Г -1С. 
The renal clearance (CLr) of all metabolites present in the urine was 
calculated as excretion rate (mg. min- 1) divided by the serum concentration 
(mg.ml"1) at the midpoint of the urine collection Interval. A different way of 
calculating the overall renal clearance: mg excreted/AUCo— is marked as 
CL/. 
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For intravenous administration the absolute bioavailability is defined as 1.0. 
For each form of administration a relative bioavailability can be defined as 
the AUCo— (active compounds: 6MNM+M+M6G) divided by AUCo— (all 
measured compounds: DNM+6MNM+M+M3G+M6G) and thus resulting in an 
intra administration comparison. 
Statistics 
Ρ values were calculated using Analysis of variance according to standard 
procedures. 
Statistical difference is defined at P<0.05. 
Results 
Fig Г -Іа shows typical serum concentration-time curves of 3,6-dinicotinoyl-
morphine and its metabolites in a patient (V3) after an i.v. dose of 30 mg 
Vilan®. 3,6-dinicotinoylmorphine disappeared rapidly from the serum with a 
half-life of 1.5 min. Ten minutes after injection, the parent compound could 
no longer be detected. The metabolite 6-mononicotinoylmorphine appeared 
instantaneously in the serum with concentrations similar to the parent drug 
and shows a biphasic plasma elimination curve with a final elimination 
half-life of 9 min. The metabolite 3-mononicotinoylmorphine could not be 
detected in the serum. Morphine was present in the first serum sample, and 
was eliminated with a half-life of 150 min. Also the morphine conjugates 
were present the first serum sample. The morphine glucuronides are the 
most abundant metabolites and their serum concentration-time curves tend 
to run parallel to that of morphine. The expected metabolite 
e-mononicotinoylmorphine-3-glucuTonide could be detected neither in 
serum nor in urine. 
Fig rV-lb and Fig Г -Іс show typical serum concentration-time curves of 
3,6-dinicotinoylmorphine and its metabolites in two patients after an i.v. 
dose of 20 mg (patient V7) and 10 mg (patient VI3) Vilan®, respectively. 
Table IV-ID summarizes the mean pharmacokinetic parameters of 
3,6-dinicotinoylmorphine, 6-MNM, morphine and its two glucuronide 
conjugates in the patients at the three different dose levels. The area under 
the serum concentration-time curve was linearly related to the dose with 
high correlation coefficients e.g. r(DNM)= 0.9605; r(6MNM)= 0.9711; r(M)= 
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0.9285; r(M3G)= 0.9900 and r(M6G)= 0.9871 fTable IV-IE). The Cmax is dose 
dependent for all metabolites: the higher the dose, the higher the Cmax.· 
Only the terminal elimination half-life for morphine was dose dependent, 
but this was not observed for its two metabolites M3G and M6G. These two 
had about the same terminal elimination half-life. The renal clearance of 
both glucuronides is less than that of morphine: the mean is 115 ml.min-1 
for the glucuronides and 200 ml.mür1 for morphine. 
A fraction of the administered dose, about 59% (23.3-78.0%), was recovered 
in the urine (Table IV-ID). Also the distribution of the total amount 
recovered over the three different compounds is shown in Table Г -ID: 44% 
is found as M3G, 5.7% as M6G and 9.9% as morphine. 
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Table IV- IA 
Pharmacokinetic parameters of 3,6-dinicotlnoylmorphlne and its metabolites 
after an i.v. dose of 30 mg Vilan®. 
patient 
parameter 
VI 
3,6-dinicotinoylmoiphine 
AUCo— 
AUCo— 
CL 
Vss 
t l/2 
MRT 
г2 
^g.h.H) 
(μΜ.η.Ι"1) 
(l.h-1) 
0) 
(h) 
(h) 
3 5 
0.07 
8 6 7 
27 
0.022 
0.031 
1.0000 
6-mononicotinoylmorphine 
Cmax 
tmax 
AUCo— 
AUCo— 
t(Dl/2 
t(2)i/2 
MRT 
MRTmt 
r2 
(ng.ml-1) 
(h) 
fcg.h.H) 
(μΜ.η.1-1) 
(h) 
(h) 
(h) 
(h) 
morphine 
Cmax 
tmax 
AUCo— 
AUCo— 
t(Dl/2 
t(2)i/2 
t(3)i/2 
MRT 
MRTmt 
r2 
CLr 
(ng.ml"1) 
(h) 
fcg.h.H) 
(μΜ.Ιι.Ι-1) 
(h) 
(h) 
(h) 
(h) 
(h) 
(ml.min"1) 
% in urine 
2 8 7 
0.027 
39 
0.10 
0.02 
0.24 
0.25 
0.22 
0.9990 
79.7 
0.22 
2 5 6 
0.90 
0.003 
0.655 
3.08 
3.81 
3.56 
0.9944 
-
-
V2 
6 3 
0.13 
4 7 4 
2 3 
0.033 
0.048 
0.9268 
118 
0.051 
29 
0.07 
0.06 
0.24 
0.29 
0.24 
0.9972 
139.5 
-
267 
0.94 
0.079 
0.360 
3.50 
4.27 
3.98 
0.9875 
8 2 
6.9 
V3 
69 
0.14 
432 
15 
0.024 
0.035 
0.9465 
2 2 4 3 
0.007 
84 
0.21 
0.02 
0.14 
0.09 
0.06 
0.9817 
271.1 
0.030 
201 
0.71 
0.005 
0.253 
2.47 
3.34 
3.25 
0.9951 
178 
11.6 
V4 
75 
0.15 
401 
2 2 
0.039 
0.056 
0.8931 
5 2 5 
0.020 
7 3 
0.19 
0.04 
0.48 
0.42 
0.36 
0.9876 
207.4 
0.036 
3 0 6 
1.07 
0.086 
0.087 
3.09 
4 .13 
3.71 
0.9959 
107 
9 . 3 
V5 
47 
0.09 
637 
2 4 
0.026 
0.038 
0.9846 
158 
0.023 
2 4 
0.06 
0.02 
0.17 
0.22 
0.19 
0.9909 
66.5 
0.31 
2 6 9 
0.94 
0.001 
0.165 
3.18 
4.48 
4.26 
0.9737 
118 
12.8 
mean±SD 
58±16 
0.12±0.03 
562±193 
22±4 
0.029±0.007 
0.042±0.010 
666±896 
0.02610.016 
50±27 
0.13±0.07 
0.03±0.02 
0.26±0.13 
0.26±0.12 
0.2110.11 
153187 
0.1210.14 
260138 
0.9110.13 
0.03510.044 
0.3010.22 
3.0610.37 
4.0110.44 
3.7510.39 
126180 
10.212.6 
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morpbJne-3-glucuronide 
Cmax (ng-rnl-1) 
tmax (h) 
AUCo— (Hg.h.l"1) 
AUCo— (μΜ.η.Γ1) 
raüo AUC(M3G/M) 
t( D i / 2 (h) 
t(2)i/2 (h) 
MRT (h) 
MRTint (h) 
г2 
CLr (rnl-mln-1) 
% in urine 
302 
1.08 
2021 
4.37 
4.9 
0.136 
2.10 
4.96 
1.15 
0.9992 
-
-
morphine-6-g lucuronide 
Cmax (ng.ml-1) 
tmax (h) 
A U C o - (ug.h.H) 
AUCo— QiM.h.l-l) 
raüo AUC(M6G/M) 
t ( l ) i / 2 (h) 
t(2)i/2 (h) 
MRT (h) 
MRTrnt (h) 
Γ
2 
CLr (ml-min-1) 
% In urine 
raüo AUC(M3G/M6G) 
41 .7 
1.42 
260 
0.56 
0.6 
0.232 
2 .76 
4 .98 
1.17 
0.9978 
-
-
7.8 
5 3 4 
0 .86 
4 4 2 6 
9 .58 
10.2 
0 .309 
5.39 
7.96 
3 .69 
0.9922 
4 3 
3 9 . 8 
6 9 . 5 
0 .90 
4 7 3 
1.02 
1.1 
0 .345 
4 .96 
7 .23 
2 .96 
0.9936 
76 
7.7 
9 .4 
2 6 3 
1.11 
1994 
4 .32 
6.1 
0 .122 
2 .38 
5 .57 
2 .23 
0.9987 
6 5 
25 .9 
39 .9 
1.33 
2 8 8 
0.62 
0.9 
0 .434 
4 .27 
6 .64 
3 .30 
0.9978 
8 5 
4 .9 
7.0 
AUCo— t o t a l (DNM+6MNM+M+M3G+M6G) 
6.00 
AUCo— a c t i v e c o m p o u n d s 
1.56 
Relat ive bioavai labi l i ty 
11.74 6 .00 
(6MNM+M+M6G) 
2 . 0 3 1.54 
325 
0 .67 
1849 
4 .00 
3.7 
0 .099 
2.11 
4 .57 
0 .44 
0.9970 
103 
59 .5 
41.2 
1.00 
212 
0.46 
0.4 
0.021 
1.57 
3.88 
0.25t 
0.9981 
150 
9.2 
8.7 
5.87 
1.72 
3 1 0 
0 .89 
3 3 7 0 
7 .29 
7.8 
0 .142 
6.90 
10.2 
5 .72 
0.9945 
4 0 
2 4 . 5 
4 5 . 8 
1.24 
507 
1.10 
1.2 
0 .287 
6 .90 
10.4 
5 .89 
0.9873 
4 6 
4 . 3 
6 .6 
9 .48 
2 .10 
3471107 
0 .92±0.18 
273211130 
5 .91±2.45 
6.5±2.5 
0 .16±0.08 
3 .78±2.23 
6 .65±2.38 
2 .6412 .11 
56±32 
37 .4116 .3 
48±12 
1.18±0.22 
348±133 
0 .7510 .29 
0 .810 .3 
0 .2610 .15 
4 .0912 .05 
6 .6212 .48 
3 .3311 .95 
78153 
6 .512 .3 
7 .911.2 
7 .8212.67 
1.7910.26 
0 .23 
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legend table IV-IA 
Сщах = maximum serum concentration 
tmax = time at which C
max
 occurs 
AUCo-» = Area under the serum concentration time curve expressed in 
mg.h.l·1 огцМ.Ь.І"1 
CL = total body clearance (parent compound) 
Vss = steady state volume (parent compound) 
ti/2 = half-life of elimination of the different phases 
MRT = mean residence time = VSS.CL (parent compound) 
The intrinsic MRT (MRT
 i n t) of the metabolite is calculated as the MRT of 
the metabolite minus the MRT of its direct parent 
r
2
 = coefficient of determination of the fitted curve 
ratio AUC(M3G/M) = AUCo— M3G /AUCo— M (in цМ.Ь.Н) 
ratio AUC(M6G/M) = AUCo— M6G /AUC0.» M (in цМ.Ь.Н) 
CLr = renal clearance calculated as excretion rate (mg.min'1) divided by the 
serum concentration (mg.ml"1) at the midst of the urine collection 
interval 
CLj." = mg excreted/AUCo— 
% in urine = total amount recovered in the urine as percentage of the dose 
of the administered compound (% molar) 
- = no urine samples available 
t = not included 
Relative bioavailability = the ratio of AUCo-» (of active metabolites: 
6MNM+M+M6G) and AUCo-~ (of all measured compounds: 
DNM+6MNM+M+M3G+M6G) 
lag time = time after which the compound appears in the serum 
tl/2abs = absorption half-life 
** = was at the top of the curve at about 4 h. 
ratio AUC = AUCo-4 (M3G)/AUCo-4(M) and AUCo-4 (M6G)/AUC0-4(M) resp. 
calculated in цМ.Ь.І"1. 
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100 
plasma cone, ug/ml " 
renal хсг. rate ug/mln 
0.01 
0.001 
Figure IV-la 
The serum concentration-time curves and the renal excretion-time 
profiles of 3,6-dinicotinoylmorphine (DNM) and its metabolites 
6-mononicotlnoylmorphine (6MNM), morphine (M). morphine-
3-glucuronide (M3G) and morphine-6-glucuronide (M6G) in a patient 
after an i.v. dose of 30 mg Vilan®. 
Table IV- IB 
Pharmacokinetic parameters of 3,6-dlnicotmoylmorphine and its metabolites 
after an i.v. dose of 2 0 m g Vilan®. 
patient V6 V7 V8 V9 VIO meaniSD 
parameter 
3,e-dinlcotinoylmorphliie 
AUCo-oo 
AUC 0 — 
CL 
Vss 
t l/2 
MRT 
г2 
^g-h.]-1) 
(μΜ.η.Ι"1) 
α-h-1) 
Ю 
(h) 
(h) 
3 3 
0.07 
6 0 4 
2 0 
0 .022 
0 .032 
0.9519 
6-mononicotinoylmorphini 
Cmax 
tmax 
AUCo— 
AUCo— 
t(Dl/2 
t(2)i/2 
MRT 
MRTint 
r2 
(ng-rnl-1) 
(h) 
fcg.h.l1) 
(μΜ.η.Ι"1) 
(h) 
(h) 
(h) 
(h) 
morphine 
Cmax 
tmax 
AUCo— 
AUCo— 
t(Dl/2 
t(2)i/2 
t(3)i/2 
MRT 
MRTmt 
Г
2 
GW 
(ng.ml-l) 
(h) 
Ûig.h.1-1) 
(μΜ.η.Ι-!) 
(h) 
(h) 
(h) 
(h) 
(h) 
(ml.min"1) 
% in urine 
3 6 8 
0.0071 
2 9 
0.07 
0 .026 
0.24 
0.20 
0.17 
0.9876 
127 
0 .006 
137 
0.48 
0 .012 
0 .062 
1.88 
2.66 
2.46 
0.9824 
3 2 2 
10.4 
3 0 
0.06 
661 
7 6 
o.oeot 
0.115 
0.9027 
e 
3 9 4 
0.0051 
2 6 
0.07 
0.022 
0.18 
0.15 
0.04 
0.9902 
115 
0.011 
8 4 
0.29 
0.006 
0.084 
1.66 
2.26 
2.11 
0.9954 
-
-
46 
0.09 
436 
11 
0.018 
0.026 
0.9813 
470 
0.0054 
32 
0.08 
0.022 
0.16 
0.14 
0.12 
0.9979 
102 
0.022 
146 
0.51 
0.008 
0.180 
2.42 
3.22 
3.08 
0.9891 
159 
8.1 
3 2 
0.06 
6 3 2 
2 0 
0.022 
0.031 
0.9855 
4 4 6 
0.0058 
31 
0.08 
0 .020 
0.19 
0.17 
0.14 
0.9823 
8 6 
0.019 
9 4 
0.33 
0 .035 
0.142 
1.93 
2.58 
2.41 
0.9936 
-
1.2 
17 
0.03 
1210 
16 
0.009 
0.013 
1.0000 
6 2 6 
0.0047 
2 4 
0.06 
0.011 
0.11 
0.10 
0.09 
0.9772 
5 6 6 
0.017 
6 4 5 t 
2.26t 
0.00 i t 
0.706 
-
-
-
0.9779 
-
-
32±10 
0.06±0.02 
709±294 
29±27 
0.018±0.006 
0.043±0.041 
4611101 
0.006±0.001 
2 8 ± 3 
0.07±0.01 
0.020±0.006 
0.17±0.05 
0.15±0.04 
0.11 ±0.05 
1991206 
0.01510.006 
115131 
0.4010.11 
0.01510.014 
0.2310.27 
1.9710.32 
2.6810.40 
2.5210.41 
2 2 4 1 1 1 7 
6.614.8 
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morphine-3-gIucuronide 
Cmax (ng.ml1) 
tmax (h) 
AUCo— (ug.h.1-1) 
AUCo— (uM.h.l"l) 
raüoAUC(M3G/M) 
t ( l ) i /2 (h) 
t(2)i/2 (h) 
MRT (h) 
MRTint th) 
r2 
CLr (ml.min1) 
% in urine 
190 
0 .53 
1597 
3 .46 
7.2 
0 .141 
5.77 
8.47 
5.81 
0.9970 
169 
54 .5 
morphine-e -g lucuTonide 
Cmax (ng-ml"1) 
tmax (h) 
AUCo— (μ&η.Η) 
AUCo— (μΜ.η.1-1) 
ratio AUC(M6G/M) 
t( l) i/2 (h) 
t(2)i/2 (h) 
MRT (h) 
MRTint (h) 
r
2 
CLr (ml.min-*) 
% I n u l i n e 
raüo AUC(M3G/M6G) 
28 .7 
0.84 
162 
0.35 
0.7 
0 .217 
3 .44 
5.29 
2 .63 
0.9766 
228 
5.2 
9 .9 
162 
0 .56 
3 9 7 7 t 
8 . 6 l t 
-
0 .103 
7.06 
24 .75 t 
22 .49 t 
0.9943 
-
-
28 .6 
1.13 
188 
0 .41 
1.4 
0 .074 
3.70 
5 .77 
3 .51 
0.9934 
-
-
6.2 
2 9 7 
0 .67 
6 3 5 4 t 
13 .75t 
-
0 .168 
5 .00 
2 1 . 8 0 t 
18 .58 t 
0.9956 
6 6 
4 2 . 8 
38 .0 
0 .98 
2 0 0 
0 .43 
0 .8 
0 .378 
3 .34 
5 .05 
1.83 
0.9975 
9 2 
3 .9 
17.2 t 
AUCo— t o t a l (DNM+6MNM+M+M3G+M6G) 
4 .43 
AUCo— a c t i v e c o m p o u n d s 
0.90 
Relat ive bioavai labi l i ty 
-
-
(6MNM+M+M6G) 
0.77 1.02 
3 3 0 
0 .47 
1660 
3.59 
10.9 
0 .064 
2 .14 
4.12 
1.54 
0.9853 
-
22 .1 
3 9 . 6 
0 .63 
161 
0 .35 
1.1 
0 .188 
2 .55 
3 .90 
1.32 
0.9864 
-
-
3 .3 
4 .41 
0.76 
232 
2 .12 
2016 
4 .36 
-
0 .024 
3.92 
6 .68 
-
0.9811 
-
-
41 .9 
1.89 
301 
0 .65 
-
0 .012 
3 .41 
5.84 
0.9784 
-
-
-
-
242±71 
0 .87±0.70 
1758±226 
3 .81±0.49 
9 .1±2.6 
0 .10±0.06 
4 .78±1 .87 
6 .42±2.19 
3 .7±3.0 
107160 
39 .8±16 .4 
35±6 
1.0910.48 
2 0 2 1 5 8 
0 .4410 .13 
1.010.3 
0 .1710 .14 
3 . 2 9 Ю . 4 3 
5 . 1 7 Ю . 7 8 
2 .3210.96 
160188 
4 .610.9 
6 .513.3 
4 . 4 2 Ю . 0 1 
0 . 8 6 Ю . 1 2 
0.20 
for legends see table IV- IA 
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"3 plasma cone, ug/ml 
0.01 
0.001 
о τ 
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Τ 3 τ 
4 
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t,B2.6h 
π — ' 6h 
Figure IV- lb 
The serum concentration-time curves of 3,6-dinicotinoylmorphine (DNM) 
and its metabolites 6MNM. M. M3G and M6G in a patient after an i.V. 
dose of 20 mg Vilan®. 
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0.001 
0.01 
Figure IV- l e 
The serum concentration-time curves of 3.6-dlnlcotlnoylmorphlne (DNM) 
and its metabolites 6MNM, M. M3G and M6G in a patient after an i.v. 
dose of 10 mg Vilan®. 
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Table IV-IC 
Pharmacokinetic parameters of 3,6-dinicotinoylmorphlne and its metabolites 
after an i.v. dose of 10 mg Vilan®. 
patient VII V12 V13 V14 V15 mean±SD 
parameter 
3,6-dinicotinoylmoipbine 
AUCo— 
AUCo— 
CL 
Vss 
t l/2 
MRT 
Γ
2 
(Hg.h.H) 
OiM.h.l-1) 
(l.h-1) 
(1) 
(h) 
(h) 
15 
0.03 
6 5 9 
4 3 
0.045 
0.065 
0.8936 
2 4 
0.05 
4 1 2 
14 
0.024 
0.034 
0.8473 
6-mononicotinoylmorpbJne 
Сщах 
tmax 
AUCo— 
AUCo— 
t(Dl/2 
t ( 2 ) 1 / 2 
MRT 
MRTint 
Г
2 
(ng.ml-1) 
(h) 
Oig.h.l-l) 
(цМ.Ь.І"1) 
(h) 
(h) 
(h) 
Ih) 
morphine 
Cmax 
tmax 
AUCo— 
AUCo— 
t(Dl/2 
t(2)i/2 
t(3)i/2 
MRT 
MRTint 
r
2 
CLr 
(ng.ml-1) 
(h) 
kg.h.l-l) 
(μΜ.Ιι.Η) 
(h) 
(h) 
(h) 
(h) 
(h) 
(ml. min - 1) 
% in urine 
119 
0.022 
29 
0.07 
0.044 
0.35 
0.40 
0.34 
0.9595 
2 8 
0.090 
58 
0.20 
0.024 
0.151 
1.66 
2.41 
2.01 
0.9268 
14 
6.9 
309 
0.004 
12 
0.03 
0.011 
0.10 
0.09 
0.05 
0.9891 
31 
0 .026 
3 9 
0.14 
0.120 
0.465 
1.07 
1.40 
1.31 
0.9844 
271 
12.1 
4 3 
0.09 
2 3 2 
13 
0.040 
0.058 
0.9254 
561 
0.011 
27 
0.07 
0.017 
0.23 
0.18 
0.12 
0.9834 
53 
0.047 
37 
0.13 
0.020 
0.128 
0.69 
0.97 
0.79 
0.9512 
328 
14.0 
14 
0.03 
701 
3 8 
0.037 
0.054 
0.8246 
2 3 7 
0.007 
14 
0.04 
0.013 
0.18 
0.19 
0.14 
0.9846 
2 8 
0.163 
4 9 
0.17 
0.006 
0.028 
1.05 
1.60 
1.41 
0.9181 
-
9.9 
21 
0.04 
4 5 6 
2 7 
0.040 
0.058 
0.9682 
2 2 6 
0.006 
12 
0.03 
0.014 
0.25 
0.23 
0.17 
0.9866 
3 4 
0.205 
4 9 
0.17 
0 .004 
0.370 
1.59 
1.72 
1.50 
0.9017 
131 
15.4 
23±12 
0.05±0.02 
492±192 
27±14 
0.037±0.008 
0.054±0.012 
290±166 
0.010±0.007 
19±8 
0.05±0.02 
0.020±0.014 
0.22±0.09 
0.2210.12 
0.16±0.12 
35±10 
0.11 ±0.08 
46±9 
0.16±0.03 
0.035±0.048 
0.23±0.18 
1.21±0.41 
1.6210.53 
1.40±0.44 
251±239 
11.713.4 
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morpbine-3-glucuroiiide 
Cmax (ng.ml1) 
tmax И 
AUCo— (μ&η.Η) 
AUCo— (цм.ьл-1) 
raUo AUC(M3G/M) 
t(l)i/2 (h) 
t(2)i/2 lh) 
MRT (h) 
MRTint (h) 
r2 
CLr (mlmùr1) 
% In urine 
126 
1.06 
839 
1.82 
9.1 
0.179 
2.42 
5.35 
2.94 
0.9975 
178 
65.7 
тогрЫпе-в-glucuronide 
Cmax (ng-ml-1) 
tmax (h) 
AUCo— öig-h.l·1) 
AUCo-» (μΜ.η.Ι"1) 
ratio AUC(M6G/M) 
t(l)i/2 (h) 
t(2)i/2 (h) 
MRT (h) 
MRTint (h) 
r2 
CLr (ml.min-1) 
% in urine 
raüo AUC(M3G/M6G) 
2 1 
1.17 
118 
0.26 
1.3 
0.290 
3.51 
5.60 
3.19 
0.9967 
133 
5.4 
7.0 
9 3 
0.63 
536 
1.16 
8.3 
0.005 
3.52 
5.28 
3.88 
0.9883 
221 
41.5 
16 
0.98 
81 
0.18 
1.3 
0.280 
3.12 
4.84 
3.44 
0.9962 
123 
3.6 
6.4 
112 
0.47 
596 
1.29 
9.9 
0.204 
3.46 
5.12 
4.15 
0.9960 
9 8 
35.9 
17 
0.85 
87 
0.19 
1.5 
0.371 
3.72 
5.26 
4.29 
0.9832 
135 
6 .5 
6 .8 
AUCo-« total (DNM+6MNM+M+M3G+M6G) 
2.38 1.56 1.77 
AUCo-« active compounds (6MNM+M+M6G) 
0.53 
Relative bioavailability 
0.35 0.39 
120 
0.60 
8 1 7 
1.77 
10.4 
0.096 
4.34 
6.46 
4.86 
0.9942 
-
57.2 
17 
0.99 
118 
0.26 
1.5 
0.093 
3.82 
5.99 
4.39 
0.9990 
-
5.1 
6 .8 
2.27 
0.47 
8 3 
1.32 
6 9 9 
1.51 
8.9 
0.097 
4.41 
6.96 
5.24 
0.9956 
125 
55.2 
13 
1.27 
9 3 
0.20 
1.2 
0.071 
3.82 
6.13 
4.41 
0.9953 
139 
6.5 
7.6 
1.95 
0.40 
107±18 
0.82±0.34 
697±133 
1.51±0.29 
9.3±0.8 
0.12±0.08 
3.6310.81 
5.83±0.82 
4.21±0.90 
158±98 
51.1±12.1 
17±3 
1.05±0.17 
99±18 
0.21Ю.04 
1.4±0.1 
0.22±0.13 
3.60±0.30 
5.56±0.53 
3.9410.58 
133±56 
5.411.2 
6.910.4 
1.98Ю.34 
0.42Ю.07 
0.21 
for legends see table IV-1 A. 
Results 
Table IV-ID 
Summary of the mean pharmacokinetic parameters of the 
morphine and its metabolites present in serum and urine 
the three different doses. 
3,6-dinicotinoyl-
subdivided over 
dose 
3,6-dJnicotinoylmorphine 
AUCo-o, 
AUCo— 
CL 
Vss 
t l/2 
MRT 
Ιμ&η.Η) 
(μΜ.η.Ι"1) 
a.h-i) 
0) 
(h) 
(h) 
6-mononicotlnoylmorphüie 
Сщах 
tm£ix 
AUCo-» 
A U C o -
t(Dl/2 
t(2)i/2 
MRT 
MRT int 
morphine 
Cmax 
tmax 
AUCo— 
AUCo— 
t(Dl/2 
t(2)i/2 
t(3)i/2 
MRT 
CLr* 
CLr 
% in urine 
(ng.ml-1) 
(h) 
(Hg.h.l-1) 
(μΜ.η.Ι"1) 
(h) 
(h) 
И 
(h) 
(ng.ml-1) 
(h) 
{μ&η.1-1) 
(μΜ.η.Η) 
(h) 
th) 
(h) 
(h) 
(ml.min-1) 
(ml.mür1) 
30 mg (n=5) 
58±16 
0.12±0.03 
0.56±0.20 
0.022±0.004 
0.029±0.007 
0.042±0.010 
666±896 
0.026±0.016 
50±27 
0.13±0.07 
0.030±0.018 
0.26±0.13 
0.26±0.12 
0.21±0.11 
153±87 
0.12±0.14 
260138 
0.91±0.13 
0.035±0.044 
0.30Ю.22 
3.06±0.37* 
4.0110.44 
125147 
126180 
10.212.6 
20 mg (n=5) 
32110 
0.06Ю.02 
0.71Ю.29 
0.02910.027 
0.018Ю.006 
0.043Ю.041 
4611101 
0.00610.001 
2813 
0.07Ю.01 
0.020Ю.006 
0.1710.05 
0.1510.04 
0.1110.05 
1991206 
0.01510.006 
115131 
0.4010.11 
0.01510.014 
0.23Ю.27 
1.9710.32* 
2.6810.40 
138192 
2241117 
6.614.8 
10 mg (n=5) 
23112 
0.0510.02 
0.4910.19 
0.02710.014 
0.03710.008 
0.05410.012 
2901166 
0.01010.007 
1918 
0.05Ю.02 
0.020Ю.014 
0.2210.09 
0.2210.12 
0.16Ю.11 
35110 
0.1110.08 
4619 
0.1610.03 
0.03510.048 
0.23Ю.18 
1.21Ю.41* 
1.6210.53 
254198 
2511239 
11.713.4 
80 Chapter Г 
morphine-3-glucuronide 
Cmax (ng.ml"1) 
tmax (h) 
AUCo-~ (iig.h.l"1) 
AUCo-. (uM.h.l"1) 
ratio AUC(M3G/M) 
t(Di/2 (h) 
t(2)i/2 (h) 
MRT (h) 
MRT mt (h) 
CLf* 
CLr 
% in urine 
(ml.min"1) 
(ml.min"1) 
morphliie-6-glucuTonide 
Cmax (ng-ml1) 
tmax (h) 
AUCo- fcg.h.l"1) 
AUCo-o. (ЦМ.ЬЛ"1) 
raüo AUC(M6G/M) 
t(l)l/2 (h) 
t(2)i/2 (h) 
MRT (h) 
MRT mt (h) 
CLr* 
CLr 
% in urine 
(ml.min"1) 
(ml.min"1) 
ratio AUC(M3G/M6G) 
347±107 
0.92±0.18 
2732±1130 
5.91±2.45 
6.5±2.5 
0.16±0.08 
3.78±2.23* 
6.65±2.38 
2.64±2.11 
45±13 
56±32 
37.4±16.3 
48±12 
1.18±0.22 
348±133 
0.7510.29 
0.8±0.3 
0.2610.15 
4.0912.05* 
6.6212.48 
3.3311.95 
64122 
78153 
6.512.3 
7.911.2 
242171 
0.8710.70 
17581226 
3.81Ю.49 
9.112.6 
0.1010.06 
4.7811.87* 
6.4212.19 
12.1110 
84166 
107160 
39.8116.4 
3516 
1.0910.48 
202158 
0.4410.13 
1.010.3 
0.1710.14 
3.2910.43* 
5.1710.78 
2.3210.96 
119141 
160188 
4.610.9 
6.513.3 
107118 
0.82Ю.34 
6971133 
1.51Ю.29 
9.310.8 
0.12Ю.08 
3.6310.81* 
5.83Ю.82 
4.2110.90 
113112 
158198 
51.1112.1 
1713 
1.2710.58 
97115 
0.21Ю.04 
1.4Ю.1 
0.1710.15 
3.4610.45* 
5.40Ю.63 
3.7810.88 
87123 
133156 
5.411.2 
6.910.4 
Relative bioavailability 0.23 0.20 0.21 
for legends see table Г -1A. 
significant difference (p£0.05) of the terminal half-life of morphine in 
comparison to the half-life of both glucuronides. 
Results 81 
Table IV-IE 
Correlation (г) of the AUCo-«, (μΜ.η.Η) as a function of the administered 
dose Vilan® (mg) using Instat (GraphPad Software, San Diego, USA) 
AUCo~ 
AUCo— 
AUCo-» 
AUCo— 
AUCo-
(DNM) 
(6MNM) 
(M) 
(M3G) 
(M6G) 
r= 0.9605 
r= 0.9711 
r= 0.9285 
r= 0.9900 
r= 0.9871 
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IV-2 Intramuscular administration 
Published In Eur J Clin Pharmacol, 41 , 375-378. (1991a) 
Published In Int J Clin Pharmacol Ther, 10, 125-132. (1995a) 
Pharmacokinetics 
The data of the unconjugated compounds, taken from the European Journal 
of Clinical Pharmacology, were recalculated using the computer package 
MW/Pharm obtained from Mediware (Groningen, the Netherlands) [Proost 
and Meyer, 1992] and listed In Table IV-2A. 
Also pharmacokinetic calculations of the conjugated compounds were 
carried out using the computer package MW/Pharm. This is a non-linear 
curve-fitting program, based on the least-square method. All data were fitted 
in a model implying an extra vascular administration with a lag time and a 
one-compartment elimination model. The coefficient of determination (r2) 
shows the fit between calculated curve and the serum-time data. The area 
under the serum concentration-time curve (AUCo—) was calculated from the 
data of the fitted curve and extrapolated to infinite time (all rest areas were 
below 25%). Total body clearance (CLIM) was calculated as Dose/AUCo—. The 
maximum serum concentration Cmax (ng.ml"1) occurs at tmax (h) in the 
fitted curve. 
The renal clearance (CLr) of all metabolites present in the urine was 
calculated as excretion rate (mg.mür1) divided by the serum concentration 
(mg.ml·1) at the midpoint of the urine collection Interval. 
Absolute bioavailability is defined in 3 levels as the percentage of the 
AUCo— of: 
the parent compound, 
the active metabolites (6MNM+M+M6G). 
all measured compounds (DNM+6MNM+M+M3G+M6G) 
after intramuscular administration in comparison to the intravenous 
administration (of the same dose Vilan®) and results in an i n t e r 
administration comparison. 
Relative bioavailability is the ratio of AUCo-«. (of active metabolites: 
6MNM+M+M6G) and A U C Q - ~ (of all measured compounds: 
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DNM+6MNM+M+M3G+M6G), and results in an intra administration 
comparison. 
Statistics 
Ρ values were calculated using analysis of variance according to standard 
procedures. 
Statistical difference is defined at P<0.05. 
Results 
Fig Г -2а shows representative serum concentration-time curves of 
3,6-dinicotinoylmorphine and its metabolites in a patient (M6) after an 
intramuscular dose of 20 mg Vilan®. 3,6-dinicotinoylmorphine (DNM) was 
detectable in serum during one hour and was eliminated with a half-life of 
0.29 h. Its apparent half-life is governed by its rate of absorption and in the 
different patients it varied between 0.11 and 0.71 h (Table IV-2A). 
6-mononicotinoylmorphine (6MNM) was almost instantaneously formed, at 
tmax (0.16 h) it reached a C
max
 of 55 ng.ml-1 and it was eliminated with a 
ti/2 of 0.30 h. Morphine (M) was present in the first serum sample, reached 
a Cmax of 36 ng.ml"1 at t
m a x
 of 0.74 h and was eliminated with a ti/2 of 
1.4 h. Morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) 
appeared simultaneously in the serum and reached their maximum 
concentration after 1.37 h. They were eliminated with almost identical half-
lives of 3.66 h (M3G) and 2.54 h (M6G). 
Fig rV-2b shows renal excretion rate-time profiles of 3,6-dinicotinoyl­
morphine and Its metabolites in the same patient of Fig Г -2а. Morphine-
3-glucuronide was the main metabolite in urine. Of the dose administered, 
63.3% appeared in the urine as M3G, 11.1% as M and 7.6% as M6G. 
Table Г -2А summarizes the pharmacokinetic parameters of 3,6-dinicotinoyl­
morphine and its metabolites in the 8 patients. The ti/2 of 3,6-dinicotinoyl­
morphine (0.32Ю.20 h) and 6-mononicotinoylmorphine (0.39Ю.09 h) are 
similar (P=0.29). The t i / 2 of morphine (1.38±0.31 h) differed significantly 
from those of M3G and M6G (P<0.01). The t i / 2 of M3G (3.06±0.84 h) and 
M6G (2.25Ю.84 h) are similar (P=0.07). The renal clearance of morphine, 
214136 ml.mln 1 , differed significantly from that of M3G 124155 ml.min-1 
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and M6G 139±46 ml.miir1 (P<0.005). The renal clearance values of both 
glucuronldes are similar (P=0.59). 
Table Г -2В compares the AUCo-» values and the bioavailability of the i.m. 
and i.v. administration of 20 mg of Vilan®. 
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Table Г -2А. 
Pharmacokinetic parameters of 3,6-dinIcotlnoylmorphine and its metabolites 
after an intramuscular dose of 2 0 m g Vilan®. 
paüent Ml M2 M3 M4 M5 M6 M7 M8 mean±SD 
parameter 
3,6-dinicotinoylmorpbine 
Cmax (ng.ml-1) 74 73 39 104 179 100 102 50 90±43 
tmax (h) 0.18 0.06 0.26 0.07 0.06 0.16 0.15 0.20 0.14±0.07 
AUCo— (μ&η.Γ1) 90 58 31 31 39 61 54 42 51±20 
AUCo— (μΜ.η.Ι"1) 0.18 0.12 0.06 0.06 0.08 0.12 0.11 0.08 0.10±0.04 
CLIM Oh"1) 0.22 0.35 0.64 0.64 0.51 0.02 0.37 0.48 0.4010.21 
tl/2 (h) 0.71 0.51 0.32 0.16 0.11 0.29 0.24 0.41 0.3410.20 
r
2
 0.92620.89160.97150.91580.98830.98120.98460.8341 
6-mononicotinoylmorphine 
Cmax (ng-ml"1) 34 38 46 60 95 55 53 33 52120 
tmax (h) 0.22 0.15 0.35 0.11 0.09 0.29 0.17 0.17 0.1910.09 
AUCo-» (μ&η.Ι"1) 30 30 50 45 40 47 44 48 4218 
AUCo— (μΜ.η.Ι-1) 0.08 0.08 0.13 0.12 0.10 0.12 0.11 0.12 0.1110.02 
ti/2 (h) 0.42 0.44 0.44 0.44 0.23 0.30 0.45 0.89 0.45Ю.19 
r
2
 0.9332 0.9757 0.9658 0.9676 0.9833 0.9835 0.9794 0.8021 
morphine 
Cmax (ng.ml1) 35 33 39 47 50 36 36 39 3916 
tmax (h) 0.66 0.71 1.25 0.74 0.47 0.74 0.48 0.90 0.7410.25 
AUCo—Oig.h.l·1) 59 121 142 127 116 102 85 96 106126 
AUCo— (μΜ.η.Η) 0.21 0.42 0.50 0.45 0.41 0.36 0.30 0.34 0.3710.09 
tl/2 (h) 0.52 2.03 1.34 1.24 1.25 1.43 1.37 1.06 1.2810.42 
Γ
2
 0.90370.88510.94940.99540.98840.98580.97660.9795 
CLr (mLmin-1) 186 170 264 221 181 234 - 245 214136 
% In urine 9.6 10.0 10.4 14.5 8.7 11.1 - 10.1 10.611.9 
86 Chapter IV 
тоірЫпе-3-gluctiroiilde 
Cmax (ng.ml1) 246 333 219 244 280 194 199 184 237150 
tmax (h) 1.53 1.20 2.58 1.35 1.32 1.32 1.17 2.14 1.58±0.51 
AUCo— (ug.h.H) 1124 2136 1563 1909 1304 1283 1228 945 1437±406 
AUCo— (uM.h.l"1) 2.43 4.62 3.38 4.13 2.82 2.78 2.66 2.05 3.11±0.88 
ratio AUC(M3G/M) 11.6 11.0 6.8 9.2 6.9 7.7 8.9 6.0 8.5±2.0 
ti/2 (h) 1.92 3.52 2.87 4.38 2.21 3.66 3.52 2.42 3.06±0.84 
Г
2
 0.99420.90540.99420.89910.98720.99100.99020.9959 
CLr (ml-mln1) 113 108 239 76 139 108 - 84 124155 
% In urine 47.1 47.7 40.7 35.8 43.1 63.3 - 41.6 45.618.8 
morphine-6-glucuronide 
Cmax (ng.ml-1) 35 42 25 26 40 41 40 24 3418 
tmax (h) 1.57 1.86 2.44 1.72 1.59 1.42 1.03 2.33 1.7510.46 
AUCo— (μ&η,Ι-1) 154 207 194 128 182 204 214 115 175138 
AUCo--» (μΜ-h.l-1) 0.33 0.45 0.42 0.28 0.39 0.44 0.46 0.25 0.3810.08 
ratio AUC(M3G/M) 1.6 1.1 0.8 0.6 1.0 1.2 1.5 0.7 1.110.4 
ti/2 (h) 1.57 1.79 3.65 2.08 1.90 2.54 3.25 1.23 2.25Ю.84 
r
2
 0.87670.98040.95880.97990.99620.98040.98860.9463 
CLr (ml.min1) 136 100 229 117 90 144 - 155 139146 
% in urine 7.5 6.6 7.4 5.0 5.7 7.6 - 5.5 6.511.1 
ratio AUC(M3G/M6G) 7.4 10.3 8.0 14.8 7.2 6.3 5.8 8.2 8.512.9 
AUCo- total (DNM+6MNM+M+M3G+M6G) 
3.23 5.69 4.49 5.04 3.80 3.82 3.64 2.84 4.0710.95 
AUCo— active (6MNM+M+M6G) 
0.62 0.95 1.05 0.85 0.90 0.92 0.87 0.71 0.8610.14 
Relative bioavailability 0-21 
for legend see table Г -1A 
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Table IV-2B 
Bioavailability a n d AUCo— (±SD) after i.m. and i.v. administration of 2 0 m g 
Vilan® in surgical patients. 
Compound 
DNM 
6MNM 
M 
M3G 
M6G 
AUCo— 
(μΜ.η.Η) 
intravenous 
n=5 
0.06±0.02 
0.07±0.01 
0.40±0.11 
3.8110.79 
0.4410.13 
AUCo— 
(μΜ-h.l-1) 
intramuscular 
n=8 
0.1010.04 
0.1110.02 
0.3710.09 
3.1110.88 
0.3810.08 
Absolute Relative 
bioavailability bioavailability 
1.56 
Active compounds: (6MNM+M+M6G) 
0.91Ю.17 0.86Ю.12 0.95 0.21 
Total 
4.78Ю.81 4.0710.89 0.85 
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•j plasma cone, ug/ml 
0.01 
0.001 
Figure IV-2a 
The serum concentration-time curves of 3.6-dmlcotlnoylmorphlne (DNM) 
and Its metabolites 6-mononlcotlnoylmorphine (6MNM), morphine (M), 
morphlne-3-glucuronlde (M3G) and morphine-6-glucuronide (M6G) in a 
patient after an i.m. dose of 20 mg Vilan®. 
plasma cone, ид/ml 
renal хсг. rate ug/min 
0.01 
0.001 
Figure IV-2b 
A combined figure of the serum concentration-time curves and the renal 
excretion-time profiles for the same patient after an i.m. dose of 20 mg 
Vilan®. 
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IV-3 Epidural administration 
Published In Pharm Weekbl (Sci). 13. 142-147. (1991b) 
Published In Blopharm Drug Dlsp. 1β. 507-520, (1995b) 
Pharmacokinetics 
All pharmacokinetic calculations were carried out using the computer 
package MW/Pharm obtained from Mediware (Groningen, the Netherlands) 
[Proost and Meyer, 1992]. The data concerning the unconjugated 
compounds, as published In the Pharmaceutisch Weekblad, were also 
recalculated using this computer package. Peak serum concentrations C
m a x 
(ng.ml" 1 ). occurring at t
m a x
 (h), were read from the fitted serum 
concentration-time curve. The ti/2 values were calculated from the slope of 
the terminal portion of the semilogarithmic serum concentration-time curve 
by linear regression analysis. The area under the serum concentration-time 
curve (AUCo—) was calculated from the data of the fitted curve and 
extrapolated to Infinite time. Total body clearance (CL) was calculated as 
dose/AUCo-oo (assuming F=l). No urine samples were taken. 
Statistics 
Ρ values were calculated using analysis of variance according to standard 
procedures. Statistical difference Is defined at P<0.05. 
Results 
In all studied patients the parent compound and the metabolites 
6-mononicotinoylmorphine, morphine, morphine-3-glucuronide and 
morphine-6-glucuroníde could be detected in serum. Fig Г -За and Г -ЗЬ 
show exemplary serum concentration-time curves of 3,6-dinicotinoyl-
morphine and its metabolites in 2 patients (no 8 and 10 respectively). 
Fig Г -За (patient E8) shows that 3,6-dinicotlnoylmorphlne was absorbed 
rapidly from the epidural space. The concentration was highest in the first 
serum sample and gradually decreased thereafter, and thus resembled an 
intravenous injection (pseudo Intravenous injection). The apparent half-life 
of 0.135 h (= 8 min). The metabolite 6-mononIcotinoylmorphlne appeared 
instantaneously in the serum and shows a biphasic serum elimination curve 
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with an apparent terminal elimination half-life of 1.9 h. Morphine was 
present in the first serum sample, reached a maximum at 5 min and was 
eliminated with an apparent half-life of 1.9 h. Fig Г -ЗЬ (also patient E8) 
shows the serum concentration-time curve of morphine and its two 
metabolites on a larger time scale. The morphine conjugates were detectable 
after 10 min. The apparent half-lives are 4.0 and 2.9 h for M3G and M6G 
respectively. 
Fig Г -Зс (patient E10) shows that 3,6-dinicotinoylmorphine was absorbed 
from the epidural space and reached a maximum at 0.120 h. The apparent 
half-life of 3,6-dinicotinoylmorphine was 8 min. The metabolite 
6-mononicotinoylmorphine shows a biphaslc plasma elimination curve with 
an apparent terminal elimination half-life of 2.1 h. Fig IV-3d (patient E10 on 
a larger time scale) shows that morphine and the glucuronides (M3G and 
M6G) are running parallel with apparent elimination half-lives of 3.8 h, 3.5 
h and 3.6 h, respectively. 
Table Г -ЗА summarizes the kinetic parameters of 3,6-dinicotinoylmorphine, 
6-MNM, M. M3G and M6G for the time interval 0-4 h after administration of 
3,6-dinicotinoylmorphine in all 10 patients. Table Г -ЗВ summarizes the 
pharmacokinetic parameters of all compounds in the patients 8-10, who 
were sampled for a longer period of time: 24 h. 
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Table І -ЭА 
Pharmacokinetic parameters of 3,6-dinlcotlnoylmorphlne and its metabolites 
after an epidural dose of 15 mg Vilan® (time interval 0-4h). 
patient 
parameter 
El E2 E3 
3,6-dlnicotlnoylmorpbine 
Cmax (ng.ml-1) 
tmax (W ι 
АиСо-Лц&ЬЛ-1) 
AUCo—(цм.ь.і-1) 
CL O.h"1) 
t l / 2 (h) ' 
MRT (h) 
102 79 98 
Б4 
106 
E5 
72 
Б6 
137 
E 7 
4 0 
0.0720.0280.0560.1320.0840.2580.149 
23 
0.05 
0.66 
18 
0.04 
0.84 
27 
0.05 
0.55 
38 
0.08 
0.39 
22 86* 
0.04 0.17* 
0.67 0.17 
16 
0.03 
0.92 
E8 
-
E9 
43 
ЕЮ m e a n i S D 
46 8 0 ± 3 3 
-0.0700.120 0 . 1 0 8 Ю . 0 6 8 
34 
0.09 
0.44 
20 
0.04 
0.76 
14 
0.03 
1.07 
2 4 ± 8 
0 . 0 5 1 0 . 0 2 
0 . 6 5 1 0 . 2 7 
0.1070.1470.1580.1640.1810.1610.1660.1350.3030.130 0 . 1 6 5 Ю . 0 5 3 
0.20 0.23 0.26 
e-mononicotinoylmoxphme 
Cmax (ng-inl-1) 
tmax th) 
AUCo-oo^g.h.I-l) 
АиСо-ооІцМ.Ь.І-
1) 
t ( l ) i / 2 (h) 
t (2 ) i/2 (h) 
MRT (h) 
morphine 
Cmax (ng-ml-M 
tmax (h) 
AUC O -4 0 igh. l- l ) 
АиСо-4(цМ.Ь.1-1) 
15 
0.12 
28 
0.07 
0.45 
1.67 
2.18 
9 
0.57 
32 
0.11 
9 
0.11 
8 
0.02 
0.09 
1.04 
1.37 
20 
0.72 
50 
0.18 
morpbine-3-glucuronide 
Cmax (ng.ml-1) 
tmax (h) 
AUC0-4fcg.h.H) 
AUCo^^M.h.l"1) 
ratio AUC(M3G/M) 
80 
2.40 
324 
0.70 
6.4 
125 
1.83 
495 
1.07 
5.9 
morphine-6-gluciiToiiide 
Cmax (ng-rnl-1) 
tmax (h) 
АиСо.4(Це.Ь.1-1) 
АиС0-4(цМ.Ь.1-1) 
raUo AUC(M6G/M) 
12 
2.74 
53 
0.11 
1.0 
18 
1.73 
68 
0.15 
0.8 
28 
0.08 
73 
0.19 
0.12 
3.64 
5.01 
16 
0.67 
43 
0.15 
146 
2.23 
698 
1.51 
10.1 
24 
2.09 
102 
0.22 
1.5 
0.32 
30 
0.19 
76 
0.19 
0.17 
3.99 
5.14 
12 
0.39 
24 
0.08 
102 
1.29 
358 
0.77 
9.6 
15 
1.46 
53 
0.11 
1.4 
0.32 
33 
0.15 
37 
0.09 
0.49 
38 
0.49 
55 
0.14 
0.180.002 
1.32 
1.60 
14 
0.52 
33 
0.12 
87 
1.65 
340 
0.74 
6.2 
15 
1.76 
57 
0.12 
1.0 
0.44 
1.04 
20 
0.68 
42 
0.15 
161 
1.51 
577 
1.25 
8.3 
21 
1.40 
7 3 
0.16 
1.1 
0.33 
22 
0.15 
27 
0.07 
0.07 
1.35 
1.80 
*+ 
«· 
** 
«* 
** 
«* 
** 
** 
** 
14 
1.63 
50 
0.11 
-
0.14 
47 
0.07 
86 
0.22 
0.12 
1.92 
2.64 
20 
0.08* 
22 
0.08 
138 
0.43 
420 
0.91 
11.4 
16 
0.73 
45 
0.10 
1.3 
0.49 
22 
0.17 
11 
0.03 
-
0.23 
0.44 
11 
0.38 
37 
0.13 
100 
1.60 
381 
0.82 
6.3 
13 
1.50 
45 
0.10 
0.8 
0.27 
23 
0.14 
25 
0.06 
0.07 
2.09 
2.52 
18 
0.34 
48 
0.17 
164 
1.73 
625 
1.35 
7.9 
2 3 
1.96 
8 3 
0.18 
1.1 
0 . 3 1 1 0 . 1 1 
2 7 1 1 1 
0 . 1 7 1 0 . 1 2 
4 3 1 2 8 
0 . 1 1 1 0 . 0 7 
0 . 1 4 1 0 . 1 3 
1 . 7 7 1 1 . 2 3 
2 . 3 7 1 1 . 5 7 
1 6 1 5 
0 . 5 3 1 0 . 1 5 
3 7 1 1 0 
0 . 1 3 1 0 . 0 4 
1 2 3 1 3 2 
1 . 6 3 Ю . 5 7 
4 6 9 1 1 3 7 
1 . 0 2 Ю . 3 0 
8 . 0 1 2 . 0 
1 7 1 5 
1 . 7 0 Ю . 5 2 
6 3 1 1 9 
0 . 1 4 1 0 . 0 4 
1 . 1 1 0 . 2 
for legends see table IV-1A 
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Table І -ЗВ 
Pharmacokinetic parameters of 3,6-dinicotinoylmorphine and its metabolites 
after an epidural dose of I S m g Vilan® (after a sampling time of 24 h). 
patient E8 E9 E10 mean 1SD 
parameter 
3,6-dinicotinoylmorphine 
Cmax 
tmax 
AUCo— 
AUCo— 
CL 
tl/2 
MRT 
Г
2 
(ng.ml-1) 
(h) 
(Rg.h.H) 
(μΜ.η.Ι"1) 
( l .h 1 ) 
lh) 
(h) 
-
-
3 4 
0.07 
441 
0.14 
0.14 
09984 
6-mononicotinoylmorphine 
Сщах 
tmax 
AUCo-» 
A U C o -
tdJi/2 
«2)1/2 
MRT 
г2 
(ng.ml'1) 
(h) 
fcg.h.l1) 
(μΜ.η.Ι"1) 
(h) 
(h) 
(h) 
morphine 
Cmax 
tmax 
AUCo-4 
AUCo-4 
AUCo— 
AUCo— 
t(Dl/2 
«2)1/2 
r2 
(ng.ml1) 
(h) 
(μ&η.Η) 
(μΜ.Η.Ι"1) 
Oig.h.1-1) 
(μΜ.Ιι.1-1) 
(h) 
(h) 
47 
0.07 
8 6 
0.22 
0.12 
1.92 
2.64 
0.9952 
2 0 
0.08t 
2 2 
0.07 
27 
0.09 
0.19 
1.93 
09694 
4 3 
0.070 
20 
0.04 
7 5 6 
0.30 
0.49 
0.9306 
2 2 
0.17 
11 
0.03 
-
0.23 
0.44 
0.9971 
11 
0.38 
3 7 
0.13 
81 
0.28 
-
5.17 
0.9995 
4 6 
0.120 
14 
0.03 
1074 
0.13 
0.27 
0.9812 
2 3 
0.14 
2 5 
0.06 
0.07 
2.09 
2.52 
0.9984 
18 
0.34 
4 8 
0.17 
9 0 
0.32 
0.11 
3.78 
0.9848 
45±2 
0.10±0.04 
2 3 ± 1 0 
0.05±0.02 
7571317 
0.19Ю.10 
0.30±0.18 
31±14 
0.13±0.05 
41 ±40 
0.10±0.10 
0.10±0.04 
1.41±1.03 
1.87±1.24 
1615 
0.3610.03 
3 6 1 1 3 
0.1210.05 
6 6 1 3 4 
0.23Ю.12 
0.1510.06 
3.6311.63 
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тогрЫпе-3-glucuronlde 
Cmax (ng.ml-1) 
tmax (W 
AUCo-4 ^ . h . I - l ) 
AUCo-4 (цМ.ЬЛ'1) 
ratio AUCo-4(M3G/M) 
AUCo— ^ . h . l - l ) 
AUCo— (цМ.Ь.Г1) 
raüo AUCo—(M3G/M) 
t l / 2 (h) 
Г
2 
morphine-6-g lucuronide 
Cmax (ng.ml 1 ) 
tmax (h) 
AUCo-4 (μ^η.Ι" 1) 
AUCo-4 (jiM.h.l"1) 
raüo AUCo-4(M3G/M) 
A U C o - (μβ-ЬЛ-1) 
AUCo— (цМ.ЬЛ-1) 
raüo AUCo—(M3G/M) 
t l / 2 (h) 
r 2 
raüo AUC(M3G/M6G) 
138 
0 .43 
4 2 0 
0.91 
13.0 
862 
1.87 
20 .8 
4 .07 
09906 
16 
0 .73 
4 5 
0.10 
1.4 
79 
0.17 
1.9 
2 .94 
09824 
11.0 
100 
1.60 
381 
0.82 
6 .3 
8 5 3 
1.85 
6.6 
4 .68 
0.9753 
13 
1.50 
4 5 
0.10 
0.8 
130 
0 .28 
1.0 
6 .05 
0.9940 
6.6 
AUCo— t o t a l (DNM+6MNM+M+M3G+M6G) 
2.42 2 .48 
AUCo— a c t i v e c o m p o u n d s (6MNM+M+M6G) 
Relat ive bioavai labi l i ty 
0.48 0.59 
164 
1.73 
6 2 5 
1.35 
7.9 
1161 
2 .51 
7.8 
3 .54 
0.9883 
2 3 
1.96 
8 3 
0 .18 
1.1 
162 
0 .35 
1.1 
3 .60 
0.9769 
7.2 
3 .27 
0 .73 
134±32 
1.25±0.72 
475±131 
1.03±0.28 
9 .1±3.5 
959±175 
2 .0810 .38 
11.7±7.9 
4 .1010 .57 
1715 
1.4010.62 
58122 
0 .1310 .05 
1.110.3 
124142 
0 .2710 .09 
1.310.5 
4 .2011 .64 
8.312.4 
2 .7210 .47 
0 .6010 .13 
0.22 
for legends see table Г -1A 
ratio AUCo-4 and ratio AUCo-. 
ratio AUCo-4 and ratio AUCo-. 
(M3G/M): difference not 
(M6G/M): difference not 
significant, P= 0.59 
significant, P= 0.38 
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1 τ ι serum cone ug/ml 1 
Figure І -За 
The serum concentration-time curves of 3,6-dinlcotlnoylmorphlne (DNM) 
and its metabolites 6-mononicotinoylmorphine (6MNM), morphine (M). 
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) in 
patient E8 after an epidural dose of 15 mg Vilan®. 
1 -a serum cone ug/ml 
0.1- ? * % 
0.01 τ 
0.001-
4 4 
a. X 
4
 M3G t1 / 2 4.0 h 
M6G t1 / 2 2.9 h 
1.9 h 
15 
Τ 
20 
T 
25 30h 
Figure І -ЗЬ 
The serum concentration-time curves of the metabolites morphine (M), 
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) in 
patient E8 after an epidural dose of 15 mg Vilan® on a larger time scale. 
0.1-
0.01 
0.001 
l ignie І -Зс 
The serum concentration-time curves of 3,6-dinicotinoylmorphine (DNM) 
and its metabolites 6MNM, M. M3G and M6G in patient 10 after an 
epidural dose of 15 mg Vilan®. 
τ serum cone ug/ml 
0.1-
0.01т 
0.001 
\M3G t1 / 23.5h 
M6G t1/2 3.6 h 6 h 
M t1 / 23.8h 
15 20 τ 
25 
30 h 
Figure IV-3d 
The serum concentration-time curves of 3,6-dinlcotlnoylmorphlne (DNM) 
and its metabolites 6MNM. M, M3G and M6G in patient 10 after an 
epidural dose of 15 mg Vilan®. 
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IV-4 Rectal administration 
Published In Pharm World Sci. 16, 248-253. (1994b) 
Pharmacokinetics 
All pharmacokinetic calculations were carried out using the computer 
package MW/Pharm® obtained from Mediware (Groningen, the Netherlands) 
[Proost and Meyer, 1992]. This is a non-linear curve-fitting program, based 
on the least-square method. Morphine was fitted as an extra vascular 
administration with a lag time and a two-compartment elimination model. 
M3G and M6G were fitted as an extra vascular administration with a lag 
time and a one-compartment elimination. The coefficient of determination 
(r2) is an estimation of the goodness of the fit. The area under the serum 
concentration-time curve of the metabolites (AUCo-») was calculated from 
the data of the fitted curve and extrapolated to infinite time. This could be 
done because the AUC of the observed data and the AUC of the fitted curve 
correlated well: r(M3G)= 0.9971, r(M6G)= 0.9907 and r(M)= 0.9987. The 
maximum serum concentration C
m a x
 (ng.ml"1) occurs at t
m a x
 (h). The renal 
clearance CL/ was calculated as mg excreted/AUCo—. As the parent 
compound was not detected in serum, pharmacokinetic parameters such as 
CL and V
s s
 could not be calculated. 
Statistics 
Ρ values were calculated using analysis of variance according to standard 
procedures. 
Statistically significant differences are assumed at P<0.05. 
Results 
Figure Г -4 shows representative serum concentration-time curves of all 
metabolites in a patient after a rectal dose of 30 mg Vilan®. The parent 
compound, 3,6-dinicotinoylmorphine (DNM) nor the metabolite 
6-mononicotinoylmorphine (6MNM) or 3-mononicotinoylmorphine (3MNM) 
were detectable in the serum. Morphine appeared after a lag time of 10 min, 
reached a C
m a x
 of 52 ng.ml"1 at t
max
 of 34 min and was eliminated with a 
final half-life of 1.7 h. Morphine-3-glucuronide and morphine-6-glucuronide 
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appeared In the serum about 17 min after administration and reached their 
maximum concentration after 1.3 h. They were eliminated with almost 
identical half-lives of 3.89 h (M3G) and 3.47 h (M6G). 
The renal excretion rate-time profiles of this patient are also shown. 
Morphine-3-glucuronide was the main metabolite in urine. Of the dose 
administered, 31.8% appeared in the urine as M3G, 7.1% as M6G and 3.4% 
as M. 
Table Г -4 summarizes the pharmacokinetic parameters of 3,6-dinicotinoyl-
morphine and its metabolites in the 8 patients. The t(2)i/2 of morphine 
(1.48±0.48 h) differed significantly from those of M3G and M6G (P<0.015). 
The ti/2 of M3G (2.8011.08 h) and M6G (2.71±1.05 h) were similar (P>0.8). 
The renal clearance of morphine (162±70 ml.mür1) differed significantly from 
that of morphine-3-glucuronide (71±19 ml.min -1) and morphine-
6-glucuronide (91±41 ml.müv1) (P<0.0035). The renal clearance values of 
both glucuronides were similar (P=0.23). 
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Figure Г -4 
The serum concentration-time curves and the renal excretion-time 
profiles for a patient after a rectal dose of 30 mg Vilan® as a 
suppository. 
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Table IV-4 
P h a r m a c o k i n e t i c p a r a m e t e r s of t h e m e t a b o l i t e s of 3 , 6 - d i n l c o t l n o y l m o r p h l n e 
af ter a r e c t a l d o s e of 3 0 m g Vllan®. 
patient R l R2 R3 R4 R5 R6 R7 R8 m e a n i S D 
parameter 
m o r p h i n e 
Cmax (ng-ml 1) 3 7 4 9 52 4 8 4 5 3 2 6 6 2 7 45±12 
tmax (h) 0.72 0.52 0.56 0.47 0.28 0.62 0 .48 0.55 0 .53±0.13 
AUCo— (μ&η.Ι"1) 77 71 103 8 3 5 5 4 7 114 31 7 3 ± 2 8 
AUCo— (μΜ.η.Ι"1) 0 .27 0 .25 0.36 0.29 0.19 0.16 0 .40 0.11 0.26±0.10 
lag-time (h) 0.16 0 .23 0.16 0.08 0.08 0.12 0 .09 0.12 0.1310.05 
t i/2abs (h) 0.37 0 .15 0.22 0.20 0.12 0.32 0 .23 0.30 0.24±0.09 
t ( l ) i/2 (h) 0.35 0 .15 0.22 0.20 0.12 0 .35 0 .23 0.30 0.24±0.09 
t(2)i/2 (h) 2 .34 1.04 1.71 1.08 1.57 1.03 1.61 0.30t 1.4810.48 
r
2
 0.96990.97000.98160.98250.97210.86450.96570.9230 
CLr* (ml.min-1) 8 2 135 9 5 122 129 2 4 0 2 2 9 2 6 1 162±70 
% in ur ine 2.2 3.3 3.4 3.5 2 .5 3.7 7.3 2.8 3.6±1.6 
morphlne-3-g lucuron lde 
Cmax (ng.ml-1) 502 3 7 1 4 5 5 5 2 0 757 3 7 9 6 0 8 514 5 1 3 ± 1 2 5 
tmax (h) 1.37 1.45 1.28 0.79 0 .73 1.21 1.02 1.64 1.1910.32 
AUCo— (Hg-h-r1) 4 1 4 7 2 0 9 6 3 0 7 8 2 2 8 5 2431 1733 2 8 3 6 2 3 0 3 2 6 1 4 1 7 4 6 
AUCo-« (μΜ.η.Ι"1) 8.98 4.54 6.66 4 .95 5.26 3.75 6 .14 4.98 5.6611.61 
radoAUC(M3G/M) 3 3 . 3 18.2 18.5 17.1 27 .7 2 3 . 4 15.4 4 5 . 3 24.9110.2 
lag-time (h) 0.21 0.16 0.22 0.11 0.11 0 .14 0 .15 0.14 0.1610.04 
t l/2abs (h) 0.26 0.39 0.25 0.16 0.17 0 .33 0 . 2 3 0.69 0.3110.17 
t i / 2 (h) 4 .84 2 .87 3.89 2 .53 1.74 2.29 2 .55 1.67 2 .8011.08 
r
2
 0.98980.99120.99840.96170.97210.98880.99230.9100 
CLr* (ml-min 1 ) 4 0 7 7 4 8 6 4 78 9 1 7 8 9 1 7 1 1 1 9 
% in ur ine 36 .1 35 .0 31.8 31 .5 4 0 . 8 34 .2 4 7 . 5 45 .1 37.816.0 
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morphine-6-glucuronide 
Cmax (ng.ml-1) 79 58 73 99 151 53 73 89 84±31 
tmax (h) 1 2 0 1.77 1.40 0.71 0.80 1.38 1.25 0.83 1.17±0.36 
AUC0—^g.h.l·
1) 481 446 455 468 490 184 415 305 406±107 
AUCo— (μΜ.η.Ι"1) 1.04 0.97 0.98 1.01 1.06 0.40 0.90 0.66 0.88±0.23 
ratio AUC(M6G/M) 3.9 3.9 2.7 3.5 5.6 2.5 2.3 6.0 3.8±1.4 
lag-time (h) 0.42 0.04 0.32 0.24 0.17 0.09 0.16 0.44 0.24±0.15 
tl/2abs (h) 0.17 0.51 0.27 0.09 0.17 0.89 0.29 0.08 0.31±0.27 
ti/2 (h) 3.65 3.90 3.47 2.91 1.74 0.89 3.07 2.08 2.71±1.05 
Γ
2
 0.9830 0.9757 0.9973 0.9883 0.9743 0.97910.9622 0.9991 
CLr* (ml.min-1) 67 76 72 69 
% in urine 7.0 7.3 7.1 7.0 
ratio AUC(M3G/M6G) 8.6 4.7 6.8 4.9 
6 3 
6.6 
5.0 
176 
7.0 
9.4 
7 4 
6.6 
6.8 
130 
8.6 
7.5 
91 ±41 
7.2±0.6 
6.7±1.8 
AUCo— total (DNM+6MNM+M+M3G+M6G) 
10.29 5.76 8.00 6.25 6.51 4.31 7.44 5.75 6.79±1.80 
AUCo-°o active compounds (6MNM+M+M6G) 
1.31 1.22 1.34 1.30 1.25 0.56 1.30 0.77 1.13±0.30 
Relative bioavailability 0.17 
for legends see table IV-1A 
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IV-5 Oral administration 
Testing the chemical stability of 3,6-dinicotinoy¡morphine under 
acidic conditions 
I. 200 μΐ 3,6-dlnicotlnoylmorphine stock solution (160 μg.ml-1 was added to 
2 ml 1 M HCl (pH=l) and placed in a water bath at 37 °C. Samples of 
50 μΐ were taken at regular time intervals, and the concentration of 
3,6-dinicotinoylmorphine was measured. 
II. 200 μΐ 3,6-dinicotinoylmorphine stock solution (160 μg.ml-1) was added to 
1 ml of freshly obtained gastric fluid (pH=2) and placed in a water bath at 
37 °C. Samples of 50 μΐ were taken at regular time intervals, and the 
concentration of 3,6-dinicotinoylmorphine was measured. 
Results 
The pH of the gastric fluid is 1-2, and under these acidic conditions we 
determined the stability of 3,6-dinicotinoylmorphine. Figure Г -5а shows the 
stability of 3,6-dinicotinoylmorphine in 1 M HCl at 37 °C; the half-life is 9 
h. Figure rV-5b shows the stability of 3,6-dinicotinoylmorphine in blank 
gastric juices (pH=2) at 37 °C, the half-life of 3,6-dinicotinoylmorphine 
under these conditions is 18 h. Considering the time-interval of the 
measurements, 3,6-dinicotinoylmorphine can be considered to be stable. 
After an oral dose of 30 mg 3,6-dinicotinoylmorphine was administered to 
patient Ol, a serum concentration of 3,6-dinicotinoylmorphine of 89 ng.ml·1 
could be measured 2 min after administration. In all the other samples 
neither 3,6-dinicotinoylmorphine nor the metabolites 6-mononicotinoyl-
morphine, or morphine could be detected. 
To check the persistence of 3,6-dinicotinoylmorphine in the stomach, we 
took two random gastric fluid samples from patient 02. The first gastric 
fluid sample, with a volume of 37 ml, was taken 1 h after 3,6-dinicotinoyl­
morphine administration and contained 10 mg 3,6-dinicotinoylmorphine. 
Four hours after administration a second gastric fluid sample (of 10 ml) was 
taken, which contained 1 mg of 3,6-dinicotinoylmorphine. 
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In conclusion 3,6-dinicotlnoylmorphine is not absorbed from the s tomach 
under these conditions and the bioavailability is 0. 
0 1 
Figure IV-5a Stability of 3,6-dinicotinoylmorphine in 1 M HCl at 37 °C. 
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Figure Г -вЬ Stability of 3,6-dinicotinoylmorphine in blank gastric juices 
at 37 °C. 
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Figure Г -5с shows the cumulative amount of 3,6-dlnlcotlnoyImorphine 
In the gastric juices as a function of time in patient ОЗ. after an oral 
dose of 30 mg 3,6-dinicotinoylmorphine. After 3.5 h o u r s 
3,6-dinicotinoylmorphine was still present in the gastric fluids. At that 
moment 49% of the initial dose had been removed as a result of the 
sampling procedure. 
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Figure IV-6d shows the 3,6-dinicotinoylmorphine concentration in the 
gastric juices of patient 0 4 a s a function of time. Here, 
6-mononicotinoylmorphine is also present, as well as an unidentified 
compound labelled X. No large fluctuations in the concentrations of both 
compounds were found, and 3,6-dinicotinoylmorphine did not disappear 
rapidly from the gastric Juices. 
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100% cumulative dose gastric juice 
subj. 04 
DNM 66% 
Figure IV-5e shows the cumulative amount of 3,6-dinicotlnoylmorphlne 
and 6-mononicotinoylmorphine In the gastric juices as a function of time. 
As all of the obtainable gastric juices were removed with the last sample 
in patient 04, the absorbed fraction could be estimated as 100% - 71% 
(the amount found in the gastric juices) = 29% of the initial dose 
(equivalent with 8.4 mg 3,6-dinicotinoylmorphine). 
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Findings 
We can now give an answer to the three questions that formed the objectives 
of this investigation: 
1. We have shown the initial presence and disposition of 3,6-dinicotinoyl-
morphine in serum. Our ability to demonstrate the presence of the parent 
compound in serum proved to be dependent on the route of 
administration. After intravenous, intramuscular or epidural 
administration the parent compound was detected; after rectal or oral 
administration the parent compound was below the detection limit in the 
serum samples (Fig V-l). 
2. Metabolites of 3,6-dinicotinoylmorphine can be detected in serum. After 
intravenous, intramuscular, epidural or rectal administration, metabolites 
were detected. After oral administration of 3,6-dinicotinoylmorphine, 
neither the parent compound nor any metabolites could be detected! 
3. The effect of the route of 3,6-dinicotinoylmorphine administration on the 
pharmacokinetics of the parent compound and metabolites is very clear: 
the route of administration determines the different rate constants 
belonging to the pathway of metabolic handling, thus the yield of the 
different metabolites. 
In addition to the above major findings this thesis provides information on 
the following aspects: 
a. In the absence of a clear definition of bioavailability, we had to redefine 
this term. A description is provided in Results sections Г -l and Г -2, and 
relevant aspects are discussed further in section V-6. 
b. As will be clear from our results presented in section Г -5, oral 
administration under these conditions does not result in an uptake of the 
drug into the human body. One general conclusion can be drawn from 
our data: administration of a drug orally Just before anaesthesia should 
be conducted with care, because there is a possibility that these drugs 
will stay in the stomach and produce unexpected effects when normal 
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functioning of the gastrointestinal tract restarts after the anaesthesia 
wears off. 
c. It Is remarkable that the AUCo-~ for all of the compounds (parent 
compound and all metabolites) Is correlated with the intravenous dose. In 
addition, only the elimination half-life of morphine is correlated with the 
administered intravenous dose of 3,6-dinlcotinoylmorphine, while for the 
other compounds (DNM, 6MNM, M3G and M6G), no such correlation can 
be found. 
The introduction described the factors involved in drug action. 
Physicochemical properties are characteristic of each chemical compound 
but are often limited to the parent compound. The limited data available on 
the metabolites are listed in Table 1-4. Pharmacokinetics will be extensively 
discussed in this section in order to describe the presence of active and 
inactive metabolites after the administration of a drug. The target in the 
biological system was described. For further information the reader is 
referred to studies on receptor binding and structure-activity relationships. 
The intention was to perform pharmacokinetic studies and to provide a 
framework within which these studies can be placed. 
116 Chapter V 
Intravenous administration (η» 15) 
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Figure V-l 
Comparison of the presence of the parent compound and the metabolites 
in serum as a function of time. 
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Table V 
Theoretical pathways of biotransformation of 3,6-dlnicotlnoylmorphine, on 
account of its chemical structure 
prodrug active metabolite inactive metabolite 
morphine-6-glucuronlde 
Î1 
morphine —> morphine-3-glucuronlde 
Î4 
6-mononicotlnoylmorphine —> 6-MNM-3-glucuronlde 
Î4 
4 3,6-dinlcotinoylmorphine —> 3-mononicotlnoylmorphine 
il 
3-MNM-6-glucuronide 
type of reaction 1 = conjugation 
2 = oxidation 
3 = reduction 
4 = hydrolysis 
118 Chapter V 
V-0 Stability of 3,6-dinicotinoylmoTpbine and its 
metabolites 
A stock solution of 3,6-diiiicotinoylmorpbine In methanol Is stable at 
-20 °C for at least 3 months when stored in aliquote and thawed only once 
just before use. 
6-mononicotinoylmorpbine Is stable in the methanol stock solution. 
3-mononicotinoylmorphine is unstable in the methanol stock solution and 
blood rapidly hydrolysises to morphine. This compound was never detected, 
a result unaffected by the way the parent compound was administered. 
When 6-mononicotinoylmorphine is formed, glucuronidation is only possible 
at the 3-position. However, there is no peak in the chromatogram present at 
a retention time that as anticipated for the compound 6-mononicotinoyl-
morphlne-3-glucuronlde (6MNM3G), which should correspond to the ratio 
between the retention times of M3G and M, in comparison with the retention 
time of 6MNM [Vree et al. 1988]. Moreover, treatment of the serum and urine 
samples with ^-glucuronidase did not result in the increase in the 
concentration of 6-mononicotinoylmorphine, while under these conditions 
M3G and M6G were completely converted to morphine. 
Morphine proved to be stable in a frozen methanol stock solution and in a 
frozen serum sample for 3 years. 
Both of the morphine glucuronides, morphine-3-glucuronlde and 
morphine-6-glucuronide, are commercially available. Deglucuronidation of 
the samples provided further information on the nature and quantity of 
these and, if present, unknown glucuronide metabolites. The calibration 
samples, with known amounts of glucuronides, were alsosubjected to 
deglucuronidation. Under these conditions the glucuronides completely 
disappeared from the chromatogram, while there was an equal molar 
increase in morphine concentration. In patient samples, the increase in 
morphine concentration after deglucuronidation was completely accounted 
for by the initial presence of M3G and M6G. This means that no 
di-glucuronide was present. After all of the different forms of administration 
had been tested, there was no evidence/indication for the existence of a 
morphine-3,6-diglucuronide, as was also reported by Patel et al. 11993]. 
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V-1 Intravenous administration 
Following Intravenous administration, 3,6-dinicotinoylmorphine is detectable 
in the serum of the human body for only 10 minutes. This rapid elimination 
from the serum may result from a wide distribution throughout the tissues 
due to the high lipid solubility of 3,6-dinicotinoylmorphine or from a high 
rate of metabolism [Vree et al. 1987a]. 
The metabolite β-mononicotinoylmorphine is present Instantaneously in 
the serum. When 20 or 30 mg Vilan® is injected, the serum concentrations 
of the parent drug and 6-mononicotinoylmorphine are almost identical. The 
metabolite concentrations are lower when 10 mg is injected. 
Morphine was present in the first serum sample, which was collected only 1 
minute after administration of the parent compound. The shape of the 
serum concentration-time curve and the initial high plasma concentration 
suggest that morphine is instantaneously formed. The rate of morphine 
formation may not entirely be due to enzymatic reactions but also due partly 
to hydrolysis of 3MNM in serum. We noted that only the elimination half-life 
of morphine showed a direct relationship with the dosage of the parent 
compound fTable Г -ID). 
Morphine is glucuronidated at the C3 and C6 positions. These two 
glucuronide conjugates are present in plasma [Boemer et al. 1975; Garrett 
and Gurkan, 1978; Garrett and Jackson, 1979] and urine [Moore et al. 
1984; Sàwe et al. 1985]. The final serum half-life of morphine varies between 
0.69 and 3.50 h (mean 2 h), as reported in the literature [Berkowitz et al. 
1975; Murphy and Hug, 1981; Nordberg et al. 1983; Moore et al. 1984]. This 
half-life is shorter than the half-life of both morphine glucuronideswith a 
mean of 3.8 h. Hanna et al. [1991] found that after administration of 
morphine, M6G declined in parallel with morphine in the terminal phase. As 
no attention was given to M3G, no conclusions can be made about the 
competing pathways. It would have been of Importance to measure M3G 
because when present in larger concentrations it can be a source of 
morphine in the terminal phase due to enterohepatic circulation and 
deglucuronidation in the intestine [Dahlström and Paalzow, 1978; Leslie et 
al. 1980; Hanks and Wand, 1989]. Unfortunately, our quantitation limit was 
not low enough to visualise the fact that after administration of 30 mg 
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Vilan®, M, M3G and M6G run in parallel in the terminal phase. Long-lasting, 
steady-state levels of morphine glucuronides were reported in patients with 
kidney failure [Osborne et al. 1993; Somogyi et al. 1993]. The terminal phase 
of morphine consists of the glucuronides and runs parallel to both 
glucuronides, as excellently shown by D'Honneur et al. [D'Honneur et al. 
1994]. Both deglucuronidation of the morphine glucuronides in the intestine 
and the enterohepatic recirculation governs the terminal half-life of 
morphine [Iwamoto and Klaassen, 1977; Chan and Matzke, 1987; Horton 
and Pollack, 1991], which is clearly visible after an oral dose of 30 mg 
morphinesulphate (Guelen, personal communication; Bourget et al. 1995). 
At a dose of 30 mg Vilan®, the concentrations of morphine reach the highest 
values, and the elimination half-life of morphine becomes close to that of 
M3G and M6G (no significant difference). In this case, both 
deglucuronidation of the morphine glucuronides in the intestine and the 
enterohepatic recirculation governs the terminal half-life of morphine 
[Iwamoto and Klaassen, 1977; Horton and Pollack, 1991]. With a lower dose, 
the net amount of recirculation is lower and the serum concentration falls 
below the quantitation limit so that the half-life of morphine becomes 
significantly different from the half-life of both glucuronides (p<0.05, Table 
IV-ID marked with *). With the lower dosages, the initial ti/2 mainly 
represents the rate of 3- and 6-glucuronidation with only minimal or not 
measurable deglucuronidation. In the final elimination phase, 
glucuronidation/ deglucuronidation reaches an equilibrium, with the renal 
excretion and faecal excretion as the terminal elimination pathways. 
renal clearance 
In urine only morphine and its conjugates were present. The renal clearance 
(Cl
r
) of all metabolites (calculated as excretion rate ^g.min - 1) divided by the 
serum concentration ^g.ml·1) at the midpoint of the urine interval) is listed 
in Table Г -1А, IB, 1С and ID. In the urine only 59% of the dose was 
recovered, and this is consistent with the reports in the literature [Somogyi 
et al. 1993], where it is attributed to a considerable first pass effect [Iwamoto 
and Klaassen, 1977; Chan and Matzke. 1987; Horton and Pollack, 1991] and 
faecal excretion. There are large inter-individual differences, but it is 
remarkable that the renal clearance of morphine (mean 200 ml.min"1) is 
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higher than that of both glucuronldes (mean 115 ml.mln-1). This is explained 
by the use of different excretion mechanisms: morphine is cleared via the 
organic cation transport system, while the glucuronides are cleared by 
glomerular filtration and tubular reabsorption [Greven 1981]. The renal 
clearances for codeine (92 ml.min'1) and codeine-6-glucuronide (122 
ml.mür1) are similar, so substitution of a methyl- or glucuronide group at 
the C3 position of morphine reduces renal clearance by approximately 50% 
[Vree and Verwey-Van Wissen, 1992). As van Crugten et al. [1991] described, 
it is an unusual phenomenon that glucuronide metabolites, which are larger 
and less lipophilic than morphine, undergo net tubular reabsorption. 
However, Carrupt et al. [1991] described that M6G. and to a lesser extent, 
M3G are far more lipophilic than predicted and in fact are not much less 
lipophilic than morphine itself. It has been reported that the clearance of 
morphine, apart from enterohepatic cycling, is influenced by several factors, 
e.g. age, race and also variation in hepatic blood flow during peri- and 
postoperative situations [Hasselström and Säwe, 1993]. 
bioavailability 
The term absolute bioavailability is used in a comparison between two or 
more forms of administration. An intravenous administration guarantees a 
systemic availability of 100%, and therefore the AUCo— after intravenous 
administration must be taken as the reference value to calculate absolute 
bioavailability for other forms of administration. When metabolites are 
formed (to which the effect can be attributed to), these metabolites should be 
included in the term absolute bioavailability. 
1. absolute bioavailability of the parent compound is 1.0 by definition. 
2. absolute bioavailability of the active compounds is 1.0 by definition (all at 
a given dose). 
3. absolute bioavailability of the pharmaceutical formulation is 1.0 by 
definition. 
A summary of the AUCo-~ and resulting absolute and relative 
bioavailabilities for the intravenous administration is given in Table V-l. 
In conclusion: after its intravenous administration, 3,6-dinicotinoylmorphine 
is biotransformed into three (active) metabolites: 6-mononicotinoylmorphine, 
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morphine and morphlne-6-glucuronide. The kinetics of M and M6G after the 
administration of 3,6-dinicotinoylmorphine resemble that after morphine 
administration. 
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Table V-l 
Summary of the m e a n AUCo— (цМ.Ь.І*1) of 3,6-dInicotinoylmorphine and its 
metabolites present in serum after intravenous administration. 
dose 30 mg (n=5) 
A U C o -
μΜ.η.Η 
intravenous 
20 mg (n=5) 
A U C o -
μΜ.η.Η 
intravenous 
10 mg (n=5) 
A U C o -
μΜ.η.Η 
intravenous 
3,6-dtnicotinoylmorphin.e 
0 . 1 2 1 0 . 0 3 
6-mononicotinoylmorphine 
0 . 1 3 1 0 . 0 7 
morphine 
0.91 1 0 . 1 3 
morphtne-3-glucuronide 
5.91 1 2.45 
morphine-6-glucwonide 
0.75 1 0.29 
0 . 0 6 1 0.02 
0 . 0 7 1 0 . 0 1 
0 . 4 0 1 0 . 1 
3.81 1 0 . 4 9 
0 . 4 4 1 0 . 1 3 
0.05 1 0.02 
0.05 1 0.02 
0 . 1 6 1 0 . 0 3 
1.5110.29 
0 . 2 1 1 0 . 0 3 
Absolute bioavailability of tbe parent compound 
1.0 1.0 1.0 
AI7Co-„ active compounds (6MNM+M+M6G) 
1.7910.33 0 . 9 1 1 0 . 1 7 
Table Г -1А.В.С 1 .7910.26 0 . 8 6 1 0 . 1 2 
Absolute bioavailability of the active compounds 
1.0 1.0 
Relative bioavailability 
0.23 0.20 
0.42 i 0 .05 a 
0.42 i 0 .07 a 
1.0 
0.21 
AUCo-«, total (DNM+6MNM+M+M3G+M6G) 
7.82 1 2.47 4.78 1 0.52 
Table Г -1А.В.С 7 . 8 2 1 2 . 6 7 4 . 4 2 1 0 . 0 1 
Absolute bioavailability of tbe pharmaceutical formulation 
1.0 1.0 1.0 
1 . 9 8 1 0 . 2 9 a 
1 . 9 8 1 0 . 3 4 a 
a
: differences due to the omission of outlyers. 
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V-2 Intramuscular administration 
When given Intravenously. 3,6-dinicotinoylmorphine has a half-life of 1 min 
and is quickly metabolised into the metabolites 6-mononicotinoylmorphine 
and morphine with a half-life of 1 min [Vree et al. 1987b; Koopman-Kimenai 
et al. 1993]. This study shows that after intramuscular administration, DNM 
is present in serum for a relatively long period, its apparent elimination half-
life is governed by its rate of absorption and varied between 0.11 and 0.71 h. 
The metabolite 6MNM is present instantaneously in the serum. The 
elimination half-life of 6MNM is similar to that of 3,6-dinicotinoylmorphine, 
0.39 ± 0.09 h (P=0.29), indicating that its rate of elimination is higher than 
the rate of absorption or formation. The whole process is governed by the 
rate of absorption of the parent drug DNM. 
M is found in the serum 5 min after administration. Its elimination half-life 
is 1.38 ± 0.31 h. The rate of the morphine formation may not entirely be due 
to enzymatic reactions but also partly due to hydrolysis of 3MNM in serum. 
Morphine is glucuronidated at the C3 and C6 position. M3G has been 
shown to be a potent functional antagonist of morphine, and M6G gives 
antinociception after intracerebro-ventricular administration to rats [Smith 
et al. 1990; Gong et al. 1991]. The conjugate morphine-6-glucuronlde 
contributes to the analgesic effect [Shimomura et al. 1971; Osborne et al. 
1990. 1993]. 
renal clearance 
In urine only morphine and its conjugates are present. The renal clearance 
(CLr) of all metabolites is listed in table Г -2А. There are large inter-
individual differences, but it is remarkable that the renal clearance of 
morphine (mean 214 ml.min-1) is higher than that of both glucuronides 
(mean 132 ml.min"1). This is explained by the different excretion 
mechanisms: morphine is cleared via the organic cation transport system, 
while the glucuronides are cleared by glomerular filtration and tubular 
reabsorption [Greven 1981]. These results are in perfect accordance with our 
results after l.v. administration: 200 (M) and 115 т І . т і п Ч М З С M6G). 
respectively. As van Crugten et al. [1991] described, it is an unusual 
phenomenon that glucuronide metabolites, which are larger and less 
Discussion 125 
lipophilic than morphine, undergo net tubular reabsorption that results in a 
net renal clearance that equals creatinine clearance. However, Carrupt et al. 
[1991] described M6G and to a lesser extent M3G as being far more 
lipophilic than predicted, being in fact are not much less lipophilic than 
morphine. 
bioavailability 
After intravenous administration of 20 mg Vilan® to a comparable group of 
surgical patients the mean AUCo— of the parent compound is 0.06 ± 0.02 
цМ.Ь.І
1
 (Table IV-IB) [Koopman-Kimenai et al. 1994a]. After intramuscular 
administration of the same dose the mean AUCo— of the parent compound 
is higher: 0.10 ±0.04 μΜ.Ιι.Η (Table Г -2А). This results in an absolute 
bioavailability of the parent compound of 156% (Table V-2). This result can 
be explained by the fact that the apparent elimination half-life is governed by 
the absorption rather than the elimination rate. 
The absolute bioavailability of this pharmaceutical formulation can be 
expressed as the AUCo— (μΜ.Ιι.Η) of the parent compound and all the 
metabolites after i.m. administration relative to that after i.v. administration 
(at the same dose). After an intravenous administration of 20 mg Vilan® the 
total sum of the area under the serum concentration-time curve (AUCo— of 
DNM+6MNM+M+M3G+M6G) is 4.78 μΜ.Ιι.Η [Koopman-Kimenai et al. 
1994a], which is in the same order of magnitude as after an intramuscular 
administration of 20 mg Vilan®, 4.07 μΜ.Ιι.Η, indicating an absolute 
bioavailability of the pharmaceutical formulation of 85% (Table V-2). If only 
the active compounds are taken into account, the AUCo-«, of 6MNM+M+M6G 
after i.v. and i.m. administration of the same dose have to be compared. The 
AUCo— (6MNM+M+M6G) are identical: 0.91 μΜ.Ιι.Η (i.v.) and 0.86 μΜ.Ιι.Η 
(i.m.), resulting in an absolute i.m. bioavailability of the active compounds of 
95%. After i.v. administration the parent compound and 6MNM comprise 
only 2.9% of the total AUCo-». Because of the slow absorption of DNM from 
the muscular mass it is longer present in the blood and, therefore, DNM and 
6MNM comprised a larger part of the total AUCo— after i.m. administration: 
5.5% (as was also indicated by the absolute bioavailability of the parent 
compound of 156%) [Koopman-Kimenai et al. 1994a]. A summary is given in 
Table V-2. The assessment of absolute bioavailability in surgical patients is 
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only feasible using a parallel study design that approximates the absolute 
bioavailability obtained from a cross-over design. 
In conclusion: The prodrug 3,6-dinicotinoylmorphine is biotransformed into 
3 (active) metabolites: 6-mononicotinoylmorphine, morphine and morphine-
6-glucuronide. Because of the relatively slow absorption of 3,6-dinicotinoyl-
morphine from the muscle mass after i.m. injection the active metabolites 
6-mononicotinoylmorphine, morphine and morphine-6-glucuronide are 
present longer in the body than after i.v. administration. The absolute 
bioavailability of intramuscular 3,6-dinicotinoylmorphine is 156% of that 
after i.v. administration. The absolute bioavailability after intramuscular 
administration of the pharmaceutical formulation and that of the active 
compounds are 85% and 95%, respectively. 
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Table V-2 
Summaiy of the area under the serum concentration-time curve (μΜ.Ιι.Η) 
and elimination half-life (h) of the 3,6-dinicotinoylmorphine and its 
metabolites present in serum after intravenous and intramuscular 
administration after the same dose(20 mg). 
dose 
3,6-dinicotinoylmorphine 
AUCo-o. (μΜ.Ιι.Η) 
t l / 2 (h) 
6-mononicotinoylmorphine 
AUCo— (μΜ.Ιι.Η) 
tl/2 И 
morphine 
AUCo-» (μΜ.Ιι.Η) 
tl/2 (h) 
morphine-3-glucuronide 
AUCo- (μΜ.Ιι.Η) 
tl/2 (h) 
morphíne-6-glucuronide 
AUCo— (μΜ.Ιι.Η) 
tl/2 (h) 
intravenous 
20 mg 
0.06 ± 0.02 
0.01810.006 
0.07 ± 0.01 
0.17 ±0.05 
0.40 ±0.11 
1.97 ±0.32 
3.81 ±0.49 
4.78 ± 1.87 
0.44 ± 0.13 
3.29 ± 0.43 
Absolute bioavailability of the parent compound 
intramuscular 
20 mg 
0.10 ±0.04 
0.34 ± 0.20 
0.11 ±0.02 
0.45 ±0.19 
0.37 ± 0.09 
1.28 ±0.42 
3.11 ±0.88 
3.06 ± 0.84 
0.38 ± 0.08 
2.25 ± 0.84 
1.56" 
·· 
ns s 
s 
s 
ns 
s 
ns 
s 
ns 
s 
AUCo-oo active compounds (6MNM+M+M6G) 
0.91 ±0.17 0.86 ±0.14 
Absolute bioavailability of the active compounds 
0.95 
Relative bioavailability 
0.21 
AUCo- total (DNM+6MNM+M+M3G+M6G) 
4.78 ± 0.52 4.07 ± 0.89 
Absolute bioavailability of the pharmaceutical formulation 
0.85 
s = significant: P<0.05 
ns = not significant 
= 1.0, is not significantly different from the i.v. dose 
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V-3 Epidural administration 
Following epidural administration, 3,6-dinicotinoylmorphine is detectable in 
the serum of the human body for 30 minutes. Ib is rapid elimination from 
the serum may result from a wide distribution throughout the tissues due to 
the high lipid solubility of 3,6-dinicotinoylmorphine and from a high rate of 
metabolism. The molecules of the parent compound in the cerebrospinal 
fluid (CSF) are rapidly absorbed into the spinal cord, and few molecules will 
remain in the CSF to be carried cranially and cause a late respiratory 
depression, which explains the reported absence of respiratory depression 
after epidural 3,6-dinicotinoylmorphine administration [Maas et al. 1987]. 
The metabolite 6-mononicotinoylmorphine is present instantaneously in 
the serum. 
Morphine is present in all patients within 5 min after dosing and reached a 
maximum after 0.53 h.(mean) The apparent elimination half-life of morphine 
can only be calculated from the data from patients E8-E10, and varies from 
1.9 to 5.2 h. (mean 3.63 ± 1.63 h). 
Morphlne-3-glucuronlde and morphine-6-glucuronide are quantified in 
the samples. In patients E1-E8 it is only possible to calculate AUCo-4 
because the elimination phase is about to begin, in patients E8-E10 both the 
AUCo— and the AUCo-4 can be calculated. The AUC ratios of M3G/M and 
M6G/M do not significantly differ from the ratios of AUCo— and AUC0-4. The 
mean apparent terminal half-lives of the two morphine glucuronides are 
4.10 h( ± 0.57 h) for M3G and 4.20 h( ± 1.64 h) for M6G, and they do not 
differ significantly from each other or from the half-life of morphine, 
3.63 ± 1.63 h (P>0.8). Hanna et al. [1991] found that after administration of 
morphine, M6G declined in parallel with morphine in the terminal phase. As 
no attention was paid to M3G, no conclusions can be made about the 
competing pathways. It would have been of Importance to measure M3G, 
since it is present in larger concentrations due to enterohepatic circulation 
and deglucuronidation In the intestine and thus could be a source of 
morphine in the terminal phase. 
In patient E8 (Fig Г -За and IV-3b) the elimination half-lives of morphine 
and the two glucuronides are not the same: 1.9 h (M), 4.0 h (M3G) and 2.9 h 
(M6G). As morphine reaches its maximum serum concentration as soon as 
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0.08 h after the dose is administered, it resembles an intravenous injection. 
In earlier studies in which we used intravenous injections of 10, 20 and 30 
mg 3.6-dinicotinoylmorphine, morphine reached its maximum concentration 
in less than 0.12 h and we found similar results: the apparent half-life of 
morphine (mean 2.0 h) was shorter than the apparent half-lives of both 
glucuronides (mean 3.8 h). 
In patient ЕЮ (Fig Г -Зс and IV-3d) it takes 0.34 h to reach the maximum 
serum concentration (18 ng.ml"1), which is comparable to the maximum 
reached in patient E8 20 ng.ml"1. 
bioavailability 
In order to calculate the bioavailability of 15 mg 3,6-dinicotinoylmorphine 
epidurally, the AUCo— after a 15-mg intravenous injection should be known. 
Because there is a good correlation between the AUCo— of the parent 
compound and all of the metabolites (as shown in Table IV-1E), an 
interpolation of the AUCo— to a dose of 15 mg intravenous is justified. Using 
this interpolated intravenous AUCo— we find that the bioavailability of the 
parent compound is 83%, the bioavailability of the active compounds is 78% 
and the bioavailability of the pharmaceutical formulation is 81%. In 
conclusion, after epidural administration the prodrug 3,6-dinicotinoyl­
morphine is biotransformed into three (active) metabolites: 6-mononicotinoyl-
morphine, morphine and morphine-6-glucuronide. 
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Table -ЭА 
Interpolation of the results in Table IV-ID gives the following mean AUCo-
(цМ.Ь.Н) for an interpolated intravenous dose of 15 mg Vilan®. 
dose 
30 mg 
AUCo-» 
μΜ.Ιι.Η 
3,6-dinicottnoylmorphine 
0.06 b 
6-mononicotinoylmoTphine 
0.07 
morphine 
0.46 
morphine-3-glucuronide 
2.96 
moTphine-6-glucuronide 
0.38 
20 mg 
A U C o -
μΜ.η.Η 
0.05 
0.05 
0.30 
2.86 
0.33 
10 mg 
AUCo-oo 
μΜ.Ιι.Η 
0.08 
0.08 
0.24 
2.27 
0.32 
mean calculated 
15 mg 
A U C o -
μΜ.Ιι.Ι'1 
"i.v." 
0.06 
0.07 
0.33 
2.70 
0.34 
AUCo-oo active compoxmds (6MNM+M+M6G) 
0.74 
AUC0-~ total (DNM+6MNM+M+M3G+M6G) 
3.50 
b
: recalculated for 15 mg = 15/30 χ AUC (0.12) = 0.06 
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Table -ЗВ 
Summary of the mean AUCo-~ (μΜ.η.1-1) from the Interpolated results from 
Table V-3A compared to the mean AUC 0 — (jiM.h.l1) (± SD) of 15 mg Vilan® 
epidurally fTable Г -ЗВ). 
dose 
3,6-dinicotinoy1morphine 
6-mononicotinoylmorphine 
morphine 
morphine-3-glucuronide 
morphine-6-glucuronide 
15 mg 
AUCo-
"i.v." 
Interpolated 
0.06 
0.07 
0.33 
2.70 
0.34 
Absolute bioavailability of the parent compound 
15 mg 
AUCo-» 
epidural 
0.05 ± 0.02 
0.10±0.10 
0.23 ±0.12 
2.08 ± 0.38 
0.27 ± 0.09 
0.83 
AUCo-oo active compounds (6MNM+M+M6G) 
3.50 2.73 
Absolute bioavailability of the active compounds 
0.78 
Relative bioavailability 
0.22 
AUCo— total (DNM+6MNM+M+M3G+M6G) 
0.74 0.60 
Absolute bioavailability of the pharmaceutical formulation 
0.81 
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V-4 Rectal administration 
When given intravenously or intramuscularly, 3.6-dinicotinoylmorphinehas 
a half-life of 1 min and is quickly metabolised into the metabolites 
6-mononicotinoylmorphine and morphine [Koopman-Kimenai et al. 1991a, 
1993]. This study shows that after rectal administration, 3,6-dinicotinoyl-
morphine is not present in serum [Vree et al. 1987c]. 
The metabolite 6-mononicotinoylmorphine can also not be detected in 
serum. Apparently the rate of hydrolysis in the alkaline colon is high. 
Morphine is found in the serum 8 min after administration. Its terminal 
elimination serum half-life varies from 1.03 to 2.34 h (mean 1.48 ± 0.48 h). 
The rate of morphine formation must be due to enzymatic reactions in the 
rectum. 
In one patient (no H) a single compartment model fitted best as can be 
concluded from the fact that both elimination half-lives t(l)i/2 and t(2)i/2 
were identical (P>0.8). The apparent terminal elimination half-life of 
morphine is smaller than the half-life of both glucuronides, mean 2.80 h for 
M3G and 2.71 h for M6G (P<0.015). 
renal clearance 
In urine only morphine and its conjugates are present. The renal clearance 
(CLr) of the metabolites is listed in table Г -4. There are large inter-individual 
differences, but it is remarkable that the renal clearance of morphine (mean 
162 ml.min"1) is higher than that of both glucuronides (mean 81 ml.min-1) 
(P<0.0035). This can be explained by the different excretion mechanisms: 
morphine is cleared via the organic cation transport system, while the 
glucuronides are cleared by glomerular filtration and tubular reabsorption 
[Greven 1981; Waltrous et al. 1970]. These results are comparable with our 
results after i.v. administration: 200 ml .min 1 (M) and 115 ml.min 1 (M3G, 
M6G) resp. As van Crugten et al. [1991] described, it is an unusual 
phenomenon that glucuronide metabolites, which are larger and less 
lipophilic than morphine, undergo net tubular reabsorption. However, 
Carrupt et al. [1991] reported that M6G and to a lesser extent M3G are far 
more lipophilic than predicted and are in fact not much less lipophilic than 
morphine itself. It has been reported that the clearance of morphine, apart 
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from enterohepatlc cycling, is influenced by several factors, e.g. age, race 
and also variation in hepatic blood flow during peri- and postoperative 
situations [Hasselström and Säwe, 1993]. 
bioavailability 
After intravenous administration of 30 mg Vilan® the mean total sum of the 
areas under the serum concentration time curves is 7.8 цМ.Ь.І"1 (AUCo-~ of 
DNM+6MNM+M+M3G+M6G) [Koopman-Kimenai et al. 1994a), which is in 
the same order of magnitude as after rectal administration of 30 mg Vilan®, 
6.8 μΜ.η.Ι"1 (AUCo— of M+M3G+M6G). Thus the absolute bioavailability of 
3,6-dinicotinoylmorphine (DNM) from a suppository is 0%, while the 
absolute bioavailability of this pharmaceutical formulation, expressed as 
morphine bioavailability (AUC o-~ of M+M3G+M6G) after administration of 
the suppository. Is 88%, both relative to i.v. administration (Table V-4). 
Rectal administration of morphine in a suppository results in a large 
variation in bioavailability (31-72%) relative to that observed following 
extravascular administration. The absolute bioavailability of morphine alone 
is 53.3 ± 17.8%. as reported by Jonsson et al. [1988]. 
Reported variation in bioavailability is in part due to the analytical 
methodology and the components measured. Morphine bioavailability as 
described in the literature is expressed relative to an intramuscular 
administration [Westerling et al. 1982; Westerling and Andersson, 1984], 
oral administration (30%) [Ellison and Lewis, 1984; Moolenaar et al. 1988; 
Kaiko et al. 1992; Babul and Darke, 1993]. rectal administration in 
tabletform (30-70%) [Kaiko et al. 1992] or other rectal formulations 
[Moolenaar et al. 1988]. 
The present study shows that administration of a suppository with 30 mg 
Vilan® gives an excellent absolute bioavailability of morphine and its 
metabolites of 88%. The lipid-soluble prodrug 3,6-dinicotinoylmorphine is 
rapidly absorbed and Immediately hydrolysed to morphine. 
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In conclusion, this study shows that administration of a suppository with 30 
mg Vilan® yields a bioavailability of this pharmaceutical formulation of 88% 
of that of morphine and its metabolites. The lipid-soluble prodrug 
3,6-dinicotinoylmorphine is rapidly absorbed and immediately hydrolysed to 
morphine. 
The action of rectally administered 3,6-dinicotinoylmorphine can be 
explained by the formation of two (active) metabolites, morphine and 
morphine-6-glucuronide. The kinetics of M and M6G following rectal 
administration of 3,6-dinicotinoylmorphine finally resemble those following 
morphine administration. 
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Table V-4 
Summary of the area under the serum concentration - time curve (μΜ.η.Η) 
(± SD) a n d elimination half-life (h) of the 3,6-dinicotinoylmorphine and its 
m e t a b o l i t e s p r e s e n t in s e r u m following i n t r a v e n o u s a n d r e c t a l 
administration of the same dose (30 mg Vilan®). 
intravenous rectal 
dose 30 mg 30 mg 
3,6-dinicotijwybnorphine 
A U C o - (цМ.Ь.1-1) 
t i/2 M 
6-mononicotinoylnwrphine 
A U C o - (цМ.ЬЛ-і) 
t i/2 (h) 
morphine 
AUCo— (μΜ.η.Η) 
t i / 2 (h) 
morphine-3-glucwonide 
AUCo-- (μΜ.Ιι.Η) 
t i /2 (h) 
morphine-6-glucwoTiide 
A U C o - (μΜ.1ι.1-ΐ) 
t i /2 (h) 
Absolute bioavailability of the parent compound 
0 
AUCo-oo active compounds (6MNM+M+M6G) 
1.7910.33 1.14 ± 0 . 2 5 
Absolute bioavailability of the active compounds 
0.64 
Relative bioavailability 
0.17 
AUCo-«, total (DNM+6MNM+M+M3G+M6G) 
7.82 ± 2 . 4 7 6.80 ± 1 . 6 3 
Absolute bioavailability of the pharmaceutical formulation 
0.88 
s = significant: P<0.05 
n s = not significant 
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0.12 ±0.03 
0.029 ± 0.007 
0.13 ±0.07 
0.256 ±0.133 
0.91 ±0.13 
3.06 ± 0.37 
5.91 ± 2.45 
3.78 ± 2.23 
0.75 ± 0.29 
4.09 ± 2.05 
-
-
_ 
-
0.26 ±0.10 
1.48 ±0.48 
5.66 ± 1.61 
2.80 ± 1.08 
0.88 ± 0.23 
2.71 ± 1.05 
s 
s 
s 
s 
s 
s 
ns 
ns 
ns 
ns 
V-5 Oral administration 
Permission for the oral administration of 3,6-dinicotinoylmorphine to 
conscious human volunteers was not given by the CEOM (the local Ethics 
Committee) and therefore anaesthesised patients were included for this 
experiment. After "oral" administration of 3,6-dinicotinoylmorphine via a 
nasogastric tube, the parent compound and the metabolites 
6-mononicotinoylmorphine and morphine were not detected in the patient's 
serum. 
Absorption of oral morphine is known to be poor, and this may account for 
the lack of correlation between the analgesic effects of morphine and the 
serum concentration in normal volunteers and patients [Comroe and Dripps, 
1948; Boemer et al. 1975; Säwe et al. 1983b, 1985, 1986; Vater et al. 1984; 
Savarese et al. 1986]. This poor absorption is considered to result from the 
highly acidic nature of the gastric environment [Säwe et al. 1985]. The low 
pH of the gastric contents and the high pKa of morphine (7.93) would result 
in extensive ionisation and lipid insolubility, thereby resulting in a poor 
passage through biological membranes and subsequently low absorption. 
These factors also determine the absorption of 3,6-dinicotinoylmorphine 
from the stomach. The pKa of 3,6-dinicotinoylmorphine (7.45) may only 
slightly improve absorption from the stomach. In this investigation patients 
were anaesthesised and in a horizontal position during surgery. Under 
anaesthesia the motility of the gastro-intestinal tract is known to be 
decreased, with little or no propulsion of the gastric contents into the 
intestine. Our data indicate that no drug uptake occurs in the stomach. 
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V-6 Bioavailability 
The term bioavailability is used in a comparison between two or more forms 
of administration. An intravenous administration guarantees a systemic 
availability of 100%, and therefore the AUCo— after intravenous 
administration must be taken as reference value. When metabolites are 
formed (to which an effect can be attributed to), these metabolites should be 
included in the term bioavailability. This is the reason why we defined 
different expressions of bioavailability: 
Absolute bioavailability (resulting in an inter-administration comparison): 
1. absolute bioavailability of the parent compound 
2 absolute bioavailability of the active compounds. 
3. absolute bioavailability of the pharmaceutical formulation 
Relative bioavailability is the ratio of AUCo-« (of active metabolites: 
6MNM+M+M6G) and AUCo-» (of all measured compounds: 
DNM+6MNM+M+M3G+M6G) and results in an intra-administration 
comparison. 
The absolute and relative bioavailabilities for intramuscular, epidural, rectal 
and oral administration are given in Table V-6. In conclusion: all forms of 
administration (except oral administration) result in a complete systemic 
bioavailability. The ratio of active metabolites in relation to the total 
metabolites as expressed by the relative bioavailability is constant, e.g. 20%, 
and independent of the form of administration. 
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Table V-β 
Absolute bioavailability of Vilan® after the various routes of administration 
compared to intravenous administration in surgical patients. 
intravenous intramuscular epidural rectal oral 
parent compound: (DNM) 
1.0 1.6 0.83 0 0 
Active compounds: (6MNM+M+M6G) 
1.0 0.95 0.78 0.64 0 
Total (DNM+6MNM+M+M3G+M6G) 
1.0 0.85 0.81 0.88 0 
Relative bioavailability of Vilan® after the various routes of administration. 
intravenous 
30 mg dose 0.23 
20 mg dose 0.20 
10 mg dose 0.21 
intramuscular 
20 mg dose 0.21 
epidural 
15 mg dose 0.22 
rectal 
30 mg dose 0.17 
oral 
30 mg dose 
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V-7 Elimination half-life 
Following administration of a (parent) compound, a metabolite Is formed, 
and within a specific time period is subsequently eliminated. The former 
process is described by an absorption rate constant k
m
, the latter by an 
eliination rate constant kei- When a metabolite shows a half-life similar to 
that of the parent drug, its elimination constant is greater than that of the 
parent drug. The plasma concentration of the metabolite at time t can be 
described according to the equation (where A, B, and с are constants): 
CmetaboUte(t) = c( Ae-k^t -B.e-k
elt) 
When kei»km and t Is approaching infinity, the metabolite elimination term 
(B.e-kel't) reaches zero and the plasma concentration of the metabolite Is 
governed by its rate of formation from the parent drug. This situation is 
clearly observed with sulphonamides, where formation of the N4-acetyl 
metabolite coincides with the breakdown of the parent compound and shows 
a high renal clearance. For instance, sulfamethoxazole and its N4-acetyl 
metabolite show a half-life of 10 h, while the Intrinsic ti/2 of the metabolite 
is 3 h [Vree and Hekster, 1987d]. The intrinsic half-life is the half-life of the 
metabolite when given as the parent drug. The plasma concentration of the 
metabolite is lower than that of the parent, and AUCparent»AUC
me
tabolite· 
An acetylatlon-deacetylation equilibrium has been demonstrated for 
sulfamerazine and the other sulphonamides [Vree et al. 1983a, 1985a,b]. 
When k e i « k
m
 and t approaches Infinity, the metabolite formation term ( 
A-e-kjjj.t) reaches zero and the plasma concentration of the metabolite Is 
governed by Its rate of elimination. For example, ti/2 of diazepam Is 30 h 
and that of its metabolite N-desmethyldiazepam is 60 h; t h u s 
AUCparent«AUC
me
tabolite Г гее et al. 1981, 1982]. 
With the benzodiazepines oxazepam, temazepam and lormetazepam two 
half-lives can be distinguished after oral administration, namely, a t(l)i/2 of 
3 h and a t(2)i/2 of 10 h. The glucuronide metabolite shows an elimination 
half-life of 10 h, with here also AUCParent«AUCmetabolite· With these 
benzodiazepines, the parent drug is almost entirely metabolised. In patients 
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with deteriorated kidney function, the final elimination half-life of both the 
parent drug (oxazepam) and its glucuronlde increases to 30-90 h, depending 
on the kidney function [Odar-Cederlôf et al. 1977; Kämpfet al. 1981; Murray 
et al. 1981; Vree et al. 1981; Greenblatt et al. 1983; Vree and Drlessen 
1986]. Ibis means that oxazepam with the second and long t(2)i/2 must be 
a metabolite of its glucuronlde and that a glucuronidatlon-deglucuronidatlon 
equilibrium exists (enterohepatic cycle, excretion via the bile into the gut, 
deglucuroni-dation and reabsorption). This conjugation-deconjugation 
equilibrium in the body results in parallel plasma concentration-time curves 
and similar t(2)i/2 values. The characteristic feature is that the difference 
between the intrinsic t i /2 values of the parent drug and the metabolite is at 
least a factor 2-3. 
When the ti/2,parent/ti/2.metabollte rat io is 3 , then the 
AUCparent»AUCmetabolite · 
When the t i /2 ,parent/ ti/2,metabolite ratio is 0 .3 , then the 
AUCparent«AUCmetabollte· 
When morphine is quickly formed for example as a result of metabolic 
conversion of 3,6-dinicotinoylmorphlne, a biphaslc elimination phase can be 
observed with t ( l ) i / 2 of 0.15 ± 0.06 h and t(2)i/2 of 3.6 ± 1.6 h (epidural 
3,6-dlnicotinoylmorphine administration). The observed t i /2 values of M3G 
and M6G are 4.1 ± 0.6 h and 4.2 ± 1.6 h, respectively. The final elimination 
half-lives of M, M3G and M6G do not differ significantly from each other 
(Table V-7B). The main characteristic of morphine kinetics is that the half-lives 
of M and its glucwonides are similar. 
The question arises whether: 
a the similar t i / 2 values of morphine and its two glucuronlde 
conjugates is the result of a conjugation-deconjugation equilibrium 
or 
b that the intrinsic half-lives are similar by pure coincidence. 
The coincidence of similar half-lives can be found for 1) parent compounds 
or 2) parent compounds and metabolite (s). Examples are given in Table 
V-7A, B. 
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Table V-7A 
Examples of coincidental similarities of elimination half-lives. 
Combination Compounds 
1. a combination of 2 parents 
Co-tiimoxazole sulphamethoxazole 
+ trimethoprim 
Co-sultrim sulphametrole 
+ trimethoprim 
tl/2 
10 h 
10 h 
10 h 
10 h 
2. a combination of parent and metabolite 
sulphamethoxazole 
N4-acetylsulphamethoxazole 
N4-acetylsulphamethoxazole (parent) 
sulphamethoxazole 
N4-acetylsulphamethoxazole 
morphine 
morphine-3-glucuronide 
morphine-6-glucuronide 
morphine-6-glucuronide (parent) 
morphine 
morphlne-3-glucuronlde 
10 h 
10 h 
3 h 
10 h+ 40 h 
40 h 
2 h 
2 h 
2 h 
2 h 
2 h 
50 h 
mechanism 
acetylation 
renal excretion 
acetylation 
renal excretion 
acetylation 
renal excretion 
renal excretion 
acetylation 
deacetylation 
+lmpaired renal excretion 
glucuronidation 
renal excretion 
renal excretion 
renal excretion 
glucuronidation 
Impaired renal excretion 
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Observations which deny the existence of an equilibrium of morphine and its 
glucuronides and favour the coincidence are: 
1. When morphine-6-glucuronide was administered intravenously or orally 
as described by Hanna et al. [1991] no free morphine could be detected in 
the plasma. If an equilibrium should exist, then it is shifted to the side of 
the conjugate and cannot be observed. The position of the equilibrium 
may also be species-dependent, and when it is shifted completely to the 
conjugation side in man, we may be examining the wrong species to 
estimate the position of this glucuronidation-deglucuronidation 
equilibrium. 
2. When morphine-3-glucuronide was administered to a cat, no morphine 
could be detected [Koopman-Kimenai, unpublished results]. The cat is 
known for its inability to glucuronidate, which might be due to a high rate 
of deconjugation. A high deconjugation rate explains the inability for 
acetylation of an aromatic amino group in dogs [Vree et al. 1983b] 
3. Glucuronidation is species-dependent. Dogs are unable to form morphine-
6-glucuronide; only morphine-3-glucuronide (and the parent compound) 
were detected after intravenous administration of morphine [Koopman-
Kimenai, unpublished results]. 
4. In patients with impaired kidney function, the final elimination half-life of 
morphine remains constant 1.5-4 h (mean 2.4 h), while that of the 
morphine-3-glucuronide varies from 14.5-118.8 h (mean 49.6 h), which 
differs from the half-life reported in patients with normal renal function, 
2.4-6.7 h (mean 4.0 h) [Säwe and Odar-Cederlöf, 1987]. This means that 
no noticeable deconjugation due to the extrahepatic cycling occurred. 
All four of the above mentioned points contribute to the conclusion that the 
t i / 2 values of morphine and its glucuronides are similar by pure 
coincidence; the metabolic clearance of morphine equals the resultant of 
metabolic formation minus renal clearance of the glucuronides. 
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Table V-7B 
Half-life of morphine and its C3 and C6-substltuted analogues. 
Compound t i / 2 ( h ) ( ± S D ) administration reference 
6-Mononicotinoylmorphlne 
0.26 ± 0 . 1 2 lv VUan® 
0.39 ± 0 . 0 9 imVilan® 
1.41 ± 1 . 0 3 epi VUan® 
this thesis 
Morphine 
3.06 ± 0.37 
1.38 ± 0 . 3 1 
3.63 ± 1.63 
1.48 ± 0 . 4 8 
ivVilan® 
imVilan® 
epi VUan® 
rectal Vilan® 
Morphine-3-glucuronide 
3.78 ± 2 . 2 3 iv Vilan® 
3.06 ± 0.84 im VUan® 
4.10 ± 0 . 5 7 epi VUan® 
2.80 ± 1.08 rectal VUan® 
Morphine-6-glucuronide 
4.09 ± 2.05 iv VUan® 
2.25 ± 0 . 8 4 im VUan® 
4.20 ± 1 . 6 4 epi VUan® 
2.71 ± 1.05 rectal VUan® 
2.05 ± 1 . 2 0 ivM6G H a n n a e t a l . [1991] 
Codeine 
1.47 ± 0 . 3 1 
Codeine-6-glucuronide 
2.75 ± 0.79 
oral codeine Vree et al. [ 1992] 
oral codeine Vree et al. [1992] 
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V-8 The ratio between plasma concentrations of the 
morphine glucuronides and morphine as the parent 
compound 
The plasma concentration of the parent drug is the resultant of the rate of 
absorption (input) and the rate of elimination (output). In the steady-state 
situation the ratio of the plasma concentration (CSs) of the parent compound 
and that of the metabolite is constant and equals the ratio between the AUC 
(as AUC = Css.time). 
Css(M3G)/Css(M)=AUC(M3G)/AUC(M) 
The same equation holds for M6G/M. When the steady-state situation is not 
reached but the plasma concentration-time curves of the parent compound 
and metabolite run parallel, it is possible to calculate a plasma 
concentration ratio in the same way. 
The renal clearance of morphine is high, however only 1-5% of the dose is 
excreted in unconjugated form. Morphine is eliminated by active tubular 
secretion [Greven, 1981]. The renal clearance values of M3G and M6G are 
similar and almost equal to creatinine clearance (125 ml/min). The healthy 
kidney function will always maintain this homeostasis in the body, operates 
in the appropriate way during the life cycle and depends on the body mass 
[Edelman, 1981; Edwards, 1975]. 
The glucuronidation capacity, expressed as the ratio of plasma concentration 
of the conjugated metabolite and parent compound, depends on age. The 
plasma concentration ratio M3G/M varies during a life-time, beginning at 
0.3 at the time of birth and increasing to 10-20 in adults. The plasma 
concentration ratio M6G/M also varies during a life-time, beginning at 0.03 
at the time of birth and increasing to 1-2 in adults. The plasma 
concentration ratio M3G/M6G remains constant, i.e. 7-10. The increase in 
the plasma concentration ratio of the Mgluc/M during a life-time indicates 
that the quantitative rate of glucuronidation increases, that the total body 
clearance increases and that the t i /2 decreases. Alterations in plasma 
concentration ratios M3G/M, M6G/M and M6G/M3G were investigated in 
order to find a correlation between ratio and VAS pain score because a 
disease could influence the ratio(s), thereby changing the distribution of the 
active and inactive metabolites in the body. Although a deterioration in 
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kidney function does change the M3G/M and M6G/M ratio. It does not 
Influence the plasma concentration ratio of M3G/M6G [Sâwe and Odar-
Cederlöf, 1987]. Hasselström and Säwe [1993] described the metabolism as 
the relation of the amount of metabolite to that of the parent compound by 
calculating the plasma AUC ratios. They concluded that these plasma AUC 
ratios must be regarded with caution and that the difference in the ratio 
when oral and intravenous administration are compared is due to differences 
in circulating morphine concentrations in volunteers with normal kidney 
function. As with deteriorated kidney function the ratio M3G/M6G remains 
constant. Differences in M3G/M and M6G/M ratios were found as listed in 
Table V-8, but the ratio between M3G/M6G was remarkably constant. I.e. a 
constant ratio between inactive and active glucuronide metabolite. 
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Table -
Ratio AUC (M3G/M). (M6G/M) and (M3G/M6G) following the various routes 
of administration. 
M3G/M M6G/M M3G/M6G 
Vilan® administration 
intravenous Vilan® 
30 mg dose 6.5 ± 2.5 0.8 ± 0.3 7.911.2 
20 mg dose 9.1 ± 2.6 1.0 ± 0.3 6.5 + 3.3 
10 mg dose 9.3 ± 0.8 1.4 ±0.1 6.9 ± 0.4 
intramuscular Vilan® 
20 mg dose 8.5 ± 2.0 1.1 ±0.4 8.5 ±2.9 
epidural Vilan® 
15 mg dose 11.7 ±7.9 1.3 ±0.5 8.3 ± 2.4 
rectal Vilan® 
30 mg dose 24.9 ± 10.2 3.8 ±1.4 6.7 ±1.8 
oral Vilan® 
30 mg dose - -
Morphine administration 
[Hasselström and Säwe, 1993] 
3.8 mg intravenous 7.7 ±1.4 0.8 ± 0.2 9.7 ±2.8 
15.2 mg oral 29.9 ±6.8 3.6 ±1.2 8.6 ±1.7 
varying doses, ratio steady-state plasma concentrations 
[Van Dongen et al. 1994]. 
29 ±14 4.6 ±2.8 6.7 ±1.0 
varying doses, ratio steady-state plasma concentrations 
[McQuayetal. 1990]. 
32 6.7 4.8* 
varying doses, ratio steady-state plasma concentrations 
[Somogyi et al. 1993] 
28.5 ±17.0 4.9 ±3.8 6.4 ±1.5 
* calculated as ratio (M3G/M) divided by ratio (M6G/M) 
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VI Summary and conclusion 
In this study, 3,6-dinicotinoylmorphine was administered to patients 
undergoing surgery [Koopman-Kimenai et al. 1991a,b, 1993, 1994a,b, 
1995a,b]. 
In chapter I we consider three interrelating factors to be involved in the 
explanation of drug action: physlcochemical properties, pharmacokinetics 
and receptor interactions and the dynamics of the biological system. 
In the human body all compounds are distributed throughout all tissues 
according to their physical and chemical properties (physlcochemical 
properties). The lipid solubility of 3,6-dinicotinoylmorphine at the 
physiological plasma pH of 7.4 is about 10-fold higher than that of morphine 
ГГаЫе 1-1). This favours penetration through the blood-brain barrier and will 
result in a high concentration of 3,6-dinicotinoylmorphine near the receptor 
in the central nervous system. 
Pharmacokinetics describes the absorption, distribution, biotransformation 
and excretion of drugs. Moreover, Wagner pointed out that pharmacokinetics 
serves to describe the relationship between the concentration of the drug 
and its metabolite(s) in body fluids in order to explain the effect of the 
administered drug (the pharmacologic response) [Wagner 1971]. The process 
of metabolism starts immediately following administration of the parent 
compound (Fig 1-3). Metabolites appear, each with individually different 
physical and chemical properties (physlcochemical properties); (Table 1-4). 
These properties will express a distribution pattern that is metabolite-
specific, and due to the physlcochemical properties it will differ from that of 
the parent compound. Possible metabolic pathways are shown in Fig 1-3, 
and the pharmacokinetics will provide information on which metabolites 
are present and In which concentration. 
Furthermore, a theoretical description of the interactions at the opioid 
receptor is given, and the biological system will adapt to the situation of 
long-term drug treatment. 
Summary and conclusion 151 
In chapter II the ins and outs of the high performance liquid 
chromatography in comparison to other methods are described. All of the 
details on the accuracy, precision and quantitation limits are given. 
In chapter ΠΙ demographic data of the patients participating in these 
studies and the anaesthetic techniquesused are described. 
In chapter IV the pharmacokinetic data resulting from the pharmacokinetic 
calculations following the different forms of administration are summarised. 
After intravenous, intramuscular and epidural administration the parent 
drug is de tected in t h e s e r u m and the metabol i tes . 
6-mononlcotinoylmorphine, morphine, morphine-3-glucuronide and 
morphlne-6-glucuronide appear. After rectal administration only morphine 
and its related metabolites morphine-3-glucuronide and morphine-6-
glucuronlde can be detected, as is depicted In Fig Г -4. 
In chapter V the results following administration of each form of 3,6-
dinicotJnoylmorphine is discussed separately, and comparisons between the 
different forms of administration are made. In general, after 3,6-
dinlcotinoylmorphine administration, 6-mononicotlnoylmorphine is formed 
as a result of rapid metabolic cleavage of the C3 bond [Proceedings of the 
Vilan® workshop, Graz 1987, Kopera and Booy, eds.,1988]. Analgesic activity 
is retained by the molecule when the 6-OH position is substituted for a 
nlcotinoyl moiety. Cleavage of the C6 bond, resulting in 3-
mononicotinoylmorphine, could never be detected because it was not formed 
and/or it was already further metabolised due to its instability. This latter 
possibility does not appear to be true because administration of 3-
mononicotlnoylmorphine directly to the rat resulted in a 10-fold lower ED50 
in comparison to an equlmolar dose of morphine [Dirksen et al. 1987]. The 
conclusion from this experiment must be that the effect of 3-
mononlcotinoylmorphine can not be due to morphine itself. 3-
Mononlcotlnoylmorphine has never been detected in our samples (except in 
calibration samples to which this compound was added). Further 
hydrolysatlon of the ester bonds left in both mononicotinoylmorphines result 
in the formation of morphine. 
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Morphine is glucuronidated at the C3 or the C6 position yielding morphine-
3-glucuronide (M3G) and morphine-6-glucuronide (M6G), respectively. The 
metabolites of morphine, M3G and M6G, are present in plasma at 
significantly greater concentrations than morphine itself after oral 
administration of morphine [Säwe et al. 1983]. Glucuronides are highly polar 
metabolites which are generally considered to be unable to cross the blood-
brain barrier and are rapidly excreted by the urinary and/or biliary routes. 
M6G and, to a lesser extent, M3G are more lipophilic than predicted and are 
in fact not much less lipophilic than morphine itself [Carrupt et al. 1991]. 
Force-field and quantum mechanical calculations indicate that the two 
glucuronides can exist in conformational equilibrium between the extended 
and folded forms. In the extended configuration the polar groups are exposed 
at the surface of the molecule giving predominatly hydrophilic forms In polar 
media such as water. In contrast, the folded configurations mask a part of 
the polar groups and are thus more lipophilic, these forms are likely to be 
the most prevelent in media of low polarity such as biological membranes. 
When 3,6-dinicotinoylmorphine is administered to patients, 6-
mononicotinoylmorphine, morphine, morphine-6-glucuronide and morphine-
3-glucuronide can be detected in the serum. 3.6-Dinicotinoylmorphine, as 
heroin, lacks morphine's free phenolic hydroxyl group at position C3. 
Receptor assays have shown that this site is especially important with 
resspect to affinity for the opioid receptors [Reden et al. 1979; Lobbezoo et al. 
1982]. The low receptor affinity of the drug fails to account for the powerful 
analgesic effect observed after its administration. The basis of the analgesic 
effect of 3,6-dinicotinoylmorphine is the formation of active metabolites. 
The metabolites 6-mononicotinoylmorphine and morphine possess a free 
hydroxyl group at the C3 position and are able to interact at the opioid 
receptor. Studies have confirmed the analgesic activity of M6G [Osborne et 
al. 1988], which is consistent with its binding to opioid receptors 
[Christensen and Jurgensen 1987], and animal studies suggest that M6G is 
more potent than morphine itself [Shimomura et al. 1971]. Although 
morphine-6-glucuronide (M6G) is considered to be a highly polar conjugate, 
it can penetrate the blood-brain barrier and react with the receptor of 
analgesic action without prior hydrolysis of the glucuronide linkage 
[Yoshimura et al. 1973]. M6G effectively binds to the μ receptor, but not to 
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the δ or к receptor, with affinities similar to morphine. Its actions were 
sensitive to the opiate antagonist naloxone [Pasternak et al. 1987]. M3G had 
poor affinity in all binding studies, which can be explained by the lack of the 
free C3 hydroxyl group and the large size of the substituent (a methoxy 
group at C3, as in codeine, only reduces receptor binding 10 fold). Both 
glucuronides are formed in the body and are eliminated from the body by 
renal clearance. 
Changes In (bio)avallability can be realized in a different way. The route of 
administration of 3,6-dlnicotinoylmorphine was varied: intravenous, 
intramuscular, epidural, rectal and oral. Epidural dosing automatically leads 
to higher concentrations in the central nervous system. Elevated 
concentrations of 3,6-dinicotinoylmorphine near the receptor will occur but 
will have no direct result because this compound does not bind to the 
receptor. 
6-Mononicotinoylmorphine, morphine and morphine-6-glucuronide are 
nowadays regarded as active compounds. An inactive parent compound, a 
"pro-drug", is subjected to metabolic conversions resulting in compounds 
having a greater potency than that of the parent compound, as evidenced by 
the significantly lower ED50. Thus, the effectiveness of the C3 nicotinoyl-
substltuted morphine derivatives is explained by the effectiveness of the 
metabolic products rather than by that of the parent compound. 
Substitutions at the C3 or C6 positions or both, however, result in 
physicochemlcal properties of the resulting molecules that differ from those 
of morphine, and such changes (especially lipid solubility) favour transport 
into the central nervous system. Moreover, these substitutions have been 
shown to enhance the safety of the drug in the specific application of 
perispinal opioid injections. Substituted molecules did not cause a high 
incidence of undesired side-effects, such as delayed respiratory depression 
[Dirksen 1983). Also, a higher lipid solubility is believed to lower the toxicity 
of the drug after systemic use. However, the necessity of metabolic 
conversion, which differs among individual physiological systems, reduces 
the predictability of the effect. 
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General conclusion 
The mainstays for the effect of a drug were outlined: I.e. physicochemical 
properties, pharmacokinetics and biological sites of action and dynamics. It 
is Important to realise that any effect elicited by the drug Is a result of the 
action of a diversity of compounds that are generated during the process of 
metabolism. All too often metabolites are considered to be weakly active or 
inactive waste products. This is not a universal rule. Actually some drugs, 
"prodrugs", depend on such "metabolic activation" [Rowland and Tozer 
1989]. 
Thus, before we draw any conclusions regarding the actions of an 
administered drug, we should define the drug's metabolites as these all may 
contribute to or modify the ultimate effect. 
The prodrug 3,6-dinicotlnoylmorphine is biotransformed into 3 (active) 
metabolites: 6-mononicotinoylmorphine, morphine and morphine-6-
glucuronide. The parent compound itself and the metabolite morphine-3-
glucuronide are thought to be inactive. All compounds (active and inactive) 
are included when the total mass balance is taken into account. 
Thus, metabolic conversion is an important and sometimes neglected aspect 
of drug action. This thesis underscores this aspect by defining the clinical 
pharmacokinetics of the prodrug Nicomorphine. 
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VII Samenvatting en conclusie 
In dit onderzoek werd 3,6-dinicotlnoylmorfine aan operatie-patiënten 
toegediend [Koopman-Kimenai et al. 1991a,b, 1993. 1994a.b, 1995a,b]. 
In Hoofdstuk I worden vier samenhangende factoren genoemd die betrokken 
zijn bij de verklaring van de werking van een geneesmiddel, namelijk: 
Fysisch-chemische eigenschappen, farmacokinetiek, receptor interacies en 
de dynamiek van het biologische systeem. 
In het menselijk lichaam worden alle chemische verbindingen over de 
weefsels verdeeld overeenkomstig hun fysische en chemische eigenschappen 
(fysisch-chemische eigenschappen). De vetoplosbaarheid van 3,6-
dinicotinoylmorfine onder fysiologische omstandigheden (pH van 7.4 in het 
plasma) is ongeveer tien maal hoger dan die van morfine (Table 1-1). Dit 
vergemakkelijkt het passeren van de bloed-hersen barrière en dat zal dichtbij 
de receptor in het centrale zenuwstelsel in een hoge concentratie 3,6-
dinicotinoylmorfine resulteren. 
Farmacokinetiek beschrijft de opname, verdeling, biotransformatie en 
uitscheiding van geneesmiddelen. Bovendien wijst Wagner erop dat de 
farmacokinetiek kan dienen om de relatie tussen concentratie van het 
geneesmiddel en zijn metabolieten in lichaamsvloeistoffen en het effect van 
het toegediende geneesmiddel (de farmacokinetische respons) te beschrijven 
[Wagner 1971]. Onmiddelijk na de toediening van de moederverbinding 
begint het metaboliseringsproces (Fig 1-3). De metabolieten verschijnen, elk 
met hun eigen fysische en chemische eigenschappen (Table 1-4). Deze 
eigenschappen bepalen een verdelingspatroon dat specifiek is voor deze 
metabolieten en dat zal afwijken van dat van de moederverbinding omdat de 
fysisch-chemische eigenschappen anders zijn. De mogelijke metabole wegen 
van 3,6-dinocotinoylmorfine staan aangegeven in Fig 1-3, en de 
farmacokinetiek verschaft de informatie welke metabolieten aanwezig zijn, 
in welke concentraties en gedurende welke tijd. 
Verder wordt er een theoretische beschrijving gegeven van de interacties met 
de opioid receptor en het biologische systeem, dat zich bij langdurig 
geneesmiddel gebruik kan aanpasssen. 
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In Hoofdstuk Π worden de voor- en nadelen van een HPLC-methode ten 
opzichte van andere analyse methoden tegen elkaar afgewogen. Details over 
precisie, nauwkeurigheid en bepalingsgrenzen worden hier gegeven. 
Hoofdstuk Ш bevat de demografische gegevens van de operatie-patiënten 
die aan dit onderzoek meegedaan hebben, en een beschrijving van de 
gebruikte anesthesle-technieken. 
Hoofdstuk Г bevat een samenvatting van de uitkomsten van de 
farmacokinetlsche berekeningen bij de verschillende toedieningsvormen. Na 
intraveneuze, intramusculaire en epidurale toediening wordt de 
aanwezigheid van de moederverbinding in het serum aangetoond en 
verschijnen de metabolieten 6-mononicotlnoylmorfine, morfine, morfine-3-
glucuronide en morfine-6-glucuronide In het serum. Na rectale toediening is 
alleen morfine met zijn twee directe metabolieten morfine-3-glucuronide en 
morfine-6-glucuronide aantoonbaar. Orale toediening bij operatie-patiënten 
resulteert niet in meetbare serumconcentraties. 
In Hoofdstuk V worden de resultaten betreffende iedere toedieningsvorm 
eerst apart besproken waarna vergelijkingen tussen de verschillende 
toedieningsvormen gemaakt worden. In het algemeen geldt: Na toediening 
van 3,6-dinicotinoylmorfine wordt de metaboliet 6-mononicotinoylmorfine 
snel gevormd door het verbreken van de C3-OH binding [Proceedings of the 
Vilan® workshop, Graz 1987, Ropera and Booy. eds.,1988]. Het molecuul 
behoudt zijn pijnstillende werking als op de C6 positie een nlcotine-zuur 
ester aanwezig is. Het verbreken van de ester binding op de C6 plaats, wat 
zou resulteren in 3-mononicotinoylmorflne, kon niet worden gemeten omdat 
deze stof niet zou kunnen worden gevormd en/of dat deze stof al verder 
gemetaboliseerd wordt als gevolg van zijn instabiliteit. Deze laatste 
mogelijkheid lijkt niet waarschijnlijk omdat toediening van 3-
mononicotinoylmorflne aan ratten resulteert in een tien maal kleinere ED50 
in vergelijking met een equimolaire dosis morfine [Dirksen et al. 1987]. Dit 
kan worden verklaard uit het feit dat 3-mononicotinoylmorfine een betere 
vetoplosbaarheid heeft dan morfine, waardoor het beter in het centrale 
zenuwstelsel kan doordringen. Daar zal het worden omgezet tot morfine wat 
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uiteindelijk aan de receptor bindt en in een pijnstillende werking resulteert. 
Hydrolyse van de resterende esterbinding in beide mononicotinoylmorflnes 
leidt tot de vorming van morfine. 
Morfine wordt geglucuronideerd op de C3 en C6 plaats hetgeen morfine-3-
glucuronide (M3G) en morflne-6-glucuronide (M6G) geeft. Na orale 
toediening van morfine [Säwe et al. 1983] worden beide glucuronide 
metabolieten in significant hogere concentraties in het plasma gevonden dan 
morfine. Glucuronides zijn polaire metabolieten waarvan verwacht mocht 
worden dat zij niet in staat zouden zijn de bloed-hersenbarriére te passeren, 
en dat zij snel uitgescheiden zouden worden via de urine en/of de gal. M6G. 
en in mindere mate M3G, bleken beter vetoplosbaar te zijn dan verwacht, in 
feite was hun vetoplosbaarheid niet veel minder dan die van morfine zelf 
[Carrupt et al. 1991]. Krachtveld- en quantummechanische berekeningen 
wijzen uit dat de twee glucuronides bestaan in een evenwicht tussen een 
uitgeklapte en gevouwen vorm. In de uitgeklapte vorm bevinden de polaire 
groepen zich aan het oppervlak van het molekuul. In de gevouwen vorm 
daarentegen liggen de polaire groepen aan de binnenkant, is het molecuul 
dus beter vetoplosbaar en zal het daarom overwegend voorkomen in een laag 
polaire omgeving zoals biologische membranen. 
Als 3,6-dinicotinoylmorfine aan patiënten wordt toegediend kan in het serum 
6-mononicotinoylmorfine, morfine, morfine-6-glucuronide en morfine-3-
glucuronide worden gedetecteerd. 3-Mononicotinoylmorfine is nooit 
gedetecteerd in onze monsters (behalve aan ijkmonsters waaraan deze stof 
was toegevoegd). 
Bij 3,6-dinicotinoylmorfine, evenals heroine, ontbreekt de vrije fenolische 
hydroxyl groep op de positie C3, wat bij het morfine molekuul wel het geval 
is. Receptoronderzoek toont aan dat deze plaats bepalend is voor de affiniteit 
tot de opioid receptor [Reden et al. 1979; Lobbezoo et al. 1982]. De lage 
receptoraffiniteit van de toegediende stof is in tegenspraak met het feit dat 
zijn toediening resulteert in een krachtig pijnstillend effect. De verklaring van 
de pijnstillende werking van 3,6-dinicotinoylmorfine moet daarom gezocht 
worden in de vorming van actieve metabolieten. 
De metabolieten 6-mononicotinoylmorfine en morfine bezitten allebei een 
vrije hydroxylgroep op positie C3 en zijn dus in staat een interactie aan te 
gaan met de opioid receptor. Onderzoeken hebben aangetoond dat ook 
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morfine-6-glucuronide pijnstillend werkt [Osbome et al. 19881, wat in 
overeenstemming is met zijn binding met de opioid receptor [Christensen 
and Jorgensen 1987]. Daarbij heeft dierexperimenteel onderzoek aangetoond 
dat M6G een grotere pijnstillende werking heeft dan morfine zelf [Shimomura 
et al. 1971]. Ondanks het feit dat M6G beschouwd moet worden als een 
polair conjugaat, kan deze stof de bloed-hersenbarriére passeren en aan de 
receptor binden zonder dat vooraf de glucuronide binding gehydrolyseerd 
wordt [Yoshimura et al. 1973]. Morfine-6-glucuronide bindt aan de μ 
receptor met affiniteiten vergelijkbaar met die van morfine, het bindt niet 
aan de δ of к receptor. Zijn werking is gevoelig voor de antagonist naloxone 
[Pasternak et al. 1987]. Morfine-3-glucuronide heeft een lage affiniteit in alle 
onderzoeken betreffende receptorbinding, wat verklaard kan worden uit het 
feit dat de stof de vrije hydroxylgroep op C3 mist en uit de grootte van de 
substituent (een methoxy groep op C3, zoals aanwezig in codeine, vermindert 
de receptorbinding met een factor 10). Beide glucuronldes worden in het 
lichaam gevormd en renaal uitgescheiden. 
Veranderingen in de (biologische) beschikbaarheid kunnen op verschillende 
manieren gerealiseerd worden. Verschillende toedieningswegen van het 3,6-
dinicotinoylmorfine werden onderzocht: intraveneus, intramusculair, 
epiduraal, rectaal en oraal. Epidurale toediening zal natuurlijk lelden tot 
hogere concentraties in het centrale zenuwstelsel. In de directe omgeving van 
de receptor zal een relatief hoge concentratie van 3,6-dinicotinoylmorfine 
aanwezig zijn, maar dit heeft geen direct resultaat omdat de 
moederverbinding niet aan de receptor bindt. 
6-Mononicotinoylmorflne, morfine en morfine-6-glucuronide worden vandaag 
de dag beschouwd als actieve stoffen. De inactieve moederverbinding, 
"prodrug", is onderhevig aan metabole omzettingen welke resulteren in 
stoffen met een grotere potentie dan die van de moederverbinding, zoals 
aangetoond met de significant lagere ED50. Dus de effectiviteit van de C3-
nicotinoyl gesubstitueerde morfinederivaten kan worden verklaard door de 
effectiviteit van zijn metabole omzettingsprodukten in plaats van die van de 
moederverbinding. Substituties aan de C3 en C6 of aan beide, zullen echter 
bepalend zijn voor de fysisch-chemische eigenschappen van het bedoelde 
molekuul in vergelijking met die van morfine en zulke veranderingen (in het 
bijzonder de vetoplosbaarheld) bevorderen het transport naar het centrale 
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zenuwstelsel. Bovendien blijken deze gesubstitueerde verbindingen de 
veiligheid bij perispinale toediening te vergroten. Gesubstitueerde 
verbindingen gaven geen hoge frequentie aan ongewenste bijwerkingen zoals 
een verlate ademdepressie [Dirksen 1983]. Tevens lijkt een hogere 
vetoplosbaarheid tot een vermindering van de toxiciteit van een medicijn na 
systemische toediening te leiden. 
De mate en snelheid van metabole omzettingen, welke van Individu tot 
individu zullen verschillen, verkleinen de voorspelbaarheid van het effect. 
Samenvatting en conclusies 163 
Conclusie 
De hoofdzaken die betrokken zijn bij het effect van een geneesmiddel worden 
beschreven: fysisch-chemische eigenschappen, farmacokinetiek, het 
aangrijpingspunt in het biologisch systeem en zijn dynamiek. Het is 
belangrijk om zich te realiseren dat elk effect wordt veroorzaakt door een 
scala aan verbindingen, die ontstaan wanneer het geneesmiddel 
gemetaboliseerd wordt. Al te vaak worden metabolieten beschouwd als 
weinig actieve of inactieve "afval"producten. Dit is echter geen algemene 
regel. Sommige geneesmiddelen, "prodrugs" genaamd, zijn voor hun werking 
zelfs afhankelijk van de zo genoemde "metabole activering" [Rowland and 
Tozer 1989]. 
Dus: voordat men uitspraken doet over de activiteit van het toegediende 
geneesmiddel, dient men de metabolieten te identificeren omdat deze alle 
kunnen bijdragen tot het uiteindelijke effect. 
De "prodrug" 3,6-dinicotinoylmorfine wordt omgezet in drie actieve 
metabolieten: 6-mononicotinoylmorflne, morfine en morfine-6-glucuronide. 
De moederverbinding zelf en de metaboliet morfine-3-glucuronide zijn 
inactief. Alle verbindingen (actief en inactief) zijn meegenomen in de 
berekening van de massa-balans. 
Dus, metabole omzetting is een belangrijk aspect in het uiteindelijke 
werkingmechanisme van een medicijn. Dit proefschrift ondersteunt dit 
aspect door de klinische farmacokinetiek van de "prodrug" Nicomorphine en 
zijn metabolieten te definieren. 
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The mainstays for the effect of a drug were outlined: i.e. 
physicochemical properties, pharmacokinetics and biological sites of 
action and dynamics. It is important to realise that any effect elicited 
by the drug is a result of the action of a diversity of compounds that 
are generated during the process of metabolism. All too often 
metabolites are considered to be weakly active or inactive waste 
products. This is not a universal rule. Actually some drugs, 
"prodrugs", depend on such "metabolic activation". 
Thus, before we draw any conclusions regarding the actions of an 
administered drug, we should define the drug's metabolites as these 
all may contribute to or modify the ultimate effect. 
The prodrug 3,6-dinicotinoylmorphine is biotransformed into 3 (active) 
metabolites: 6-mononicotinoylmorphine, morphine and morphine-6-
glucuronide. The parent compound itself and the metabolite 
morphine-3-glucuronide are thought to be inactive. All compounds 
(active and inactive) are included when the total mass balance is 
taken into account. 
Thus, metabolic conversion is an important and sometimes neglected 
aspect of drug action. This thesis underscores this aspect by defining 
the clinical pharmacokinetics of the prodrug Nicomorphine. 
